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SUMMARY 
 
In the human cell, many processes are facilitated by proteins, which are regulated by 
the attachment of chemical groups, so called post-translational modifications (PTMs). 
ADP-ribosylation is an important PTM, which is involved in a variety of cellular 
processes and its misregulation or loss is implicated in a broad range of diseases. 
Many questions regarding ADP-ribosylation are still unanswered; especially which 
amino acids that serve as acceptors for ADP-ribosylation and which enzymes are able 
to revert the modification on a specific protein and residue. 
The aim of this thesis was to shed light on these questions, to identify the 
acceptors of ADP-ribose and to analyze mono-ADP-ribosylhydrolases. Therefore, 
novel electron transfer dissociation (ETD) and higher-energy collisional dissociation 
(HCD) mass spectrometry (MS/MS) protocols were established and combined in order 
to optimize the challenging analysis of ADP-ribosylation by MS/MS. The optimized 
protocol led, for the first time, to the highly accurate identification of several ADP-
ribosylation sites on proteins extracted from cells. The mapped sites included glutamic 
acid, arginine and lysine residues on known targets such as histone H1 and H2B. 
Many of these sites are also targets of other PTMs, suggesting a lively crosstalk 
between ADP-ribosylation and other PTMs. 
 Macrodomain containing proteins are known to bind ADP-ribose and were 
identified here as novel mono-ADP-ribosylhydrolases. The human proteins MacroD1, 
MacroD2 and C6orf130, as well as the archaeal enzyme Af1521, were able to 
hydrolyze glutamic acid linked mono-ADP-ribose, catalyzed by the mono-ADP-
ribosyltransferase ARTD10 in vitro and in vivo. Structural modeling and mutagenesis 
identified a common core structure containing Asp102 and His106 of MacroD2 that is 
implicated in the hydrolytic reaction. Importantly, MacroD2 could revert the inhibitory 
ADP-ribosylation of the disease relevant kinase GSK3! and thereby restore its activity. 
Taken together, the establishment of a novel mass spectrometry workflow represented 
an important step towards the identification of the ADP-ribosylome. The identification 
of a variety of ADP-ribosylation acceptor sites in cellular proteins challenges the old 
dogma, which states that mainly glutamates serve as acceptors of poly-ADP-ribose in 
human cells. Furthermore, the identification of macrodomain containing proteins as 
novel mono-ADP-ribosylhydrolases closes a gap in the cellular ADP-ribosylation 
cycle and opens a new chapter in mono-ADP-ribosylation metabolism.  
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ZUSAMMENFASSUNG 
 
In der menschlichen Zelle werden viele Vorgänge von Proteinen übernommen, welche 
durch chemische Modifikationen, die post-translationellen Modifikationen (PTM), 
reguliert werden. ADP-Ribosylierung ist eine wichtige PTM, die an vielen zellulären 
Prozessen beteiligt ist und deren Fehlregulierung oder Verlust mit Krankheiten 
assoziiert wird. Viele Fragen in Verbindung mit ADP-Ribosylierung sind bis heute 
unbeantwortet, besonders bezüglich der Aminosäure-Akzeptoren für ADP-Ribose und 
der Enzyme welche die Modifikationen wieder entfernen. 
 Das Ziel dieser Arbeit war es, diese Fragen zu beleuchten, Akzeptoren für 
ADP-Ribose zu identifizieren, sowie mono-ADP-Ribosylhydrolasen zu analysieren. 
Zu diesem Zweck wurden neue Massenspektrometrie Protokolle entwickelt, welche 
zum ersten Mal zur akkuraten Identifizierung von ADP-Ribosylierungsstellen auf 
extrahierten Proteinen führten. Unter anderem konnten Lysine und Arginine auf den 
bekannten Akzeptorproteinen Histon H1 und H2B lokalisiert werden. Viele dieser 
Modifikationsstellen sind auch Ziele anderer PTMs, was einen regen Austausch 
zwischen ADP-Ribosylierung und anderen PTMs suggeriert. 
Proteine mit Makrodomänen binden ADP-Ribose und wurden hier als neue 
mono-ADP-ribosylhydrolasen identifiziert. Die menschlichen Proteine MacroD1, 
MacroD2 und C6orf130, sowie Af1521 aus Archaebakterien, waren in der Lage mono-
ADP-Ribose von Glutamaten zu entfernen, welche von der mono-ADP-
Ribosyltransferase ARTD10 in vitro und in vivo katalysiert wurde. Strukturmodelle 
und Mutagenese ermöglichten die Identifizierung einer Kernstruktur bestehend aus 
den Aminosäuren Asp102 und His106 von MacroD2, welche an der Hydrolasereaktion 
beteiligt ist. MacroD2 konnte auch die inhibierende ADP-Ribosylierung der 
krankheitsrelevanten Kinase GSK3? entfernen und dadurch deren Kinaseaktivität 
wieder herstellen. 
Die Etablierung neuer Massenspektrometrie Protokolle war ein wichtiger 
Schritt zur Identifizierung des ADP-ribosyloms einer Zelle. Die Identifizierung 
verschiedener ADP-Ribosylierungsstellen steht in Kontrast zu einem alten Dogma, 
welches Glutamate als primäre ADP-Ribose Akzeptoren in menschlichen Zellen 
darstellt. Desweiteren schliesst die Identifizierung von Makrodomänen-proteinen als 
ADP-Ribosylhydrolasen eine grosse Lücke im ADP-Ribosylierungskreislauf und 
eröffnet ein neues Kapitel im mono-ADP-Ribosylierungsmetabolismus. 
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1 INTRODUCTION   !
1.1 Post translational modifications 
Post-translational protein modifications (PTMs) are defined as the attachment of 
chemical groups or peptides to specific amino acids of proteins or the processing of 
proteins by proteolytic cleavage (1). Until now, proteomic studies have identified more 
than 200 different PTMs that add a high level of complexity to the proteome, 
generating over 1 million different proteins from only 20,000 to 25,000 protein coding 
genes (Figure 1) (2,3).  
 
 
While changes or mutations in the genome are rather rare, PTMs allow cells to quickly 
regulate protein structure, function and interactions, as they can affect the overall 
chemical property of the modified amino acid (5). Furthermore, PTMs allow the cell to 
adapt and cope with stress conditions such as environmental stimuli, pathogens or 
diseases.  ! "#$$%&'()*#) post-translational modifications are the covalent modification of 
amino acids with small chemical groups such as phosphate, acetate or methyl. These 
PTMs are not only attached, but can also be removed to reverse a certain PTM in a fast 
Figure 1: Post-translational modifications increase proteome complexity. Starting from a 
genome with 20-25’000 genes, the transcriptome represents a new level of complexity, which is 
further increased by the extremely high number and diversity of PTMs, resulting in over 
1’000’000 different proteins. Modified from (4). !
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and dynamic way. Since several amino acids can be modified by different chemical 
groups, PTMs can influence each other; for example by competing for the same 
acceptor amino acid or by recruiting modifying enzymes (1). This phenomenon is well 
studied in the context of the so called `histone code`, where a variety of modifications 
of the histone tails orchestrate the recruitment of readers and additional writers of 
PTMs to influence DNA replication, transcription and repair (2,6). 
 Other types of PTMs comprise the addition of polypeptide groups instead of a 
small chemical group, such as ubiquitin and ubiquitin-like modifications (e.g., SUMO 
and NEDD) (1,7). Finally, also mechanisms that irreversibly alter amino acid 
properties (e.g., through the deamination of arginine to citrulline (8)) or the proteolytic 
cleavage of precursor proteins (9) are referred to as post-translational modifications. 
 
1.2 ADP-ribosylation 
ADP-ribosylation as a post-translational modification is known since 50 years, but 
nevertheless it is still poorly understood (10,11). It is an ancient modification that is 
conserved in all organisms from bacteria to humans, except in yeast, and is catalyzed 
by ADP-ribosyltransferases (ARTs) (12). ADP-ribosylation is the enzymatic 
attachment of ADP-ribose to proteins by ARTs using NAD+ as a substrate. ARTs 
cleave the energetic bond between the nicotinamide and ADP-ribose moieties and 
transfer the latter to amino acids of themselves (i.e., auto-modification) or of target 
protein (13), while releasing nicotinamide as a side-product. 
ADP-ribosylation can be divided into two subtypes (14): the first class defines 
a reaction in which only one ADP-ribose group is transferred to the target amino acid 
of proteins (mono-ADP-ribosylation) (15). The second class involves the elongation of 
the initial ADP-ribose moiety to generate long ADP-ribose chains (poly-ADP-
ribosylation). In both types, the acceptor site is initially mono-ADP-ribosylated, which 
is in the case of poly-ADP-ribosylation followed by an elongation reaction (Figure 2). 
In vitro, this elongation step leads to the production of long polymers of ADP-ribose 
(PAR), reaching up to 200-400 ADP-ribose moieties, that are connected via ribose-
ribose glycosidic bonds (13,16). PAR can be additionally branched, for which ADP-
ribose chains are attached to the existing polymers in a non-linear manner (Figure 2) 
(16). The distance between branching points varies between 1 and 40 ADP-ribose 
units (17).!!
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1.2.1 Bacterial toxins as ADP-ribosyltransferases 
During host invasion, bacterial pathogens make use of protein toxins that mono-ADP-
ribosylate intracellular targets, which leads to the neutralization of the phagocytotic 
functions of immune cells, the disruption of the cytoskeleton or the inhibition of signal 
transduction (19,20). These toxic effects lead to apoptotic or necrotic cell death and 
causes diseases like diphteria, cholera and whooping cough. Bacterial toxins are well 
studied and the acceptor amino acids for ADP-ribosylation are defined in many cases 
(Table 1). 
Based on structural aspects, bacterial toxins are divided into two main subclasses that 
harbor either a H-Y-E (found in the Diphteria toxins) or a R-S-E motif (found in the 
Cholera toxin) in their catalytic domain (12). 
Figure 2: ADP-ribosylation metabolism. Poly-ADP-ribose (PAR) is for example synthesized 
by ARTD1 using NAD+ as the ADP-ribose donor. The ADP-ribose moieties are linked via 1”-2’ 
ribose-ribose glycosidic bonds (a) whereas PAR branching points are linked via 1”-2” ribose-
ribose glycosidic bonds (b). Modified from (18). !
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!1.2.2 The mammalian ARTD Family 
Shortly after the identification of ADP-ribose as PTM, the first enzyme, which is able 
to synthesize PAR was discovered and named poly-ADP-ribose polymerase (PARP) 
(21). For nearly two decades, PARP was believed to be the only ADP-
ribosyltransferase, capable of ADP-ribose polymer synthesis. In the late nineties with 
the sequencing of the human genome additional genes sharing the same catalytic 
domain were identified, suggesting that several other proteins might be able to 
synthesize PAR (22). Thanks to many studies providing information about protein 
structure and sequence, up to now 22 human proteins that harbor a catalytic domain 
similar to the one found in PARP have been identified (12). Based on available amino 
acid sequences and crystal structures, the mammalian ARTs can be grouped into two 
groups with different catalytic motifs (12). One group shares structural similarities 
with the bacterial cholera toxin and is therefore named ADP-ribosyltransferase 
Cholera toxin like (ARTC). Currently, the ARTCs comprise five members in human 
(ARTC1-5), which are all located at the cell membrane facing the extracellular space 
(12). The second group shares structural similarities to the bacterial diphteria toxin and 
is therefore named ADP-ribosyltransferase Diphteria toxin like (ARTD). Eighteen 
human ARTD members (ARTD1-18, ARTD1 representing the initial PARP protein) 
are currently distinguished and found in different compartments within the cell. The 
ARTD family can be further subdivided based on amino acid differences in the 
catalytic core domain. ARTDs that were though to synthesize PAR are characterized 
!
Exotoxin Bacterium Target Role in pathogenesis Target AA 
Diphtheria toxin C. diphtheriae EF-2 Inhibition of protein synthesis diphtamide 
Exotoxin A P. aeruginosa EF-2 Inhibition of protein synthesis diphtamide 
Cholera toxin V. cholerae EF-2 Inhibition of protein synthesis diphtamide 
Heat-labile 
enterotoxin 
E. coli Gs Inhibition of GTPase activity of Gs arginine 
Pertussis toxin B. pertussis Gi 
Uncoupled Gi protein–mediated signal 
tansduction 
cysteine 
C2 C. botulinum Actin Actin depolymerization arginine 
C3stau2 S. aureus Rho A Traps Rho GTPase in GDP-bound state asparagine 
1.2.2 The mammalian ARTD Family 
Shortly after the identification of ADP-ribose, the first enzyme, which is able to 
synthesize PAR was discovered and named poly-ADP-ribose polymerase (PARP) (21). 
For nearly two decades, PARP was believed to be the only ADP-ribosyltransferase, 
until in the late nineties with the sequencing of the human genome additional genes 
sharing the same catalytic domain were identified, suggesting that several other 
proteins might be able to synthesize PAR (22). Thanks to many studies providing 
information about protein structure and sequence, up to now 22 human proteins that 
harbor a catalytic domain similar to the one found in PARP were identified (12). 
Based on available amino acid sequences and crystal structures, the mammalian ARTs 
can be grouped into two groups with different catalytic motifs (12). One group shares 
structural similarities with the bacterial cholera toxin and is therefore named ADP-
ribosyltransferase Cholera toxin like (ARTC). Currently, the ARTCs comprise five 
members in human (ARTC1-5), which are all located at the cell membrane facing the 
extracellular space (12). The second group shares structural similarities to the bacterial 
diphteria toxin and is therefore named ADP-ribosyltransferase Diphteria toxin like 
(ARTD). Eighteen human ARTD members (ARTD1-18, ARTD1 representing the 
initial PARP protein) are currently distinguished and found in different compartments 
within the cell. The ARTD family can be further subdivided based on amino acid 
differences in the catalytic core domain. ARTDs that were though to synthesize PAR 
are characterized by the presence of the conserved amino acid triad H-Y-E, whereas 
mono- DP-ribosyltransferases lack the glutamate residue in position three of the triad 
(Figure 3) (12). This glutamate residue was described to be critical for the elongation 
step of the PAR formation. Interestingly, although ARTD3 harbors the H-Y-E triad, 
Table 1: Examples of bacterial ADP-ribosyltransferases. Shown are the transferases, their 
target proteins and amino ac ds, as well as the cellular reaction. Modified from (19) and (20). 
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by the presence of the conserved amino acid triad H-Y-E, whereas mono-ADP-
ribosyltransferases lack the glutamate residue in position three of the triad (Figure 3) 
(12). This glutamate residue was described to be critical for the elongation step of the 
PAR formation. Interestingly, although ARTD3 harbors the H-Y-E triad, the enzyme 
was reported to catalyze only mono-ADP-ribosylation (23), suggesting that other 
amino acids or specific conditions are most likely important for PAR formation. 
 
 
Based on the biochemical characterization of the ARTD family, the members can be 
sub-divided into three groups: the family founding enzyme ARTD1 (PARP1) as well 
as ARTD2 (PARP2) generate branched PAR and are representative of the first group. 
In the cell, ARTD1 is the most abundant nuclear ARTD and accounts for 
approximately 90% of the PAR formation (24), whereas ARTD2 is less abundant, less 
active and responsible for the majority of the remaining PAR formation in mice 
lacking ARTD1 (24,25). The enzymatic property of ARTD3 is still under debate (see 
above), as both mono- and poly-ADP-ribosylation activity were reported (23,26). A 
Figure 3: Structural comparison of H-Y-E motif containing ARTs. The overall structure and an 
enlargement of the active site are shown for the bacterial Diphtheria toxin, chicken ARTD1 and 
human ARTD10. The six !-sheets that form a scaffold for the catalytic domain are highlighted in 
rainbow colors. Ligands and conserved motif side chains are shown as sticks. Modified from (12). !
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second group of enzymes consists of the telomere associated ARTD5 and ARTD6 
(Tankyrase1 and 2), which are also able to modify themselves and several target 
proteins (27,28). In contrast to the first group, ARTD5 and ARTD6 are oligo-ADP-
ribosyltransferases, which synthesize unbranched ADP-ribose chains with a maximum 
length of 20 units (28). The third group contains enzymes lacking the glutamate 
residue in the above-mentioned triad motif, limiting them to mono-ADP-
ribosyltransferases, as shown for ARTD8 (PARP14) and ARTD10 (PARP10) (29). 
Moreover, although all identified ARTD family members share the catalytic domain, it 
is not clear whether all proteins are enzymatically active (12). Recent studies provided 
evidence, that ARTD9 and ARTD13 do not posses catalytic activity (29,30). For the 
other members of the ARTD family a catalytic activity was postulated but requires 
experimental validation (12). 
 
1.2.3 Functions of cellular protein ADP-ribosylation 
Cells are constantly exposed to a broad variety of stress situations caused by 
exogenous and endogenous sources. For example, the release of pathogen- or damage-
associated molecular pattern molecules (DAMPs or PAMPs, respectively) induces 
cellular stress responses and often the formation of reactive oxygen species (31-33). A 
common mechanism, which is involved in the regulation of the cellular response to 
oxidative stress is the formation of nuclear PAR (13,34). In addition to its role in the 
cellular stress response, ADP-ribosylation was described to regulate important cellular 
processes such as replication, transcription, chromatin architecture, and telomere 
maintenance (10,34-36). These various processes are regulated through ADP-
ribosylation, which is a rather large and negatively charged PTM. It affects the 
function of the modified proteins as well as the complex formation with other factors 
that are thus direct or indirectly influenced by mono- or poly-ADP-ribosylation (37). 
ADP-ribosylation was described to inhibit protein-protein or protein-nucleic acid 
interactions, leading for example to chromatin decondensation or the release of DNA 
binding proteins from chromatin (38,39). In contrast, ADP-ribose can also serve as a 
scaffold to recruit and build protein complexes, which is well documented by ADP-
ribose binding motifs (see chapter 1.5). Additionally, ADP-ribosylation influences 
other PTMs such as ubiquitination, which results in the degradation of target proteins 
(40). Furthermore, in vitro studies showed, that the acetylation of K16 on histone H4 
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inhibits its ADP-ribosylation, suggesting that both PTMs are competing for histone 
H4K16 modification (41).  
 
1.3 ADP-ribose degradation 
The enzymatic activities that degrade PAR to ADP-ribose and reverse mono-ADP-
ribosylation are currently poorly understood. This is partly due to the difficulty to 
analyze the different ADP-ribose structures (mono- and branched poly-ADP-ribose), 
to identify the different acceptor sites, and to define the chemical linkages within PAR 
and between the ADP-ribose and its acceptor site (42,43). The different linkage types, 
however, strongly suggest that different enzymes (ADP-ribosylhydrolases) likely exist. 
 
1.3.1 Poly-ADP-ribose glycohydrolase (PARG) 
PARG is the best-studied PAR degrading enzyme and comprises at least five isoforms: 
A nuclear 110-111 kDa isoform, three cytoplasmic isoforms with sizes of 102, 99 and 
60 kDa, and a 55 kDa mitochondrial version (44,45). All isoforms result from 
alternative splicing or translation reinitiation of one single gene locus (13,46). PARG 
is the enzyme responsible for the majority of the PAR degrading activity in cells. It 
hydrolyses the 2'–1'' glycosidic ribose-ribose bonds of PAR into free ADP-ribose 
moieties, which can function as second messenger in various compartments of the cell 
or can be recycled into ATP (13,46). Recent structural studies elucidated the 
enzymatic reaction mechanism and identified several moieties that are important for 
PAR binding and hydrolysis (47,48). The terminal ribose of the PAR chain is bound 
by PARG and the ribose-ribose O-glycosidic linkage forms an oxocarbenium 
intermediate with E115 in the catalytic core. Subsequently, a water molecule attacks 
the intermediate, resulting in the release of an ADP-!-ribose’’ (47). The catalytic 
center of PARG was reported to have structural homology to macrodomains (47). Due 
to steric hindrance the protein bound ADP-ribose could not be hydrolyzed by PARG, 
resulting in a mono-ADP-ribosylated protein.  
 Although ARTD1 knockout mice are viable (49), a complete PARG knockout 
in mice (affecting all isoforms) is embryonic lethal, confirming that PAR is formed 
and highlighting crucial physiological and developmental functions (50). This also 
implies that PAR accumulation within the cell is deleterious and thus underlines the 
importance of counteracting PAR formation. In line with this, PARG or ARTD1 
knockout mice show a genomic instability phenotype under genotoxic stress 
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conditions (51-53). In addition and similar to ARTD1 inactivation, inhibition of PARG 
also caused synthetic lethality in BRCA2 deficient tumors (54). 
 
1.3.2 ADP-ribosylhydrolases (ARHs) 
In the early nineties, a new hydrolase for mono-ADP-ribosylated arginine residues was 
purified and characterized (55). It was a 39 kDa protein that was identified as an ADP-
ribosylarginine hydrolase in in vitro experiment and represented the founding member 
of the family of ADP-ribosylhydrolases (ARHs). Later, two more members of this 
family were identified by in silico sequence analysis, named ARH2 and 3 accordingly 
(56). Further studies revealed that ARH1 is indeed a mono-ADP-ribose hydrolase able 
to cleave ADP-ribose-arginine catalyzed by the bacterial cholera toxin (57). In contrast, 
no evidence for an enzymatic activity of ARH2 could be found so far (57). 
Interestingly, ARH3 has no activity towards mono-ADP-ribose modifications, but 
rather degrades PAR in a manner similar to PARG, although most PAR-hydrolyzing 
activity of the cell is assigned to PARG (57,58). As there is no structural similarity 
between the catalytic domains of ARH3 and PARG, but rather between ARH3 and 
ARH1 (56,58), the presence of two independent and different mechanisms of PAR 
degradation in human cells is possible. So far, ARH1 is the only enzyme able to revert 
mono-ADP-ribose of a modified arginine residue, which might be synthesized by 
ARTC family members (56,59,60).! However, since ARH1 and the ARTC are not 
localized in the same cellular compartment, the ARH1 substrate might be synthesized 
by a so far unidentified arginine specific intracellular ART. 
 Very little is known about the biological function of the ARH protein family in 
vivo, but loss of ARH1 rendered mice more prone to tumor formation (61), indicating 
that the balance between ADP-ribose synthesis and degradation is a critical 
mechanism for proper cellular functions and survival. 
 
1.3.3 The mysterious hydrolase/lyase 
Early studies identified an additional protein in rat liver that was able to remove mono-
ADP-ribose but not PAR from histone H2B and H1 (62,63). Even though the reaction 
product seemed to be slightly modified in comparison to ADP-ribose, this so-called 
lyase is a good candidate for an additional family of ADP-ribosylhydrolase. It had a 
size of 83 kDa and was reported to remove ADP-ribose from glutamic acid or lysine 
residues. Unfortunately, no further studies regarding this lyase were published and 
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therefore additional experimental evidence would be required to confirm the existence 
of this potential missing link in the ADP-ribose metabolism. 
 
1.3.4 Nudix box hydrolases 
In humans, an additional family of enzymes able to hydrolyze ADP-ribose exists. In 
contrast to the above mentioned enzymes, the nudix box containing enzymes do not 
remove protein bound ADP-ribose or PAR, but hydrolyze the pyrophosphate bond 
within ADP-ribose, generating AMP and ribose 5-phosphate (64). The nudix 
superfamily is conserved in all kingdoms of life and is defined by its characteristic 23 
amino acid nudix box motif Gx5Ex5[UA]xREx2EExGU, where U is a hydrophobic 
amino acid (64,65). Nudix proteins are pyrophosphohydrolases that act on a variety of 
substrates containing a nucleoside diphosphate linked to another moiety (64). In 
humans, NUDT5 and NUDT9 were shown to be ADP-ribose pyrophosphatases, 
however, NUDT5 is not specific for only ADP-ribose (66-68). Both enzymes were 
suggested to control the free ADP-ribose levels in the cell, thereby protecting proteins 
from non-enzymatic glycation by free ADP-ribose. In contrast, nudix proteins were 
also shown to be affected by cytotoxic agents, leading to an accumulation of free 
ADP-ribose in addition to the enhanced PAR formation under stress (68). 
 
1.4 PARP inhibitors 
The misregulation of ADP-ribosylation is implicated in a broad range of diseases such 
as acute and chronic inflammatory disorders, neurodegenerative and vascular diseases, 
diabetes, age-related diseases as well as several types of cancer (13,34,69). Since 
ARTD1 is by far the most active nuclear ARTD in the cell, many companies started to 
develop inhibitors against ARTD1 as single agents or to potentiate the cytotoxic effect 
of other drugs for cancer therapy (70,71). This class of molecules is known as PARP 
inhibitors, many of which are NAD+ competitors and may thus not only inhibit 
ARTD1 but also other ARTD family members or enzymes using NAD+ as a substrate. 
Most PARP inhibitors are therefore based on NAD+ or nicotinamide analogues that are 
designed to enter the catalytic pocket and block the enzymatic activity. The first 
generation of inhibitors (e.g., 3-aminobenzamide (3-AB)) already proved to have 
therapeutic potential, but was too unspecific and not potent enough to be of medical 
value (72). Recent development of PARP inhibitors led to the chemical synthesis of a 
new inhibitor generation that reach Kd values in the nM range, strongly improving 
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their inhibitory potential. Currently, nine third-generation inhibitors are under 
evaluation and some have already entered phase three clinical trials with promising 
results (72,73). Nevertheless, the use of ADP-ribosylation inhibitors is still a matter of 
debate because different studies showed that many compounds are not specific for a 
certain ARTD family member or inhibit other NAD+ consuming enzymes like Sirtuins. 
In addition, completely unrelated off target effects were observed (71,72).  
 The breakthrough for PARP inhibitors in cancer research occurred when two 
publications demonstrated synthetic lethality of Breast Cancer 1/2 (BRCA1/2) 
deficiency (resulting in cells with impaired homologous recombination (HR)) and 
PARP inhibitors in breast cancer cell lines (74,75). These reports suggested that PARP 
inhibitors could be used as single agents in cancer cell types with a defect in HR 
(69,71,76). The inhibition of ARTD1 on DNA-repair intermediates during DNA repair 
is believed to generate DNA single strand breaks that are converted into double strand 
breaks during replication. As these breaks are not repaired in HR deficient tumors, 
they would eventually lead to cell death (69). Recent reports indicate that also other 
mechanisms might account for the observed synthetic lethality (71,73). 
 Similar to BRCA1/2, also phosphatase and tensin homolog (PTEN) deficient 
tumours are sensitive to PARP inhibitors (77). Despite the early success in the 
treatment of BRCA-deficient cell lines in vitro, many of these tumours resist therapy 
by PARP inhibitors. Recent phase II trials of the PARP inhibitor Olaparib describe 
objective responses of 33% in BRCA-deficient ovarian cancer and 41% in BRCA-
deficient breast cancers (78,79). Although these response rates were significantly 
higher than for cytotoxic chemotherapy, they are lower than observed with other 
targeted therapies, which have tumour response rates of 50-70% (80). Nevertheless, in 
contrast to other current cancer drugs, PARP inhibitors are well tolerated and have 
very low toxic side effects, what makes them a promising tool for future cancer 
therapy. 
 
1.5 Readers of ADP-ribosylation 
Mono- and poly-ADP-ribose modifications not only change the charge and enzymatic 
properties of target proteins, but also recruit a broad range of reader proteins (37). 
These proteins bind the ADP-ribose moieties with subnanomolar to micromolar 
affinities and can thereby be targeted to sites of ADP-ribosylation. So far, four 
different domains that bind mono- or poly-ADP-ribose could be identified (81). PAR-
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binding zinc-fingers (PBZs), WWE domains and PAR-binding motifs (PBMs) are 
poly-ADP-ribose binding modules, whereas macrodomain-containing proteins can 
recognize mono- and/or poly-ADP-ribose (Fig. 4). !
 
1.5.1 The PAR-binding zinc finger (PBZ) 
The PAR-binding zinc finger (PBZ) is a small unordered fold with a zinc-coordinated 
backbone that can interact with one or two ADP-ribose units in a PAR chain and the 
connecting pyrophosphate bond as well as with the "(1->2) O-glycosidic bond 
between the ADP-ribose moieties (Fig. 4) (37,82,83). PBZ domains were so far only 
identified in a few DNA-damage response proteins like aprataxin and PNK–like factor 
(APLF) or in checkpoint with forkhead-associated and RING domains (CHFR) (82,83). 
Both proteins are recruited to sites of DNA damage in a PBZ- and PAR-dependent 
manner. Misregulation of CHFR is implicated in tumor progression most probably due 
to its function in the antephase checkpoint, which is aberrant upon loss of the PBZ 
domain (82,84). 
Figure 4: Binding behavior of ADP-ribose readers. A terminal ADP-ribose (blue), a (n-1) 
ADP-ribose (pink), and the structures recognized by ADP-ribose binding proteins are shown. 
WWE domains bind to the glycosidic bond and the surrounding parts of the two ADP-ribose 
units. PBZs recognize both phosphate groups within an ADP-ribose group as well as the 
adenosine of the proximal and the adenine ring of the distal ADP-ribose. Macrodomains in 
contrast interact with the whole terminal ADP-ribose moiety. Modified from (37). !
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1.5.2 Macrodomain-containing proteins  
The macrodomain is a protein domain consisting of 130-160 amino acids with a mixed 
"/! fold that is conserved from viruses and bacteria to humans and currently over 300 
macrodomain-containing proteins are known (37,85). The first human macrodomain 
was identified in the histone variant called macroH2A (86). Up to now, ten genes 
encoding 14 macrodomain-containing proteins, which harbor one to three folds, were 
predicted by sequence homology in humans (87,88). 
 
The so far best-studied macrodomain containing proteins are the histone variants 
macroH2A1 and macroH2A2, which are involved in X-chromosome inactivation, 
epigenetic silencing and chromatin rearrangement (86,90,91). Misregulation of macro 
H2A1 and macroH2A2 is implicated in melanoma progression and Huntington disease 
(92,93) . The Snf2-like helicase ALC1, which remodels chromatin upon DNA-damage, 
is another example (94). A second group consists of MacroD1, -D2 and -D3 (GDAP2), 
which are small proteins associated to different diseases such as breast cancer, Kabuki 
syndrome and neuroblastoma (95,96). A special group is formed by the macrodomains 
of ARTD7, -8 and -9 (B-aggressive lymphoma: BAL3, -2, -1), because these proteins 
Figure 5: Human macrodomain containing proteins. A representative overview of the human 
macrodomain containing proteins and their domain structure. Modified from (89). 
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contain an ART domain as well as two or three macrodomains, which potentially 
enables them to bind to ADP-ribosylated proteins. They have been implicated in 
lymphoma aggressiveness and survival through inhibition of tumor suppressors via 
interferon and interleukin signaling (30,97,98).  
 A subgroup comprising human ARTD8, MacroD2, and viral SARS-CoV was 
shown to efficiently bind mono-ADP-ribosylated proteins (96,99-101). In contrast, 
PAR binding was observed for human macroH2A1.1 and the macrodomain of ARTD9 
as well as for the viral SFV protein. A third group, able to bind both mono-ADP-ribose 
and PAR, contains human MacroD1, viral HEV, as well as archaeal Af1521 
(96,100,102). Since it was suggested that macrodomains bind to the terminal ADP-
ribose of PAR, it is likely that the differences in the binding of mono- and/or poly-
ADP-ribose are due to steric reasons. 
 Interestingly, some macrodomain proteins also exhibit a catalytic function in 
addition to their ability to bind ADP-ribose. Human MacroD1, MacroD2 and orphan 
macrodomain (C6orf130) as well as E.coli YmdB are able to deacylate O-acetyl-ADP-
ribose (OAADPr) (103,104). OAADPr is the product of a protein deacetylation 
reaction, catalyzed by the NAD+ dependent Sirtuins (105). Macrodomains deacylate 
OAADPr, thereby producing ADP-ribose and acetate (104). Additional properties, 
which are poorly understood and investigated, include binding of OAADPr and 
poly(A) as well as ADPR-1’’P phosphatase activity (87,96).  
 
1.5.3 The WWE domain 
The WWE domain is a globular domain that is defined by two conserved tryptophan 
(W) and a glutamic acid (E) residues and is usually found as single or double domain. 
So far, WWE domains were identified in two protein families; the E3 ubiquitin ligases 
(e.g., RNF146, DELTEX1 or Trip12) and the ARTDs (ARTD8 and ARTD11-14) 
(12,37,106). WWE domains have the ability to interact with iso-ADP-ribose within the 
PAR chain (Fig. 4) (40,106). Some WWE domains have mutations in their binding 
motif that abolish PAR binding, but which might turn them into mono-ADP-ribose 
binders (40,107). Examples are the WWE domains of DDHD2, of ARTD8 and, 
depending on the study, also of ARTD11 that are believed to bind the terminal ADP-
ribose as well as a mono-ADP-ribose modification. The fact that all WWE domain 
containing proteins interact with ADP-ribose and either have ubiquitination activity or 
are members of the ARTD family suggests that both mechanisms are tightly linked 
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and influence each other. For example, ADP-ribosylation could be a signal or 
recruiting factor for E3 ubiquitin ligases that subsequently mark proteins for 
degradation or influence their properties (40). 
 
1.5.4 PAR binding motifs (PBMs) 
The first motif described to interact with PAR was the PAR binding motif (PBM), 
which is found in various proteins of the DNA damage signaling network and in DNA 
repair factors (e.g., p53, XRCC1, MRE11, ATM, Ku70/86 and DNA-PK) 
(22,108,109). The PBM consists of a stretch of amino acids with the sequence: 
[HKR]1-X2-X3-[AIQVY]4-[KR]5-[KR]6-[AILV]7-[FILPV]8 (37,109). The PBM non-
covalently interacts with free PAR in vitro, which could act as a scaffold to recruit 
different DNA-repair proteins or functions as a signaling factor that is sensed by PBM 
domain containing proteins. This mechanism was so far only described in vitro and 
needs to be further validated in vivo. 
 
1.6 ADP-ribose acceptor sites 
In the case of bacterial ARTs, the acceptor amino acids were mapped successfully 
because most toxins modify exactly one protein or a class of proteins at one specific 
residue (19,20) (Table 1). Most sites were indirectly identified by chemical protection 
of potential acceptors, Edman-degradation, thin layer chromatography and other 
chemical methods and later confirmed by site directed mutagenesis (110-112). This 
led to the identification of several sites and the main acceptors are arginine, asparagine, 
diphtamine and cysteine (19). More recently, a study using mass spectrometry 
identified threonine 148 of actin and glutamine 61 and 63 of RhoA as ADP-ribose 
acceptors modified by P. luminescens, leading to actin clustering (113). 
 Despite substantial efforts, the identification of the amino acids that are 
modified in mammals by a distinct ARTD has not been possible. The acceptor sites for 
PAR in mammals were first characterized over thirty years ago based on the chemical 
properties and stability of the modification on ARTD1, the core histones and linker 
histone H1 (114-116). As the majority of the analyzed ADP-ribose modifications (over 
70%) were sensitive to alkali and neutral NH2OH, but stable to acid, a carboxylester 
linkage was suggested (Table 2) (116). Such a linkage points to glutamate and 
aspartate residues as acceptors, which was believed for many years without further 
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validation. The remaining 30% of the modifications were, however, NH2OH resistant 
and 15% were even alkaline resistant, clearly indicating that other linkages must exist  
(115).    
 
 
Indeed, a few years later, experiments with two mammalian ARTCs from avian 
erythrocytes confirmed that NH2OH resistant and alkali stable fraction represent an 
ADP-ribose arginine linkage (116-118). Based on these findings, it was postulated that 
NH2OH resistant mono-ADP-ribose on arginine residues is used for further elongation 
by ARTs that synthesize PAR (116).  
 More recent work using site directed mutagenesis studies of ARTD1 identified 
lysine residues as acceptors (119). In contrast, site directed mutagenesis for ARTD10 
identified glutamates as acceptors sites (29). As these studies are either correlative or 
relying on mutagenesis experiments that can potentially alter protein structures and 
therefore introduce a bias, mass spectrometry methods were of need to pinpoint ADP-
ribosylation on specific amino acids (see chapter 1.7.4). 
 Moreover, the linkages within PAR or between ADP-ribose and the acceptor 
residue can potentially be of different chemical nature and therefore exhibit different 
biochemical properties. The ribose 5-phosphate of ADP-ribose has three potential 
linkage acceptors, which are the OH-groups at C-1, C2 and C-3 (114). Preliminary 
studies suggested an attachment at C-1 in the case of modified glutamates, but these 
results were only indicative and not conclusively proven (114). In contrast, mono-
ADP-ribosylation of arginines was analyzed by NMR and could be identified as C-1 
linked (120). Furthermore, it was shown that the enzymatic reaction results in an 
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acetylations, methylations and phosphorylations [13]. Other
post-translational modifications of histone tails include ADP-
ribosylation, biotinylation, O-GlycNAcylation, sumoylation or ubiq-
uitination, which may all contribute to the histone code and to
epigenetic regulation [14,15].
Overall, only a small fraction of all histone proteins (less than
1%) are ADP-ribosylated [16–18]. Experiments with histones
purified from rat liver nuclei and from HeLa cells show that all his-
tone proteins (H1, H2A, H2B, H3 and H4) can be modified, although
the modifying ART was not identified [19–21]. Histone ADP-
ribosylation is suggested to be a covalent modification [18] with
primarily ADP-ribose monomers or short oligomers rather than
with long polymers [19]. Depending on the chromatin composi-
tion, the ADP-ribosylation pattern of histone proteins varies. While
histone H1 is the main ADP-ribose acceptor in native chromatin,
histone H2B is the most ribosylated histone in H1-depleted
chromatin [22]. In addition, differential modification of histones
may also reflect changes in the accessibility of different histones
due to altered chromatin structure, for example following DNA
fragmentation [23]. This is confirmed by the observation that
histones in nucleosomes proximal to the site of attack by micrococ-
cal nuclease were found to be extensively ADP-ribosylated [21].
Furthermore, ARTD1 is able to ribosylate the five individual his-
tone proteins in vitro [24–29]. In contrast to ARTD1, ARTD2 (for-
mally called PARP2) is unable to modify single histones in vitro
[26]. ARTD3 (PARP3) interacts with histones H2B and H3, but it
is not clear whether ARTD3 is able to modify these histones [30].
Recently, it was shown that ARTD3 can ADP-ribosylate histone
H1.2 in vitro [31]. ARTD10 (formally called PARP10) is localized
in the cytoplasm and the nucleus and was shown to mono-
ADP-ribosylate core histones [32–34]. Other members of the ARTD
family have not yet been tested and characterized for their ability
and specificity to modify histones.
3. ADP-ribose acceptor sites and linkages in histones
The core histones are predominantly poly-ADP-ribosylated at
their basic amino-terminal region that protrudes from the nucleo-
some [19,35]. Specific glutamic acid residues in histones H1 and
H2B, as well as the C-terminal lysine residue of H1, were reported
as ADP-ribose acceptors [36–38], but these findings have not been
confirmed by mass spectrometry and the ARTs responsible for
these modifications have not been determined. More recently, it
was shown by mass spectrometry and electron-transfer dissocia-
tion (ETD) that specific lysine residues in the tails of H2A (K13),
H2B (K30), H3 (K27 and K37) and H4 (K16) can be modified by
ARTD1 [26]. ETD is a fragmentation technique of protonated pep-
tides by electron transfer from radical anions and is particularly
suited for the analysis of protein modifications because it is less
likely to cause the removal of side chains (e.g. ADP-riboses or phos-
phate groups) than conventional collision-induced dissociation
(CID) mass spectrometry [26,39,40].
Extraction of isolated and precipitated ADP-ribosylated histones
results in an acid soluble histone fraction likely comprised of mono-
ADP-ribosylated proteins and an acid insoluble fraction of poly-
ADP-ribosylated histones [41]. The chemical linkages in both of
these fractions are alkali labile and in some cases also susceptible
to neutral hydroxylamine [18,42,43]. This difference in the suscepti-
bility to neutral hydroxylamine suggests the presence of both ester-
and ketamine bonds [5,23,44] (Table 1). The same types of linkages
are suspected in crude chromatin and in isolated nuclei [8,45].
4. Degradation of the ADP-ribose modification
The importance of poly-ADP-ribose turnover is highlighted by
the fact that deletion of the major poly-ADP-ribose glycohydrolase
(PARG) in Drosophila and mouse leads to embryonic lethality
[46,47]. However, the proteins and reactions that reverse the
poly-ADP-ribose modification are only little understood despite
this essential function. The fact that not all ADP-ribose acceptor
sites have been characterized and different types of linkages occur
complicates the study of putative ADP-ribose degrading enzymes.
In human, only three ADP-ribosyl hydrolases (ARHs) and one
poly-ADP-ribose glycohydrolase (PARG) have been described so
far [48–51]. The poly-ADP-ribose polymer can be degraded by
PARG and ARH3, which hydrolyze glycosidic bonds between two
ADP-ribose units, thus releasing ADP-ribose moieties from the
polymer [51]. An ADP-ribosyl prote n lyase exhibiti g activity
towards glutamic acid linked ADP-ribosyl moieties has been once
reported, but this protein has not been cloned yet [51–53]. The
only enzyme that was shown to release the primary ADP-ribose
moiety from the protein acceptor is ARH1, which cleaves off a
mon -ADP-ribose from arginine residues [48]. It is not known if
ARH1 is able to hydrolyze the ADP-ribose-lysine linkage and other
enzymes hydrolyzing this ketamine-bond have neither been de-
scribed. Depending on the particular amino acid residue that is
modified (e.g. lysine), a mono-ADP-ribose moiety may t us remain
on the protein and serve as a stable long-term epigenetic mark.
5. Proteins that read the ADP-ribose code
Proteins that decipher the ADP-ri ose code and induce changes
in chromatin structure are an important component of the histone
code concept. Recently, two types of protein modules that specifi-
cally interact with poly-ADP-ribose in vivo have been identified
(Fig. 1). A short 20-amino acid motif comprised of mainly basic
and hydrophobic amino acids present in important DNA damage
checkpoint proteins was also shown to bind poly-ADP-ribose in
vitro, but this interaction has so far not been confirmed in vivo
[54,55].
Macrodomains are highly conserved globular modules with
high affinity for ADP-ribose [56]. The histone variant macroH2A
occurs in three isoforms (macroH2A1.1, macroH2A1.2 and
macroH2A2), of which only the macroH2A1.1 isoform binds ADP-
ribose in vitro, specifically recognizing terminal ADP-riboses [57].
In combination with activated ARTD1, macroH2A1.1 seems to
adapt gene expression to different metabolic states of the cell by
chromatin compaction and looping of chromosome regions [57].
Similarly, the macrodomain containing protein ALC1 (Amplified
in Liver Cancer 1) is targeted to sites poly-ADP-ribose accumula-
tion and stimulated upon poly-ADP-ribose binding [57–59].
Poly-ADP-ribose binding zinc finger (PBZ) domains are neces-
sary for the function of CHFR (checkpoint protein with FHA and
RING domains) in antephase checkpoint control and for targeting
APLF (C2orf13/PALF/XIP1) to sites of chromosome damage
[60,61]. Interestingly, APLF contains two tandem PBZ domains,
which synergize in their binding to multiple ADP-riboses of the
poly-ADP-ribose chain [62]. Despite the identification of several
proteins that recognize the ADP-ribose modification, important
Table 1
ADP-ribose can either be linked to the negatively charged acceptors glutamic and
aspartic acid via ester bonds or to positively charged arginine or lysine residues
(ketamine bonds).
Ketamine bond Ester bond
Treatment
Hydroxylamine Resistant Highly sensitive
Alkali Partially resistant Highly sensitive
Acid Partially sensitive Partially sensitive
Examples ADP-ribose–arginine ADP-ribose–glutamic acid
ADP-ribose–lysine ADP-ribose–aspartic acid
1596 M.O. Hottiger / FEBS Letters 585 (2011) 1595–1599
Author's personal copy
acetylations, methylations and phosphorylations [13]. Other
post-translational modifications of histone tails include ADP-
ribosylation, biotinylation, O-GlycNAcylation, sumoylation or ubiq-
uitination, which may all contribute to the histone code and to
epigenetic regulation [14,15].
Overall, only a small fraction of all histone proteins (less than
1%) are ADP-ribosylated [16–18]. Experiments with histones
purified from rat liver nuclei and from HeLa cells show that all his-
tone proteins (H1, H2A, H2B, H3 and H4) can be modified, although
the modifying ART was not identified [19–21]. Histone ADP-
ribosylation is suggested to be a covalent modification [18] with
primarily ADP-ribose monomers or short oligomers rather than
with long polymers [19]. Depending on the chromatin composi-
tion, the ADP-ribosylation pattern of histone proteins varies. While
histone H1 is the main ADP-ribose acceptor in native chromatin,
histone H2B is the most ribosylated histone in H1-depleted
chromatin [22]. In addition, differential modification of histones
may also reflect changes in the accessibility of different histones
due to altered chromatin structure, for example following DNA
fragmentation [23]. This is confirmed by the observation that
histones in nucleosomes proximal to the site of attack by micrococ-
cal nuclease were found to be extensively ADP-ribosylated [21].
Furthermore, ARTD1 is able to ribosylate the five individual his-
tone proteins in vitro [24–29]. In contrast to ARTD1, ARTD2 (for-
mally called PARP2) is unable to modify single histones in vitro
[26]. ARTD3 (PARP3) interacts with histones H2B and H3, but it
is not clear whether ARTD3 is able to modify these histones [30].
Recently, it was shown that ARTD3 can ADP-ribosylate histone
H1.2 in vitro [31]. ARTD10 (formally called PARP10) is localized
in the cytoplasm and the nucleus and was shown to mono-
ADP-ribosylate core histones [32–34]. Other members of the ARTD
family have not yet been tested and characterized for their ability
and specificity to modify histones.
3. ADP-ribose acceptor sites and linkages in histones
The core histones are predominantly poly-ADP-ribosylated at
their basic amino-terminal region that protrudes from the nucleo-
some [19,35]. Specific glutamic acid residues in histones H1 and
H2B, as well as the C-terminal lysine residue of H1, were reported
as ADP-ribose acceptors [36–38], but these findings have not been
confirmed by mass spectrometry and the ARTs responsible for
these odifications have not been determined. More recently, it
was shown by mass spectrometry and electron-transfer dissocia-
tion (ETD) that specific lysine residues in the tails of H2A (K13),
H2B (K30), H3 (K27 and K37) and H4 (K16) can be modified by
ARTD1 [26]. ETD is a fragmentation technique of protonated pep-
tides by electron transfer from radical anions and is particularly
suited for the analysis of protein modifications because it is less
likely to cause the removal of side chains (e.g. ADP-riboses or phos-
phate groups) than conventional collision-induced dissociation
(CID) mass spectrometry [26,39,40].
Extraction of isolated and precipitated ADP-ribosylated histones
results in an acid soluble histone fraction likely comprised of mono-
ADP-ribosylated proteins and an acid insoluble fraction of poly-
ADP-ribosylated histones [41]. The chemical linkages in both of
these fractions are alkali labile and in so e cases also susceptible
to neutral hydroxylamine [18,42,43]. This difference in the suscepti-
bility to neutral hydroxylamine suggests the presence of both ester-
and ketamine bonds [5,23,44] (Table 1). The same types of linkages
are suspected in crude chromatin and in isolated nuclei [8,45].
4. Degradation of the ADP-ribose modification
The importance of poly-ADP-ribose turnover is highlighted by
the fact that deletion of the major poly-ADP-ribose glycohydrolase
(PARG) in Drosophila and mouse leads to embryonic lethality
[46,47]. However, the proteins and reactions that reverse the
poly-ADP-ribose modification are only little understood despite
this essential function. The fact that not all ADP-ribose acceptor
sites have been characterized and different types of linkages occur
complicates the study of putative ADP-ribose degrading enzymes.
In human, only three ADP-ribosyl hydrolases (ARHs) and one
poly-ADP-ribose glycohydrolase (PARG) have been described so
far [48–51]. The poly-ADP-ribose polymer can be degrad d by
PARG and ARH3, which hydrolyze glycosidic bonds between two
ADP-ribose units, thus releasing ADP-ribose moieties from the
polymers [51]. An ADP-ribosyl protein lyase exhibiting activity
towards glutamic acid linked ADP-ribosyl moieties has been once
reported, but this pro ein ha not been clone yet [51–53]. The
only enzyme that was shown to release the primary ADP-ribose
moiety from the protein acceptor is ARH1, which cleaves off a
ono-ADP-ribose from arginine residues [48]. It is not known if
ARH1 is abl to hydrolyze the ADP-ribose-lysine linkage and other
enzymes hydrolyzing this ketamine-bond have neither been de-
scribed. Depending on the particular amino acid residue that is
modified (e.g. lysine), a mono-ADP-ribose moiety may thus remain
on the protein and serve as a stable long-term epigenetic mark.
5. Proteins that read the ADP-ribose code
Proteins that decipher the ADP-ribose code and induce changes
in chromatin structure are an important component of the histone
code concept. Recently, two types of protei modules that sp cifi-
cally interact with poly-ADP-ribose in vivo have been identified
(Fig. 1). A short 20-amino acid motif comprised of mainly basic
and hydrophobic amino acids present in important DNA damage
checkpoint proteins was also shown to bind poly-ADP-ribose in
vitro, but this interaction has so far not been confirmed in vivo
[54,55].
Macrodomains are highly conserved globular modules with
high affinity for ADP-ribose [56]. The histone variant macroH2A
occurs in three isoforms (macroH2A1.1, macroH2A1.2 and
macroH2A2), of which only the macroH2A1.1 isoform binds ADP-
ribose in vitro, specifically recognizing terminal ADP-riboses [57].
In combination with activated ARTD1, acroH2A1.1 seems to
adapt gene expression to different metabolic states of the cell by
chromatin compaction and looping of chromosome regions [57].
Similarly, the macrodomain containing protein ALC1 (Amplified
in Liver Cancer 1) is targeted to sites poly-ADP-ribose accumula-
tion and stimulated upon poly-ADP-ribose binding [57–59].
Poly-ADP-ribose binding zinc finger (PBZ) domains are neces-
sary for the function of CHFR (checkpoint protein with FHA and
RING domains) in antephase checkpoint control and for targeting
APLF (C2orf13/PALF/XIP1) to sites of chromosome damage
[60,61]. Interestingly, APLF contains two tandem PBZ domains,
which synergize in their binding to multiple ADP-riboses of the
poly-ADP-ribose chain [62]. Despite the identification of several
proteins that recognize the ADP-ribose modification, important
Table 1
ADP-ribose can either be linked to the negatively charged acceptors glutamic and
aspartic acid via ester bonds or to positively charged arginin or lysine residues
(ketamine bonds).
Ketamine bond Ester bond
Treatment
Hydroxylamine Resistant Highly sensitive
Alkali Partially resistant
cid s n itive Partially sensitive
Examples ADP-ribose–arginine ADP-ribose–glutamic acid
lysi e aspartic acid
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Table 2: Chemical stability of ADP-rib se bonds. ADP-ribose can be linked to acceptor 
amino acids via ketamine bonds (arginine) or ster bonds (gluta ic and aspartic acid). The 
two linkages result in different stabilities towards certain chemicals. Modified from (35). 
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ribosyl-guanidinium linkage in " conformation, which undergoes anomerization to a ! 
linkage in a 1:1 ratio under physiological conditions (120). All these results illustrate 
the high complexity of ADP-ribosylation. The specific types of linkages have 
potentially far reaching biological implications, since they may affect the interaction 
with other proteins as well as the removal of different modifications by ADP-
ribosylhydrolases. 
 
1.6.1 Non-enzymatic, covalent ADP-ribosylation 
While research has focused on enzymatically catalyzed ADP-ribosylation, a covalent, 
non-enzymatic ADP-ribosylation has also been described (121,122). ADP-ribose is a 
potent histone glycation and glycoxidation agent in vitro (121). Glycation is the 
covalent binding of an ADP-ribose molecule through Schiff base formation to lysine 
residues, which is stable upon treatment with hydroxylamine. Incubation of ADP-
ribose with histones H1, H2A, H2B, and H4 in vitro at pH 7.5 and 37°C over night 
resulted in the formation of ketoamines derived from a Schiff base by an Amadori 
rearrangement (121,123,124). In the case of an Amadori rearrangement the attached 
ADP-ribose would be linked via a C1 linkage (124). Based on the long incubation time, 
which is substantially longer than common incubation times of ADP-ribosylation 
reactions, glycation needs to be considered in vivo if very high concentrations of free 
ADP-ribose are generated from NAD+ or PAR.  
 
1.7 Toward identifying the ADP-ribosylome 
The tools to study ADP-ribosylation are currently very limited. Especially the lack of 
suitable antibodies for mono-ADP-ribosylation or for site-specific modifications 
restricts the analysis of ADP-ribosylation. Until now, most studies that identified 
ADP-ribosylated proteins and their ADP-ribose acceptor sites were performed in a 
targeted manner, analyzing only a few candidate proteins. It is therefore of great 
importance to establish new methods for the analysis of ADP-ribosylated proteins and 
the identification of their modification acceptor sites. Advances in proteomics 
technologies, especially in mass spectrometry (MS), and the use of ADP-ribose 
readers as tools to purify or enrich ADP-ribosylated proteins recently opened new 
possibilities to study this complex protein modification and broaden our horizon in 
terms of the ADP-ribosylome. 
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1.7.1 Identification of ADP-ribosylated proteins by protein microarrays 
Protein microarrays are a first option to study protein interactions and modifications in 
large scale and have been already successfully applied for the identification of kinase 
substrates (125). Recently, two studies utilized ProtoArrays® covering around 8’000 
proteins immobilized on glass slides to identify target proteins for ARTD2, ARTD8 
and ARTD10 (126,127). In both cases, recombinant ARTDs were used to in vitro 
modify the spotted proteins with biotinylated-NAD+ and modified proteins were 
subsequently visualized by fluorescent labeling of the biotin moiety in NAD+. Of the 
8’000 spotted proteins, 51 were ARTD2 substrates, 142 were ARTD8 substrates and 
78 proteins were modified by ARTD10. Among the identified proteins were already 
known targets, confirming the applicability of the protein microarray for ADP-
ribosylation target identification. As protein microarrays are only applicable for in 
vitro approaches, alternative techniques such as mass spectrometry are key to obtain 
further insights in cellular ADP-ribosylation. !
1.7.2 Enrichment strategies for ADP-ribosylated proteins  
Since the fraction of modified proteins is usually in the low digit percentage range, 
researchers commonly use antibodies or enrichment strategies specific for certain 
PTMs. This reduces the complexity of the cell lysate, enables the purification of the 
modified proteins or peptides, and the subsequent identification of the proteins and 
modification sites by mass spectrometry. One prominent example is the well-studied 
phospho-proteome (128,129). Due to the availability of only one antibody against 
PAR and the lack of good antibodies against mono-ADP-ribosylated proteins, 
alternative methods for the identification of ADP-ribosylated proteins had to be 
established. Up to now, three studies employing different methods aimed to identify 
the ‘ADP-ribosylome’. The first study made use of the above-described macrodomain 
Af1521 and its ability to bind ADP-ribosylated proteins, which were enriched, 
separated by SDS-PAGE, and analyzed by mass spectrometry (130). To reduce the 
background, a non-binding mutant of Af1521 was used in a pre-clearing step. This 
method led to the identification of ADP-ribosylated proteins, including previously 
known targets such as ARTD1, Elongation factor-1-" and GDH1. However, the fact 
that the binding occurred under native conditions allowed also an indirect enrichment 
of proteins by binding to PARylated proteins. This together with less than 20 
identified proteins limits the relevance of this analysis.  
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A second, more elegant study used a clickable analogue of NAD+ (6-alkyne-NAD) for 
the identification of ARTD1 substrate proteins (131). ARTD1 knockdown lysates were 
supplemented with ARTD1 and 6-alkyne-NAD, which was subsequently conjugated 
to Biotin-N3 in a click chemistry reaction and modified proteins were purified with 
streptavidin and analyzed by mass spectrometry. This assay identified over 70 proteins, 
with a partial overlap to the earlier described study. However, this procedure might be 
biased by the NAD analogue that is spiked into the lysate, which does not represent 
cellular conditions and might be prone to the identification of false positive hits.  
 A third study utilized the commonly used monoclonal PAR-binding antibody 
10H (132) to enrich poly-ADP-ribosylated proteins from cellular extracts (109). To 
increase the amount of ADP-ribosylated proteins, PARG knockdown cells were 
additionally treated with 100 µM N-methyl-N’-nitro-N’-nitro-soguanidine (MNNG) to 
induce genotoxic stress. Modified proteins were enriched by immunoprecipitation 
using the 10H antibody, under conditions still allowing indirect complex formations, 
and afterwards separated by SDS-PAGE. This procedure led to the identification of 
over 300 PAR-associated proteins with various cellular functions. The majority 
comprised proteins involved in DNA damage response, DNA- and RNA metabolism 
and regulation as well as cell death and cell-cycle regulation (109). This study 
increased the number of identified PAR interacting proteins tremendously, but could 
unfortunately not fully distinguish between poly-ADP-ribosylated proteins and 
proteins that are forming a complex with modified proteins. Additionally, mono-ADP-
ribosylated proteins could not be identified due to the fact that the 10H antibody binds 
only poly- and not oligo- and mono-ADP-ribose modifications (132). 
 
1.7.3 Detecting ADP-ribosylated peptides by MS/MS 
As PAR is very complex due to its length and the branched structure, the detection by 
MS/MS is very challenging. Especially as ADP-ribose is unstable upon conventional 
CID fragmentation, which results in undefined and variable modification masses, 
proper database searches are not possible. To overcome this drawback, the complexity 
of PAR can be reduced by different methods. The pre-treatment of the samples with 
PARG reduces the modification to one protein-bound ADP-ribose moiety. A second 
option is the use of mutant ARTD enzymes that are only able to catalyze mono-ADP-
ribosylation, resulting in defined modification masses. A third possibility is the 
enzymatic reduction of ADP-ribose (e.g., phosphodiesterbond within ADP-ribose), 
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which would reduce the complexity further and generate a defined chemical group for 
identification by MS.  
 Recent studies reduced the complexity of PARylation by using a mutated 
ARTD1 carrying an E to Q mutation at position 988, which hinders PAR formation, 
making ARTD1 E988Q an inefficient mono-ADP-ribosyltransferase (133,134). With 
this approach D387, E488 and E491 within the automodification domain of the 
ARTD1 E988Q mutant could be identified as auto-ADP-ribosylation sites by CID 
mass spectrometry (135).  
 Another recent study analyzed the in vitro automodification of ARTD1 by 
cleaving the pyrophosphate bond of ADP-ribose by phosphodiesterase 1 (PDE1) in 
vitro. This reaction reduces the complexity of the modification and turns it into a 
chemically more stable group (i.e., phospho-ribose). The newly formed terminal 
phosphate group was used to enrich modified peptides with conventional 
phosphopeptide enrichment strategies. This study identified several glutamic acid as 
well as lysine residues in ARTD1 as potential acceptors, however, the unambiguous 
annotation of the exact modification site was not possible due to lacking sequence 
information in the CID spectra (136). !
1.7.4 Identification of ADP-ribosylation acceptor sites by MS/MS 
Earlier studies on ADP-ribosylated substrates revealed that the site identification with, 
at this time, state-of-the-art mass spectrometry techniques was not possible (137). 
Furthermore, detailed studies on the fragmentation behavior of ADP-ribose and 
modified peptides revealed that the modification is almost completely fragmented 
under conventional MS conditions using collision-induced dissociation (CID) (138). 
Although the fragmentation profile generates always the same fragments (Figure 6), 
with ions indicative for ADP-ribosylated peptides, the peptide backbone fragmentation 
with CID is too weak to gain enough information for peptide sequence and 
modification site determination. The identification of the acceptor site within a 
modified peptide by CID-MS remained therefore challenging. 
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Recently, novel fragmentation techniques for the identification of ADP-ribosylated 
peptides by MS have been established. Electron capture dissociation (ECD) is a 
nonergonic process, leading to a high proportion of random peptide backbone 
cleavages during fragmentation (140). This process is especially suited for highly 
charged peptides since it leads to the stabilization of labile PTMs on the peptide and to 
a better c and z ion series, which allows better sequence assignments (141). When 
ECD was applied to a chemically ADP-ribosylated standard peptide containing only 
arginine as a potential acceptor, the modification as well as its site could be annotated, 
underlining the power of this method (138). A second fragmentation method that uses 
a comparable chemistry to ECD is electron transfer dissociation (ETD). The advantage 
of ETD is its better availability and accessibility due to lower machine costs (142). 
ETD was also successfully applied to chemically ADP-ribosylated peptides and more 
complex protein mixtures and enabled the identification of modified arginine as well 
as lysine residues (143,144). The first study that used ETD to detect ADP-ribosylation 
sites on histones that were enzymatically modified by ARTD1 in vitro identified lysine 
residues as acceptors and thereby showed the robustness of the ETD approach (41). 
 A third recently introduced fragmentation technique is higher energy collisional 
dissociation (HCD) (145). The advantage of HCD over CID is a better coverage of the 
whole mass range and the ability to acquire MS and MS/MS spectra at high resolution, 
thereby recording smaller fragment ions, which leads to better sequence and PTM 
assignment (146,147). Therefore, HCD could be a useful tool for ADP-ribosylation 
studies, but has not been yet evaluated.  
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$" Figure 6: Nomenclature of ADP-ribose fragments. The fragments are defined as described by 
Hengel et al. (138). The ADP-ribose ions showing strong signals in the HCD MS/MS spectra are 
shown (m1, m3, m6, m8, m10). Modified from (139). 
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2 AIM OF THE THESIS 
ADP-ribosylation is an important post-translational modification with many cellular 
functions and implications in various human diseases. All above described studies 
revealed that the investigation of the ADP-ribosylome is still at an early development 
state. The two most aggravating limitations are the identification of ADP-ribose 
acceptor sites as well as the lack of enzymes that are able to reverse the mono-ADP-
ribosylation.  
 It was therefore the aim of this thesis to define the ADP-ribose acceptor amino 
acids that are modified by ARTD1 and ARTD10 by mass spectrometry and to identify 
as well as biochemically characterize proteins that are able to remove protein-bound 
mono-ADP-ribose. 
 !
 !  
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3 RESULTS 
3.1 Overview of published manuscripts        
3.1.1 Identification of distinct amino acids as ADP-ribose acceptor sites by mass           
           spectrometry 
 
Authors: Florian Rosenthal, Simon Messner, Bernd Roschitzki, Peter Gehrig, 
Paolo Nanni and Michael O. Hottiger 
Journal: Methods Mol Biol. 2011;780:57-66. 
Contributions: Planning, performing and evaluating the experiments. Preparation of 
the figures and drafting of the manuscript. PG and PN helped to plan 
and perform the MALDI and LC-MS/MS experiment respectively. 
SM and BR gave technical input. 
 
3.1.2 Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases 
 
Authors: Florian Rosenthal*, Karla L H Feijs*, Emilie Frugier, Mario Bonalli, 
Alexandra H Forst, Ralph Imhof, Hans C. Winkler, David Fischer, 
Amedeo Caflisch, Paul O. Hassa, Bernhard Lüscher and Michael O. 
Hottiger 
* equal contribution 
Journal: Nat Struct Mol Biol. 2013 Apr;20(4):502-7 
Contributions: Performing and evaluating the experiments. In particular in vitro de-
ADP-ribosylation experiments including kinetics and inhibition 
experiments (Figures 1b-f,i; 2a-c; 3c; Suppl. Figures 1b,c,e-f; 2c; 
3b,c), product analysis by HPLC and LC-MS/MS (Figures 2f,g; Suppl. 
Figures 2b,d), preparation of the figures and revision of the 
manuscript. !
3.1.3 Inheritance of silent rDNA chromatin is mediated by PARP1 via 
noncoding RNA 
 
Authors: Claudio Guetg, Fabian Scheifele, Florian Rosenthal, Michael O. 
Hottiger and Raffaella Santoro 
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Journal: Mol Cell. 2012 Mar 30;45(6):790-800 
Contributions: Enrichment of poly-ADP-ribosylated nucleolar proteins by 
aminophenyl boronate affinity chromatography (Figure 6d). 
 
3.1.4 Crosstalk between SET7/9-dependent methylation and ARTD1-mediated  
          ADP-ribosylation of histone H1.4 
 
Authors: Ingrid Kassner, Marc Barandun, Monika Fey, Florian Rosenthal and 
Michael O. Hottiger 
Journal: Epigenetics Chromatin. 2013 Jan 5;6(1):1 
Contributions: In vitro poly-ADP-ribosylation time course of ARTD1 and histones 
(Suppl. Figure 1). 
 
3.2 Overview of submitted manuscripts !
3.2.1 Identification of ADP-ribosylation sites in cell extracts by higher energy    
          collisional dissociation (HCD)-based mass spectrometry 
 
Authors: Florian Rosenthal*, Paolo Nanni*, Simon Barkow-Oesterreicher and 
Michael O. Hottiger 
* equal contribution 
Journal: Manuscript submitted 
Contributions: Planning, performing and evaluating all experiments with input and 
technical support of PN and SBO. 
 
3.2.2 Proteome-wide Identification of Poly(ADP-ribosyl)ation targets in different 
           Genotoxic Stress Responses 
 
Authors: Stephanie Jungmichel, Florian Rosenthal, Michael O. Hottiger and 
Michael L. Nielsen 
Journal: Manuscript submitted 
Contributions: In vitro poly-ADP-ribosylation assay with ARTD1 and ARTD1 on 
candidate proteins from the SILAC screen (Figure 6d).  
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Chapter 4
Identification of Distinct Amino Acids as ADP-Ribose 
Acceptor Sites by Mass Spectrometry
Florian Rosenthal, Simon Messner, Bernd Roschitzki, Peter Gehrig,  
Paolo Nanni, and Michael O. Hottiger
Abstract
ADP-ribosylation is a well-known post-translational protein modification, which regulates a variety of 
 cellular processes. The proteins able to catalyze mono- or poly ADP-ribosylation of proteins belong to the 
family of ADP-ribosyltransferases. A variety of nuclear proteins has been described to be ADP-ribosylated, 
including ARTD1 itself and histone proteins. Despite intensive research during the last 40 years, the accep-
tor amino acids in ARTD1 or histone proteins could be identified and confirmed only recently by MS/MS 
and by site-directed mutagenesis. The establishment of a standardized protocol including the specific 
enrichment of ADP-ribosylated proteins and peptides and subsequent mass spectrometric analysis allows 
the identification of ADP-ribose acceptor sites of modified proteins and to address the functional contribu-
tion of ADP-ribosylation in vitro as well as in vivo.
Key words: ARTD1, ADP-Ribosylation, Electron transfer dissociation, Boronic acid, Enrichment
ADP-ribosyltransferase diphtheria toxin-like 1 [ARTD1, formerly 
called poly(ADP-ribose) polymerase 1 (PARP1)) is a nuclear 
 partially chromatin-associated protein that is present in most 
eukaryotes apart from yeast (1, 2). ARTD1 is responsible for the 
main formation of nuclear polymers of ADP-ribose (PAR) using 
NAD+ as substrate. ARTD1 has been suggested to catalyze at least 
three different enzymatic reactions: the attachment of the first 
ADP-ribose moiety onto an acceptor amino acid (initiation reaction), 
the addition of further ADP-ribose units onto already existing ones 
(elongation reaction), and the generation of branching points 
1. Introduction
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(branching reaction). PAR acceptor proteins include a variety of 
nuclear proteins, most prominently ARTD1 itself, as well as  histone 
proteins (3).
In initial studies, glutamic acid residues of histone H1 and 
H2B were suggested to be acceptors of ADP-ribose in vivo due to 
the chemical properties of the linkage (4, 5). Despite intensive 
research during the last 40 years, the acceptor amino acids of 
ARTD1 or other proteins could not been identified by MS/MS 
or confirmed by site-directed mutagenesis. However, intensive 
site-directed mutagenesis studies of the automodification domain 
of ARTD1 and ARTD2 revealed recently that individual lysine 
residues of these domains function as acceptor sites for auto-ADP-
ribosylation (6). Furthermore, studies utilizing novel protocols 
that involve electron transfer mass spectrometry, identified for the 
first time by MS/MS several lysine residues in peptides represent-
ing the core histone tails to be ADP-ribosylated in vitro by ARTD1 
(7). The identification of acceptor sites of large proteins or pro-
tein complexes requires the enrichment of ADP-ribosylated poly-
peptides with boronic acid resins, to first reduce the complexity of 
the samples and second to facilitate the identification by mass 
spectrometry. Thus, the establishment of standardized protocols 
including the specific enrichment of ADP-ribosylated proteins 
and peptides and subsequent MS/MS analysis allows the identifi-
cation of ADP-ribose acceptor sites of modified proteins and to 
address the functional contribution of ADP-ribosylation in vitro 
as well as in vivo.
 1. hARTD1 is expressed and purified from insect cells as carboxyl-
terminal His-tagged protein and stored in liquid nitrogen.
 2. hPARG is expressed and purified from insect cells as carboxyl-
terminal His-tagged protein and stored in liquid nitrogen.
 3. ?-Nicotinamide adenine dinucleotide hydrate (NAD+), >99% 
(Sigma–Aldrich) is dissolved in Milli-Q water at 10 mM and 
aliquots are stored at −20°C.
 4. Histone mix from calf thymus (Roche) is dissolved in Milli-Q 
water at 1 ?g/?L and aliquots are stored at −80°C.
 5. Biotinylated peptides representing histone tails; H2A (aa 
3–23), H2B (aa 18–37), H3 (aa 23–42), H4 (aa 1–22), or 
H4K16ac (aa 1–22) are custom synthesized by PiProteomics 
and dissolved in Milli-Q water at 1 ?g/?L and aliquots are 
stored at −80°C.
 6. ARTD1 inhibitor 3-aminobenzamide (3AB), 97% (Sigma– 
Aldrich).
2. Materials
2.1. ADP-Ribosylation 
Assays
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 7. ADP-ribosylation buffer: 50 mM Tris–HCl pH 8.0, 4 mM 
MgCl2, 250 ?M DTT, 1 ?g/mL protease inhibitors pepstatin, 
leupeptin, and bestatin. Always prepare fresh ADP-ribosylation 
buffer.
 1. Sequencing grade, modified trypsin (Promega) is reconstituted 
to a final concentration of 0.1 ?g/?L in 50 mM acetic acid and 
stored at −80°C.
 2. Endoproteinase Glu-C sequencing grade (Roche) is reconsti-
tuted to a final concentration of 0.1 ?g/?L in Milli-Q water 
and stored at −80°C.
 3. Trypsin digestion buffer: 50 mM Tris–HCl pH 8.0, 1 mM 
CaCl2, 5% acetonitrile.
 4. Glu-C digestion buffer: 25 mM Ammonium bicarbonate, 5% 
acetonitrile.
 1. Boronic acid resin: Prosep-PB affinity resin (Millipore).
 2. Binding/wash buffer: 250 mM Ammonium acetate, 50 mM 
MgCl2, 100 mM Tris–HCl, 500 mM NaCl (pH 8.8) (see 
Note 1).
 3. Wash buffer: 250 mM Ammonium acetate, 50 mM MgCl2 
(pH 8.8).
 4. Elution buffer: 0.1 M Acetic acid.
 1. Reversed-phase ?-C18 ZipTips (for MALDI-MS) and C18 
ZipTips (for LC-ESI-MS/MS) (Millipore).
 2. Wetting solution: 80% acetonitrile in H2O or 50% MeOH in 
H2O.
 3. Wash solution: 0.1% TFA in H2O.
 4. Elution solution: 50% MeOH, 0.1% TFA in H2O (see Note 2).
 1. MALDI matrix solution 1: 4 mg ?-cyano-4-hydroxycinnamic 
acid in 1 mL of 0.3 mM di-ammonium hydrogen citrate 
(Fluka), 60% acetonitrile in H2O.
 2. MALDI matrix solution 2: 10 mg of 2,5-dihydroxybenzoic 
acid in 1 mL of 70% acetonitrile in H2O.
 3. Instrumentation: 4800 MALDI TOF/TOF system (AB 
Sciex).
 1. HPLC solvent A: 1% acetonitrile, 0.2% formic acid in H2O.
 2. HPLC solvent B: 80% acetonitrile, 0.2% formic acid in H2O.
 3. Self-made capillary tip column (0.075 mm ID × 100 mm), col-
umn material: reverse phase Magic C18, AQ, 3 ?m, 200 Å.
 4. Instrumentation: LTQ-Orbitrap XL ETD (Thermo Scientific), 
Eksigent nanoHPLC 1D plus (Eksigent Technologies).
2.2. Protease Digestion
2.3. Protein and 
Peptide Enrichment
2.4. ZipTip Desalting
2.5. MALDI TOF/TOF 
Mass Spectrometry
2.6. LC-MS/MS 
Analysis
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The generally low abundance of ADP-ribosylated proteins 
 (estimated to be <1% for histones) is a drawback in the assignment 
of modification sites. We therefore recommend to enrich ADP-
ribosylated proteins or peptides and optimized the usage of boronic 
acid-based resins (8). The protocol allows the accumulation of 
modified substrates and increases the possibilities of a successful 
analysis, including site determination.
The heterogenic nature of the modification, reaching from 
mono- to branched poly-ADP-ribose makes it particularly difficult 
to identify the ADP-ribose acceptor sites. It is thus necessary to 
reduce the complexity of different PAR chain lengths by treatment 
with poly(ADP-ribose) glycohydrolase (PARG) before subsequent 
analysis by mass spectrometry. Moreover, the predominantly used 
fragmentation method in mass spectrometry, collision induced 
 dissociation (CID), is a useful tool for the detection of ADP-
ribosylated peptides but lacks sufficient peptide backbone fragmen-
tation to identify the acceptor amino acid (9). Recent advances in the 
field of mass spectrometry led to the utilization of electron capture 
dissociation (ECD) and electron transfer dissociation (ETD). 
These fragmentation methods preserve labile post-translational 
modifications on their targets (10) and therefore allow the identi-
fication of ADP-ribosylation and the determination of the modifi-
cation site (9, 11).
 1. For in vitro ADP-ribosylation of histones incubate 3 ?g  histone 
mix or 22 nmol biotinylated histone peptides with 10 pmol 
hARTD1 in the presence of 5 pmol annealed double-stranded 
oligomer (5?-GGAATTCC-3?) and 100 or 150 ?M NAD+ in 
ADP-ribosylation buffer (see Note 3).
 2. Reaction volume: 25 ?L, reaction conditions: 15 min, 30°C.
 3. Terminate the reactions by the addition of 3AB to a final 
 concentration of 20 mM.
 4. To reduce the complexity of PAR, samples are incubated 
 additionally with 1 ?g hPARG, to generate mainly mono-ADP-
ribosylated polypeptides. Adjust the concentrations of MgCl2 
to 10 mM, NaCl to 50 mM and incubate at 37°C for 1 h.
 5. For the identification of acceptor sites in peptides proceed 
immediately with step 3 of Subheading 3 or ZipTip-desalting 
and mass spectrometry. Intact modified proteins need to be 
proteolytically cleaved prior to mass spectrometry either before 
or after enrichment.
 1. Adjust the buffer conditions in the sample to the ones described 
for the relevant protease in the Subheading 2.
3. Methods
3.1. ADP-Ribosylation 
Assays
3.2. Protease Digestion
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 2. Reduce the disulphide bridges by adding DTT to a final 
 concentration of 10 mM and incubate for 1 h at 65°C (see 
Note 4).
 3. Alkylate cysteines by adding iodoacetamide to a final concen-
tration of 50 mM and incubate for 1 h at room temperature in 
the dark.
 4. To block the reaction, add DTT to a final concentration of 
50 mM and incubate for 10 min at room temperature.
 5. Add trypsin or Glu-C in a 1:50 ratio (w/w). Incubate the 
Glu-C digests at 25°C to avoid autolysis. Reaction time should 
be 4–12 h. The trypsin digests should be incubated at 37°C for 
1–4 h (see Note 5).
 6. Proceed either with peptide enrichment or ZipTip-desalting 
and mass spectrometry.
 1. Use 15 ?L of a slurry of Prosep-PB resin per binding reaction 
and wash the beads in 1 mL binding/wash buffer (see Note 6).
 2. Spin resins at 4°C for 1 min at 600 × g and discard the 
supernatant.
 3. Resuspend the equilibrated beads in 1 mL binding/wash buf-
fer containing the ADP-ribosylated samples. Incubate at 4°C 
for 1 h under constant rolling.
 4. Spin beads at 4°C for 1 min at 600 × g and discard the 
supernatant.
 5. Wash the beads twice in 1 mL binding/wash buffer at 4°C for 
10 min.
 6. Wash the beads once in 1 mL wash buffer at 4°C for 10 min.
 7. Spin beads at 4°C for 1 min at 600 × g and completely discard 
the supernatant.
 8. Resuspend the beads in 200 ?L elution buffer and incubate at 
4°C for 15 min under constant rolling.
 9. Spin at 4°C for 1 min at 600 × g and save the supernatant con-
taining the ADP-ribosylated peptides or proteins.
 10. Repeat steps 8 and 9 once and pool the supernatants.
 11. Spin the pooled supernatants in a vacuum concentrator till 
dryness (see Note 7). Store dried samples at −20°C or proceed 
with ZipTip-desalting and mass spectrometry. An example 
result of a peptide enrichment experiment is shown in Fig. 1.
 1. Depress pipettor plunger to a dead stop. Using the maximum 
volume setting of 10 ?L, aspirate wetting solution into the tip. 
Dispense to waste and repeat the procedure three times.
 2. Aspirate the wash solution, dispense to waste, and repeat the 
step three times.
3.3. Enrichment  
of ADP-Ribosylated 
Peptides
3.4. ZipTip Desalting
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 3. Bind peptides to ZipTip by fully depressing the pipette plunger 
to a dead stop. Aspirate and dispense the sample ten times for 
maximum binding of the peptides.
 4. Aspirate wash solution into the tip and dispense to waste. 
Repeat once.
 5. For MALDI-analysis. Elute the bound samples directly into 
matrix solution on the target plate. Pipette approximately 
0.7 ?L of MALDI matrix solution onto the target plate by 
using a regular pipette tip. Aspirate and dispense matrix  solution 
through the ZipTip three times without introducing air into 
the sample (caution: acetonitrile evaporates rapidly).
 6. For LC-MS/MS-analysis. Elute the bound samples in 20 ?L 
 elution solution. Aspirate and dispense the elution solution five 
times and save it in a new vial. Spin the eluted samples in a 
Fig. 1. MALDI-MS spectra of synthetic peptides that represent parts of the N-terminal tails of all four core histones. 
Peptides were modified according to Subheading 3.1. (a) Mass spectrum showing the masses of the input sample with 
mainly unmodified histone peptides. (b) Mass spectrum of the same sample after the procedure explained in Subheading 3.3. 
The enrichment generates a sample with highly abundant modified peptides. To increase the sensitivity, MALDI-MS was 
performed in linear mode. ADPR = ADP-ribose.
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vacuum concentrator till dryness. The dry samples can be stored 
at −20°C or proceed with mass spectrometry (see Note 7).
 1. MALDI analyses are performed on a 4800 MALDI TOF/
TOF system equipped with a Nd:YAG laser operating at 
200 Hz. Mass spectra are acquired in positive reflector mode 
or linear mode in the mass range from 500 to 4,000 Da and 
generated by accumulating data from 2,000 laser shots (see 
Note 8). In order to preserve the unstable bonds of ADP-
ribosylated amino acid residues and to reach the optimal values 
for general peptide analyses the laser intensity is reduced by 
approximately 200 arbitrary units.
 2. First, mass spectra are recorded from peptide standards and 
the default calibration parameters are updated. Subsequently, 
mass spectra are acquired for all sample spots on the MALDI 
target plate and calibrated using the default calibration 
parameters.
 1. Peptide solutions are analyzed on a LTQ-Orbitrap XL ETD 
instrument connected to an Eksigent nanoHPLC 1D plus. 
4 ?L of peptide mixtures are injected by an autosampler on a 
self-made reverse phase tip column for 16 min with a flow rate 
of 500 nL/min. The peptide elution is performed with a flow 
rate of 200 nL/min and a linear gradient from 3 to 48% 
 acetonitrile in 36 min. The acetonitrile concentration is raised 
to 80% in 4 min and the column is cleaned with 80% acetonitrile 
for 7 min.
 2. The eluting peptides are analyzed on an Orbitrap with a reso-
lution of 60,000 at m/z 400, at a target value of 5 × 105 and 1 
micro scan. MS/MS is performed in the linear ion trap with a 
target value of 1 × 104 in data-dependent decision tree mode, 
using the following criteria to trigger ETD fragmentation (see 
Note 9): charge state is 3 and the m/z is less than 650, charge 
state is 4 and the m/z is less than 900, charge state is 5 and the 
m/z is less than 950. For higher charge states ETD is per-
formed per default (see Note 10).
 3. Fluoranthene is used as anion with target value of 1 × 105 (see 
Note 11) and reaction time is set to 100 ms (see Note 12) with 
additional supplemental activation. Maximum injection time 
for both MS and MS/MS was set to 300 ms.
 1. For database searches mgf-files with mascot generic format are 
created by the use of Mascot Distiller 2.3 with standard 
Orbitrap opt-file (see Note 13).
 2. The search is done with a human database with common con-
taminants (117865 sequences) and a concatenated decoy database. 
3.5. MALDI TOF/TOF 
Mass Spectrometry
3.6. LC-MS/MS 
Acquisition
3.7. Database Search
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The peptide tolerance (see Note 14) is set to 5 ppm and the 
MSn tolerance to 0.6 Da. For the synthetic peptides, biotin is 
defined as fixed modification at the peptide N terminus. ADP-
ribosylation on lysine, arginine, cysteine, and glutamic acid 
residues is defined as variable modification without neutral loss 
during fragmentation (see Note 15).
 1. These buffer conditions are optimized for synthetic histone 
peptides. Therefore, the concentrations of Tris–HCl and NaCl 
might need further adjustments for given peptides.
 2. Note that MALDI-MS samples can be directly eluted onto the 
MALDI sample plate in MALDI matrix solution (see 
Subheading 3.4, step 5).
 3. Higher NAD+ concentrations can trigger the generation of 
very long ADP-ribose polymers that might interfere with trans-
ADP-ribosylation or subsequent analysis.
 4. Subheading 3.2, steps 2–4 are not absolutely necessary for the 
proteolytic cleavage of histone proteins but might be crucial in 
case of other target proteins.
 5. The trypsin/protein ratio and the incubation time result in an 
incomplete cleavage of the substrate proteins. Due to the high 
abundance of lysines and arginines in histone proteins, a com-
plete cleavage would lead to very short peptides that are no 
longer suitable for ETD mass spectrometry.
 6. The enrichment protocol with the Prosep-PB resin can also be 
adapted for the use in liquid chromatography.
 7. Avoiding complete dryness increases peptide recovery.
 8. Due to the labile nature of the modification, minor ADP-
ribosylation is significantly better detectable in linear mode.
 9. The use of supplemental activation largely decreases charge 
reduced precursor signals in the MS/MS and allows a better 
assignment of fragment masses.
 10. If precursor signal intensity is very weak but the m/z ratio is 
known, MS/MS can be specifically acquired on that m/z value 
over the entire LC-MS run to achieve good data quality. It has 
to be assured, that the corresponding charge state for correct 
supplemental activation is selected.
 11. In some cases it is beneficial to increase the anion population 
to 3 × 105 target value.
4. Notes
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 12. For precursor masses with known charge state it is beneficial to 
optimize the activation time for better fragmentation efficiency.
 13. If CID and ETD data are saved in one LC-MS/MS RAW file 
it is necessary to choose the “no-merge” option in the 
Mascot Distiller option file. Otherwise the more intense CID 
fragment masses will cover all usually less intense ETD 
 fragment masses.
 14. If you choose to acquire MS/MS on a specific precursor  signal 
over the complete LC-MS run, you have to modify the 
header of the extracted peak list (e.g., mgf file) manually 
with the correct monoisotopic precursor mass and the  correct 
charge state.
 15. In some cases for data-dependent acquisition of higher charge 
states the second isotope (13C) is chosen as precursor. 
In that case it is advantageous to allow the Mascot search 
engine to use the second isotope by setting the isotope error 
to 1.
It is important to note that, in contrast to other reports, 
we observed partial fragmentation of the ADP-ribose at the 
phosphodiester bond by application of ETD, as revealed by 
the presence of a m/z 348 ion, which corresponds to adenos-
ine monophosphate. However, conventional collision induced 
dissociation (CID) mass spectrometry of ADP-ribosylated 
H4 peptide did not reveal any ADP-ribose acceptor sites, 
since the ADP-ribose was cleaved off from the peptide during 
fragmentation. The commonly used CID, instead of ETD, 
might thus explain why numerous efforts to identify ADP-
ribosylated residues failed in the past. Consequently, we 
would strongly recommend ETD as standard technique for 
future investigations on ADP-ribosylated peptides, opening 
new opportunities to screen for modified residues in a 
 systems-biology setup.
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ADP-ribosylation is a PTM involved in many biological processes 
including the regulation of chromatin structure, transcription and 
DNA repair1–6. ARTD10 is a mono-ADP-ribosyltransferase that 
transfers ADP-ribose to aspartate or glutamate residues by substrate-
assisted catalysis7. Recently, GSK3? was identified as a new substrate 
of ARTD10. Mono-ADP-ribosylation noncompetitively inhibits 
GSK3? kinase activity8.
Although many ADP-ribosyltransferases (including ARTDs and 
ADP-ribosyltransferases cholera toxin-like (ARTCs)) that ADP-
ribosylate different amino acid acceptor sites have been identified9, 
the enzymes able to reverse this modification are largely unknown. 
Irreversible ADP-ribosylation is highly detrimental and causes embry-
onic lethality10,11. In humans, the deficiency of an ADP-ribose hydro-
lase is the cause of fatal glutamyl ribose 5-phosphate storage disease12. 
Therefore, enzymes that remove ADP-ribose modifications must 
exist. The mammalian hydrolases characterized so far include the 
mono-ADP-ribosylarginine hydrolase 1 (ARH1) as well as poly-ADP-
ribose glycohydrolases (PARG and ARH3). Whereas ARH1 is the only 
hydrolase that specifically removes mono-ADP-ribose from arginine 
residues, ARH3 and PARG hydrolyze the O-glycosidic ribose-ribose 
1-2? bonds within ADP-ribose polymers13,14. In contrast, enzymes 
catalyzing the removal of specific mono-ADP-ribose marks of modi-
fied aspartates or glutamates, such as those synthesized by ARTD10, 
are currently unknown (Supplementary Fig. 1a).
Macrodomains are a family of evolutionarily conserved proteins that 
bind mono- or poly-ADP-ribose (PAR), poly(A) or O-acetyl-ADP-ribose 
(OAADPr)15–18. Macrodomain proteins are involved in diverse cel-
lular processes15 and have been implicated in transcriptional regula-
tion19–22, chromatin remodeling23,24 and developmental processes 
as well as in B-cell lymphomagenesis25–27. Macrodomain-containing 
proteins localize to the nucleus (for example, MacroD1v2) or to mito-
chondria (MacroD1v1) or are found in the cytoplasm (MacroD1v2, 
MacroD2 or C6orf130)18. In addition to the binding of ADP-ribose, the 
human MacroD1, MacroD2 and C6orf130 possess C2- or C3-specific 
OAADPr deacetylase activity28,29 and weak C1-specific phosphatase 
activity toward ADP-ribose-1?-phosphate (Appr-1?-p), a product of 
ARTD18 (TPT1) and cyclic nucleotide phosphodiesterases17,30,31. On 
the basis of structural and functional analyses, several residues in the 
active centers of macrodomains were identified that participate in 
the catalytic mechanism28,29. Notably, the catalytically important resi-
dues of MacroD1 are not conserved in C6orf130, which indicates that 
sequence variation within the macrodomain family allows a different 
set of catalytic residues to perform OAADPr hydrolysis29.
Here we test the hypothesis that macrodomain-containing proteins 
possess ADP-ribosylhydrolase activity and thereby to characterize 
the missing mono-ADP-ribosylhydrolases. We provide evidence that 
the human proteins MacroD1, MacroD2 and C6orf130 as well as the 
archaebacterial macrodomain Af1521 are able to hydrolyze ARTD10-
catalyzed mono-ADP-ribosylation. Notably, MacroD2 rendered the 
inhibitory effect of GSK3? ADP-ribosylation reversible. Treatment 
with MacroD2 removed the ADP-ribose moiety from GSK3?, which 
was sufficient to restore kinase activity in vitro and in cells. These 
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Macrodomain-containing proteins are new mono-ADP-
ribosylhydrolases
Florian Rosenthal1,2,6, Karla L H Feijs3,6, Emilie Frugier4, Mario Bonalli1, Alexandra H Forst3, Ralph Imhof1, 
Hans C Winkler1, David Fischer5, Amedeo Caflisch4, Paul O Hassa1, Bernhard Lüscher3 & Michael O Hottiger1
ADP-ribosylation is an important post-translational protein modification (PTM) that regulates diverse biological processes.  
ADP-ribosyltransferase diphtheria toxin-like 10 (ARTD10, also known as PARP10) mono-ADP-ribosylates acidic side chains and  
is one of eighteen ADP-ribosyltransferases that catalyze mono- or poly-ADP-ribosylation of target proteins. Currently, no enzyme 
is known that reverses ARTD10-catalyzed mono-ADP-ribosylation. Here we report that ARTD10-modified targets are substrates 
for the macrodomain proteins MacroD1, MacroD2 and C6orf130 from Homo sapiens as well as for the macrodomain protein 
Af1521 from archaebacteria. Structural modeling and mutagenesis of MacroD1 and MacroD2 revealed a common core structure  
with Asp102 and His106 of MacroD2 implicated in the hydrolytic reaction. Notably, MacroD2 reversed the ARTD10-catalyzed, 
mono-ADP-ribose–mediated inhibition of glycogen synthase kinase 3b (GSK3b) in vitro and in cells, thus underlining the 
physiological and regulatory importance of mono-ADP-ribosylhydrolase activity. Our results establish macrodomain-containing 
proteins as mono-ADP-ribosylhydrolases and define a class of enzymes that renders mono-ADP-ribosylation a reversible modification.
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data highlight the important physiological 
function of endogenous mono-ADP-ribo-
sylation for intracellular signaling and regu-
latory processes.
RESULTS
Macrodomain proteins are mono-ADP-ribosylhydrolases
To investigate whether macrodomain-containing proteins are able 
to release the mono-ADP-ribose moiety from ARTD10-modified 
target proteins, we incubated different macrodomains with in vitro–
radiolabeled mono-ADP-ribosylated ARTD10 (full length or the 
catalytic domain, consisting of residues 818–1025) as a substrate 
(Fig. 1a,b and Supplementary Fig. 1b,c). Human MacroD1, MacroD2 
and C6orf130 robustly hydrolyzed the mono-ADP-ribosyl linkage 
of modified full-length ARTD10 or the ARTD10 catalytic domain. 
Notably, the structurally related archaebacterial macrodomain pro-
tein Af1521 was also active, whereas neither the human histone vari-
ant MacroH2A1.1 nor the mouse macrodomains 1 or 2 of ARTD8 
(PARP14) were able to remove mono-ADP-ribose under the tested 
conditions (Fig. 1a,b and Supplementary Fig. 1b,c). Pulldown 
experiments revealed that mono-ADP-ribosylhydrolase activity of 
the tested macrodomains correlated with the ability to bind mono-
ADP-ribosylated ARTD10 (Supplementary Fig. 1d). In contrast to 
their activity toward mono-ADP-ribosylated substrates, MacroD1 
and MacroD2 were each completely inactive toward PAR synthesized 
by ARTD1 (PARP1) in the presence of high NAD+ concentrations, 
whereas the known PAR hydrolase PARG exhibited strong activ-
ity toward this substrate (Fig. 1c). However, PARG was not able to 
completely remove all ADP-ribose modifications from automodified 
ARTD1, even when tested under low NAD+ concentrations (result-
ing in mono- and oligo-ADP-ribosylation; Supplementary Fig. 1e 
and as suggested in ref. 13). The nature of the modified protein did 
not affect PARG-dependent hydrolysis, because histones modified 
by ARTD1 under low NAD+ concentrations were also not com-
pletely demodified (Supplementary Fig. 1f). Notably, prior PARG 
treatment rendered ARTD1, histone H1 and core histones at least 
partially susceptible to hydrolysis by MacroD2 (Supplementary 
Fig. 1f,g), which suggests that the acceptor residue and/or the link-
age (C1 versus C2 or C3) between the ADP-ribose moiety and the 
acceptor residue are critical for the newly identified enzymatic 
activity. Consequently, PARG treatment probably generates mono-
ADP-ribosylated residues that serve as substrates for hydrolysis 
by MacroD2. Comparably, PARG was inactive toward ARTD10- 
catalyzed mono-ADP-ribosylated histone H1, whereas MacroD2 
demodified this substrate, irrespective of PARG treatment (Fig. 1d). 
These results suggested that MacroD2 is able to release mono- 
ADP-ribose from acceptor proteins but is inactive toward polymers 
or oligomers of ADP-ribose.
To biochemically characterize the enzymatic reaction catalyzed by 
MacroD2, we performed concentration- and time-dependent experi-
ments. MacroD2 efficiently removed ADP-ribose modifications from 
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Figure 1 MacroD1, MacroD2, C6orf130 
and Af1521 hydrolyze mono-ADP-ribose 
modifications. (a,b) Protein mono-ADP-
ribosylhydrolase activity of MacroD1, MacroD2, 
C6orf130, mouse ARTD8 (mMacro1 and 
mMacro2), macroH2A1.1 and Af1521.  
Auto-ADP-ribosylated ARTD10 de-ADP-
ribosylated by the indicated proteins is shown 
on SDS-PAGE with Coomassie blue (CB) 
staining or autoradiography (32P). Shown are 
representative blots and quantification from 
two independent experiments, averaged and 
normalized to the untreated control (n = 2; 
mean ? range). (c) Hydrolase activity assays 
showing that MacroD-like macrodomains  
have no activity toward polymers of ADP- 
ribose, whereas PARG has strong activity.  
Auto-poly-ADP-ribosylated ARTD1 (with  
160 ?M radioactive NAD+ to induce poly-
ADP-ribosylation) was used with the indicated 
hydrolases. (d) Activity assays as in a, showing 
that PARG cannot hydrolyze ADP-ribose  
from mono-ADP-ribosylated ARTD10 or  
from histones. (e) Concentration-dependent 
removal of the mono-ADP-ribose from ARTD10  
(818–1025) by MacroD2 under nonsaturating  
conditions. (f) Time course of MacroD2 activity 
toward mono-ADP-ribosylated ARTD10 catalytic 
domains. (g) Identification of cofactors (1 mM 
each) for ADP-ribose hydrolysis by MacroD2. 
(h) Effect of ADP-ribose and nicotinamide 
(40 ?M each) on MacroD2-mediated de-ADP-
ribosylation of ARTD10. (i) The ADP-ribose 
analog ADP-HPD inhibits MacroD2 in a 
concentration-dependent manner (4, 40  
and 400 ?M).
np
g
© 
20
13
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
39
504 VOLUME 20 NUMBER 4 APRIL 2013 NATURE STRUCTURAL & MOLECULAR BIOLOGY
A R T I C L E S
ARTD10 (818–1025) in a concentration-dependent manner (Fig. 1e). 
Furthermore, mono-ADP-ribose hydrolysis by MacroD2 was time 
dependent and removed >60% of the modifications within 15 min 
(Fig. 1f). Further characterization of the enzymatic activity revealed 
that MacroD2 activity was not markedly affected by the addition of 
magnesium, calcium or manganese as cofactor (Fig. 1g). Notably, 
MacroD2 activity was inhibited by the addition of the ADP-ribose 
analog adenosine 5?-diphosphate (hydroxymethyl) pyrrolidinediol 
(ADP-HPD) and by ADP-ribose itself in a concentration-dependent 
manner, whereas addition of nicotinamide did not influence the 
mono-ADP-ribosylhydrolase activity (Fig. 1h,i). These observations 
indicated that free ADP-ribose is able to inhibit the mono-ADP-ribose 
hydrolyzing activity by competing with protein-linked mono- 
ADP-ribose for binding to the active site. Together, these experi-
ments thus defined MacroD1, MacroD2, C6orf130 and Af1521 as new 
specific mono-ADP-ribosylhydrolases.
MacroD2 is a mono-ADP-ribosylhydrolase for acidic residues
To define the specificity of MacroD2 mono-ADP-ribosylhydrolase 
activity, we characterized and analyzed different substrates. Hydroxyl-
amine treatment was reported to remove ADP-ribose from glutamate 
and arginine residues32. Treatment of ARTD10 with hydroxylamine 
for 60 min at 37 °C released the modification of the enzyme, as already 
observed earlier (Fig. 2a and ref. 7), which suggests that MacroD2 
is able to hydrolyze mono-ADP-ribose from acidic acceptor sites or 
arginine. To further investigate whether MacroD2 removed ADP-
ribose from arginine acceptor amino acids, the arginine-specific 
ADP-ribosyltransferase CDTa was used33. MacroD2 showed no 
activity toward actin modified by CDTa (Fig. 2b), which indicates 
that modified arginine residues cannot be hydrolyzed by MacroD2. 
In contrast, the arginine-specific hydrolase ARH1 was able to remove 
the ADP-ribose from arginine-modified ?- or ?-actin but was not able 
to remove ADP-ribose from ARTD10 (Fig. 2c), which confirms that 
ARTD10 is not modified at arginine residues. Actin modified at thre-
onine residues by the threonine-specific transferase TccC3 (ref. 34) 
could not be demodified by either ARH1 or MacroD2 (Fig. 2b). To 
exclude that lysine residues were modified by ARTD10 and consecu-
tively demodified by MacroD2, we mutated all ARTD10 lysine residues 
to arginines. This mutant (ARTD10-?K) showed reduced ADP-
 ribosylation activity toward both itself and GSK3?, a newly identified 
ARTD10 target (Fig. 2d and Supplementary Fig. 2a), which indicated 
that mutation of these lysine residues interferes with the enzymatic 
activity of ARTD10. However, the inactive mutant ARTD10-G888W-
?K could be modified in trans by the catalytic domain of ARTD10 to 
a comparable extent as ARTD10-G888W (Fig. 2e), thus implying that 
lysines are not the acceptor sites. Of note, ARTD10-?K and ARTD10-
G888W-?K were still demodified by MacroD2 to a comparable 
extent as were wild-type ARTD10 or ARTD10-G888W, respectively 
(Fig. 2d,e), which suggests that the same residues (for example, aspar-
tates or glutamates) are automodified in ARTD10-?K and wild-type 
ARTD10 and consecutively demodified by MacroD2. In conclusion, 
these results suggested that MacroD2 probably releases ADP-ribose 
from ADP-ribosylated acidic residues.
To confirm that MacroD2 removes ADP-ribose from its tar-
get protein, the reaction products were analyzed by LC-MS and 
HPLC. Upon incubation of ARTD10 with MacroD2, a product that 
eluted at the same time as the ADP-ribose standard and had the 
expected mass of 558.064 Da was detected, thus showing that 
MacroD2 indeed removed ADP-ribose from ARTD10 (Fig. 2f,g and 
Supplementary Fig. 2b–d).
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Figure 2 MacroD2 is a mono-ADP-ribosylhydrolase specific for aspartates  
and glutamates. (a) Demodification of mono-ADP-ribosylated ARTD10  
by hydroxylamine treatment. SDS-PAGE analysis of in vitro–labeled  
ARTD10 demodified by MacroD2, PARG or hydroxylamine. (b,c) Quantification  
of ADP-ribosylhydrolase assays with different substrates, analyzed by  
SDS-PAGE. The mean ? range is shown (n = 2). MacroD2 does not  
remove ADP-ribose modifications generated by the arginine-specific  
enzyme CDTa (gray bars) or TccC3 (white bars) (b), and ARH1  
does not demodify mono-ADP-ribosylated ARTD10 (c). (d) ADP-ribosylation  
assay with [32P]-NAD+ and subsequent incubation with MacroD2. Samples  
are immunoprecipitates of overexpressed hemagglutinin (HA)-tagged  
HA-ARTD10 or HA-ARTD10-?K. (e) Trans-ADP-ribosylation by the  
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contrast is shown to visualize immunoprecipitated HA-ARTD10.  
(f) Extracted ion chromatograms of mass 558.064, the monoisotopic  
mass of the ADP-ribose [M-H] adduct. The elution time window of ADP-ribose was between 6 and 7 min. (g) MS-MS spectrum of mass 558.064. Typical 
mass fragments of ADP-ribose as seen in the ADP-ribose standard (top spectrum) are present in the MS-MS spectrum of ARTD10 + MacroD2 samples 
(bottom spectrum).
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Modeling of MacroD2 and of residues implicated in catalysis
Homology modeling and atomistic simulations were carried out to 
shed light on the hydrolysis reaction mechanism. First, the three-
dimensional structure of MacroD2 was modeled by using the X-ray 
structure of MacroD1 as a template (Fig. 3a). Except for their flexible 
loops, the human MacroD1, MacroD2 and C6orf130 structures are 
highly similar, as emerges from their superposition (Fig. 3b). This 
structural likeness, along with their similar enzymatic activities, 
suggested a conserved mode of action.
Second, the ADP-ribose product of the hydrolysis reaction was 
automatically docked to MacroD2 and followed by multiple explicit 
solvent molecular dynamics simulations of the complex to validate 
the binding mode. The mono-ADP-ribosylhydrolase activity was 
then studied by mutational analysis of MacroD2 and by comparison 
with existing mutants of MacroD1 (ref. 29) because these two 
macrodomain-containing proteins are closely related.
To confirm that the hydrolase activity of MacroD2 is dependent 
specifically on the macrodomain, we mutated the conserved glycine 
at position 100 of MacroD2 (Supplementary Fig. 3a) to a glutamate, 
which is predicted to block the ADP-ribose–binding site in macrodo-
main proteins35, or to an isoleucine. The resulting MacroD2 mutants 
lacked hydrolase and ADP-ribose–binding activity under the same assay 
conditions, which provided evidence that the macrodomain is respon-
sible for the catalytic activity toward ARTD10-mediated mono-ADP- 
ribosylation and that the interaction with ADP-ribose is specific (Fig. 3c,d 
and data not shown). Notably, MacroH2A1.1 contains a glutamate at 
the corresponding position 225 instead of a glycine (Supplementary 
Fig. 3a), which possibly explains its inactivity due to its inability to 
bind mono-ADP-ribosylated ARTD10. However, although mutation 
of Glu225 of MacroH2A1.1 to a glycine resulted in a gain of binding, 
it did not restore its enzymatic activity (Supplementary Fig. 3b), thus 
indicating that additional residues are important for the activity.
Multiple explicit solvent molecular dynamics simulations of the 
MacroD2–ADP-ribose complex, together with defining conserved resi-
dues between MacroD1, MacroD2 and C6orf130, was used to propose 
site-specific mutants of MacroD2. Of particular note were Asp102 and 
its buried neighbor His106, which by modeling were predicted to be 
located near the 2- and 3-hydroxyl groups of the distal ribose (Fig. 3e). 
Mutational analysis, guided by the in silico predictions, indicated par-
tial involvement in catalysis of Asp102 and His106 of MacroD2 as 
well as Asp184 and His188 of MacroD1 (Fig. 3c and Supplementary 
Fig. 3c). Pulldown experiments revealed that the MacroD2 mutants 
were still able to bind mono-ADP-ribosylated ARTD10 under the 
conditions tested for their enzymatic activity but that increasing the 
salt concentration to 500 mM reduced their affinity to the substrate to 
some extent (Supplementary Fig. 3d). On the basis of our findings, 
a model emerges for MacroD2-catalyzed hydrolysis of mono-ADP-
ribosylated aspartate or glutamate residues (Fig. 3f). In this model, 
which is similar to the one previously suggested for the hydrolysis 
of OAADPr by MacroD1 (ref. 28), Asp102 or Asp184 acts as a 
general base that deprotonates a water molecule, which then acts 
as a nucleophile to attack the carbonyl carbon. We note that our 
mutagenesis data do not exclude participation of additional residues 
and/or transition-state stabilization due to induced fit.
MacroD2 regulates GSK3b function in vitro and in cells
GSK3? is a key regulator in processes ranging from cell structure and 
survival to diseases such as Alzheimer’s disease, cancer and diabetes36, 
and it was recently identified in a screen for ARTD10 target proteins 
(ref. 8 and Supplementary Fig. 2a). To address whether the ARTD10-
catalyzed ADP-ribosylation of GSK3? is reversible (in addition to 
the observed ribosylation of ARTD10 and histones (Figs. 1a,b,d 
and 2e)), the ADP-ribosylhydrolase activity of MacroD2 on GSK3? 
was analyzed. Notably, MacroD2 removed the ADP-ribosylation from 
both ARTD10 and GSK3? in vitro (Fig. 4a). These findings support 
the notion that ARTD10-mediated mono-ADP-ribosylation of tar-
get proteins in general is a reversible PTM. To test whether removal 
of the inhibitory mono-ADP-ribose by MacroD2 is sufficient to 
restore GSK3? kinase activity, mono-ADP-ribosylated GSK3? was 
demodified by MacroD2 and consecutively used in kinase assays 
with a primed peptide substrate. Although the ADP-ribosylated 
protein showed little in vitro kinase activity compared to the control, 
de-ADP-ribosylation restored the GSK3? activity (Fig. 4b).
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(n = 2; mean ? range). (d) ADP-ribose binding to wild-type (WT) and 
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To address whether MacroD2 also reversed ARTD10-mediated 
ADP-ribosylation in cells, HA-GSK3? was coexpressed with the 
fluorescently tagged DsRed-ARTD10 alone or together with GFP-
MacroD2, and subsequently immunoprecipitated and included in 
a kinase assay (Fig. 4c). The presence of MacroD2 enhanced the 
kinase activity of GSK3?, which suggested that MacroD2 antagonized 
the ARTD10-mediated inactivation of GSK3? without affecting 
protein expression (Fig. 4d). These data indicated that MacroD2 
hydrolyzes mono-ADP-ribosyl linkages in cells, thus rendering 
mono-ADP-ribosylation a dynamic modification that can regulate 
the activation or inactivation of proteins such as GSK3?.
DISCUSSION
The biochemical experiments, mutational analyses and structural pre-
dictions presented here suggest that certain macrodomain-containing 
proteins such as MacroD1, MacroD2, C6orf130 or Af1521, but neither 
the macrodomains 1 and 2 of ARTD8 nor macroH2A1.1, are bona fide 
protein mono-ADP-ribosylhydrolases. These results thus fill a major 
gap in understanding of the ADP-ribosylation cycle and define these 
proteins as new mono-ADP-ribosylhydrolases that reverse the PTM 
catalyzed by ARTD10.
The Appr-1??-p phosphatase activity and the OAADPr-hydrolyzing 
activity of macrodomain proteins have been previously described and 
studied28–30. OAADPr represents an ADP-ribose that is O-acetylated 
at the C2 or C3 atom, whereas the PAR chain features C1 linkages37–39. 
The OAADPr hydrolysis by MacroD-like macrodomains suggests that 
these proteins hydrolyze ADP-riboses with C2 or C3 linkages at the 
proximal ribose. In contrast, the lack of MacroD1 or MacroD2 and 
C6orf130 activity toward PAR suggests that the glycosidic (ribose-
ribose 1?-2?) linkages at the C1 atom of ADP-ribose polymers are not 
attacked, whereas these bonds within PAR are efficiently degraded 
by PARG and ARH3. The inefficient hydrolysis of ADP-ribose 
from ARTD10 by PARG suggests that the C2 or C3 atoms form the 
glycosidic bond to a glutamate or aspartate (similar to the linkage 
in OAADPr) rather than to the C1 atom as in PAR. Alternatively, 
MacroDs might recognize not only the ADP-ribose but also parts 
of the modified target protein. Moreover, the inability of PARG and 
MacroD1 or MacroD2 to completely remove the protein-linked ADP-
ribose unit from ARTD1 suggests that at least some of the modifica-
tions catalyzed by ARTD1 are linked to yet another acceptor site.
The MacroD2-mediated reaction seems to be very efficient because 
at a 1:10 ratio (MacroD2/ARTD10) more than 60% of the modifica-
tion synthesized by ARTD10 was removed within 15 min in vitro. 
Owing to the low rates of enzymatic mono-ADP-ribosylation, it was 
not possible to generate sufficient amounts of mono-ADP-ribosylated 
MacroD2 substrate that would allow substrate-saturated conditions 
to exactly determine Vmax and Km. In addition, it has been previously 
shown that ARTD10 is ADP-ribosylated at multiple sites7. Because the 
MacroD2 affinity for these different acceptor sites probably varies, it is 
impossible to determine exact kinetics with such a substrate. However, 
chemical synthesis of defined mono-ADP-ribosylated peptides, which 
could serve as substrates, is currently not possible.
The activity of MacroD-like proteins toward other acceptor sites 
remains to be tested, but the different chemical nature of these link-
ages probably requires specific enzymes for the different acceptor sites 
(for example, ARH1). Furthermore, the specificity may additionally be 
determined by protein-protein interactions. However, as MacroD2 is 
expressed in the cytoplasm and MacroD1 exhibits nuclear and mitochon-
drial localization18, these two proteins are likely to encounter different 
protein substrates but catalyze the same mono-ADP-ribosylhydrolysis 
reaction. ARTD10 and most of the other mono-ARTDs are mainly local-
ized in the cytoplasm40. ARTD10-modified target proteins thus require 
cytoplasmic MacroD proteins for demodification.
On the basis of crystal structures, several residues in MacroD1 and 
C6orf130 were mutated in other studies to identify side chains involved 
in OAADPr hydrolysis28,29. Notably, we find that corresponding resi-
dues are implicated in MacroD1- and MacroD2-mediated hydrolysis 
of residues ADP-ribosylated by ARTD10. Mutating any of the puta-
tive catalytic residues (Asp102 and His106 of MacroD2) individually or 
together resulted in only a partial loss of activity, which indicates that 
other residues might compensate for the single mutations, to a certain 
extent. This observation is further supported by the fact that C6orf130 is 
active even though the residues identified in MacroD1 and MacroD2 are 
not conserved in C6orf130 (Supplementary Fig. 2a), which again points 
at sequence variation allowing different sets of residues to confer hydro-
lase activity. The residues Ser35 and Asp125, crucial for the hydrolysis of 
OAADPr by C6orf130, would indeed be strong candidates28.
The removal of ADP-ribose from GSK3? is sufficient to restore 
kinase activity, which indicates that mono-ADP-ribosylation is a 
dynamic PTM that directly influences the catalytic activity of its 
substrates in a reversible manner. The hydrolases identified here 
represent the missing link in the regulatory network formed by 
mono-ADP-ribosylation, which may prove highly important for 
diverse signaling networks as implied by the diversity of ARTD10 
substrates identified8.
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Figure 4 MacroD2 functionally and specifically regulates mono-
ADP-ribosylation of GSK3? in vitro and in cells. MacroD2 but not the 
catalytically inactive macrodomains of ARTD8 removes mono-ADP-ribose  
from ARTD10 and GSK3?. (a) Coomassie blue (CB) staining and 
autoradiography (32P) results of in vitro assays with tandem-affinity 
purification (TAP)-tagged ARTD10 and GST-GSK3? coupled to beads.  
(b) Scintillation counting of kinase assays using [?-32P]ATP and substrate 
peptide with modified or demodified GST-GSK3?. (c) Scintillation counting 
results as in b with HA-GSK3? from U2OS cells expressing DsRed-ARTD10, 
GFP-MacroD2 or both. (d) Input blot showing expression of DsRed-ARTD10, 
GFP-MacroD2 and HA-GSK3? in U2OS cells and immunoprecipitation 
efficiency of HA-GSK3? (lower blot). Data are represented as mean ? s.d.  
of at least triplicate measurements from representative experiments.  
*P < 0.05; NS, not significant by two-tailed Student’s t test.
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In summary, the findings presented here define the macrodomain-
containing proteins MacroD1, MacroD2 and C6orf130 as protein mono-
ADP-ribosylhydrolases and thus establish mono-ADP-ribosylation 
of acidic residues by ARTD10 as a reversible PTM. The MacroD-like 
proteins unite specific ADP-ribose binding with ADP-ribose degrada-
tion and thereby define new players in ADP-ribose metabolism and 
function. MacroD-like hydrolases form the functional antagonists of 
intracellular mono-ADP-ribosyltransferases. Notably, substrates of 
the mono-ADP-ribosyltransferase ARTD10 include many kinases, 
which may thus be activated and inactivated by the opposite activities 
of MacroD2 and ARTD10.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Purification of recombinant proteins. Macrodomain cDNAs were amplified 
by PCR, cloned into a pET28-GST vector according to standard protocols, 
recombinantly expressed in E. coli BL21 and purified by using Ni Sepharose 
High Performance beads (Amersham Biosciences) according to the manu-
facturer’s protocol. GSK3? was purified from SF9 cells8. Bound MacroD2 
was cleaved from the beads with PreScission protease 3C (GE Healthcare) or 
eluted with 200 mM imidazole. Protein concentration was determined with a 
spectrophotometer ND-1000 (Nanodrop), and cleavage was verified by SDS-
PAGE. ARTD10 was purified by using the TAP-tagging method as described 
before7. Cloning and purification of mMacro1 and mMacro2 of ARTD8 has 
been described41.
De-ADP-ribosylation assay with recombinant proteins. Unless otherwise 
stated, 50 pmol recombinant purified GST-ARTD10 or His-ARTD1 were 
incubated with 100 nM [32P]nicotinamide adenine dinucleotide ([32P]NAD+, 
PerkinElmer) for 15 min at 30 °C in reaction buffer (10 mM potassium phos-
phate, pH 7.2, 10 mM MgCl2, 1.25 mM DTT, 1 ?g/ml pepstatin, 1 ?g/ml 
bestatin, 1 ?g/ml leupeptin) and in the case of His-ARTD1 supplemented with 
5 pmol annealed double-stranded oligomer (5?-GGAATTCC-3?). The reaction 
was stopped by filtration through a G50 column (GE Healthcare). De-ADP- 
ribosylation reactions were performed with 10 pmol MacroD2 protein at 30 °C 
for 15 min and stopped by the addition of SDS-PAGE loading buffer and boiling 
(5 min, 95 °C). De-ADP-ribosylation of automodified proteins was visualized 
by SDS-PAGE and autoradiography. Bands were quantified by using GelEval 
(http://www.frogdance.dundee.ac.uk).
ADP-ribosylation assays with immunoprecipitated proteins. ADP-ribosylation 
assays were carried out at 30 °C for 30 min. The reaction mixture (50 mM Tris-
HCl, pH 8.0, 0.2 mM DTT, 5 mM MgCl2 and 50 ?M ?-NAD+ (Sigma) and 1 ?Ci 
[32P]?-NAD+ (Amersham Biosciences)) was added to IgG beads with immuno-
precipitated HA-ARTD10 or HA-ARTD10-?K and optionally 0.5 ?g substrate 
protein in a total reaction volume of 30 ?l. Reactions were stopped by adding SDS 
sample buffer and were subsequently boiled and run on SDS-PAGE. Incorporated 
radioactivity was analyzed by autoradiography.
ADP-ribosylation of actin by bacterial toxins. In vitro ADP-ribosylation of actin 
was performed as reported42. Briefly, 2 ?g ?/? actin was incubated with either 100 ng 
recombinant TccC3hvr or 50 ng CDTa in the presence of 100 nM [32P]NAD+, 
150 ?M cold NAD+ and reaction buffer (5 mM HEPES, pH 7.5, 0.1 mM CaCl2, 
0.5 mM NaAc, 0.1 mM ATP). TccC3hvr and CDT1 reactions were incubated for 
30 min at room temperature or 37 °C, respectively.
De-ADP-ribosylation assays with immunoprecipitated proteins. ADP- 
ribosylation assays were terminated by placing on ice and washing with high-salt 
buffer (50 mM Tris-HCl, pH 8.0, 0.2 mM DTT, 5 mM MgCl2, 200 mM NaCl). 
MacroD2 (500 ng) was added to the beads in 30 ?l high-salt buffer. After incuba-
tion (30 °C, 20 min), the reaction was stopped by addition of SDS sample buffer 
and boiling for analysis by SDS-PAGE and autoradiography. For subsequent 
kinase assays, beads with coupled GST-GSK3? were cooled and washed after 
incubation with MacroD2.
Chemical de-ADP-ribosylation. For chemical de-ADP-ribosylation with 
hydroxylamine, automodified ARTD10 was supplemented with 0.8 M hydroxyl-
amine in a 1:1 ratio (v/v). The reactions were incubated at 37 °C for 1 h and 
subsequently stopped by the addition of SDS loading buffer.
GST-macro pulldown assays with ARTD10 proteins. GST- or His-tagged 
macrodomains were immobilized on glutathione or Ni Sepharose (Amersham 
Biosciences) at 4 °C (wild type and mutants) and incubated with automodified 
ARTD10 (full length; 100 ng) or GST-ARTD10 (818–1025; 50 ng) proteins for 
2 h at 4 °C in 1,200 ?l of binding buffer (100 mM Tris, pH 7.6, 250 mM NaCl, 
125 mM KCl, 50 mM KAc, 1.5% NP-40 (high salt) or 75 mM NaCl, 25 mM KCl, 
15 mM KAc, 1% NP-40 (low salt), 10% glycerol and protease inhibitors) and 
washed 5× with binding buffer (1,200 ?l) for 25 min at 4 °C. Bound proteins 
were dissolved by boiling and were loaded on an SDS-PAGE gel for subsequent 
autoradiography.
Kinase assays. [?32P]ATP was diluted to 0.16 ?Ci/?l in 250 ?M ATP in 3× kinase 
assay buffer (5 mM MOPS, pH 7.2, 2.5 mM ?-glycerophosphate, 1 mM EGTA, 
0.4 mM EDTA, 4 mM MgCl2, 50 ?M DTT and 40 ng/?l BSA). GST-GSK3?  
(25 ng) or precipitate was incubated in a reaction volume of 25 ?l (5 ?l 0.16 ?Ci/?l 
[32P]ATP solution, 5 ?g substrate peptide RRRPASVPPSPSLSRHS(pS)HQRR 
(Millipore)). After incubating (30 °C, 15 min), the reaction was stopped by plac-
ing on ice. Aliquots of 10 ?l were spotted on P81 paper in duplicate, washed 
with 0.5% phosphoric acid and air dried before scintillation counting. Data are 
presented as mean ? s.d. of at least triplicate measurements from representative 
experiments. Statistical significance was determined by employing two-tailed 
Student’s t test.
LC-MS and HPLC analysis of ADP-ribose. For HPLC analysis, released ADP-
ribose or ADP-ribose standards were purified over Microcon Ultracel YM-3 
columns and subjected to reversed-phase liquid chromatography on an Accucore 
C18 2.7 ?m, 150 × 2.1 mm ID Column. A water-methanol gradient from 0% 
to 20% MeOH at a flow rate of 200 ?l/min was applied. Free ADP-ribose was 
monitored by UV absorbance at 260 nm. For LC-MS analysis, 10 ?M ADP-ribose 
standard and samples were analyzed by using hydrophilic interaction chroma-
tography (HILIC) coupled to accurate MS. The chromatographic separation of 
ADP-ribose was performed on a 0.2 ?m × 150 mm BEH amide column, using 
a linear gradient of acetonitrile to water, 0.5 mM ammonium acetate, pH 9. For 
MS, we used negative mode with a capillary voltage of 1.2 kV. Data were acquired 
in MS and MS-MS mode. Extracted ion chromatograms from the MS data 
were generated by using the monoisotopic mass of ADP-ribose adduct [M-H] 
558.064 and a mass window of 10 mDa. For relative quantification of ADP-ribose, 
MS scans in the elution time range of ADP-ribose were combined, and the ion 
abundance of mass 558.064 was calculated.
Homology modeling of MacroD2. The MacroD2 homology model (obtained by 
Modeller43–46; Supplementary Note) with the lowest discrete optimized protein 
energy assessment score47 was selected for minimization and molecular-dynamics 
refinement. Following 0.5 ns of NVT and subsequent 0.5 ns of NPT equilibration 
during which the protein heavy atoms and protein C? atoms were, respectively, 
positionally restrained, two 100-ns trajectories were generated by using different 
random seeds (MD runs I and II). Trajectory analyses (Supplementary Fig. 4a–c) 
were performed with the MD-analysis tool WORDOM48,49.
Docking and molecular-dynamics simulations of ADP-ribose in MacroD2. 
From the MD simulations of the apo-MacroD2 homology model, a trajectory 
frame was selected that maximized the solvent-accessible surface area of puta-
tive binding-site residues within the mixed ?/? macrodomain fold35, and which 
maintained similar Asp78 ?1 and ?2 angles relative to the corresponding residue 
of Af1521 (PDB 2BFQ).
Water molecules and ions were removed from this frame. AutoDock Vina50 
was employed to dock the ADP-ribose ligand to the mixed ?/? fold. The 20 top- 
ranking poses were minimized with CHARMM by using the CHARMM27 force 
field for the protein atoms and the CHARMM general force field51,52 for ADP-
ribose. Upon structural superposition of MacroD2 and Af1521, the minimized 
pose of ADP-ribose having the lowest r.m.s. deviation value relative to the one 
in Af1521 (PDB 2BFQ) was immersed in a box of TIP3P water molecules and 
subjected to ten explicit water MD runs of 10 ns each at 300 K.
For each run, the distance between the center of mass of the putative binding 
site of MacroD2 and that of ADP-ribose was calculated by using WORDOM48,49. 
Residues forming the putative binding site were those having at least one atom 
within 5 Å of any ligand atom following equilibration.
A total of 65% of the obtained MD trajectory frames presented a binding-site 
ligand center-of-mass distance of <6 Å; above this distance, the distal ribose of 
the ligand rarely re-entered the binding site. Unbinding of ADP-ribose within 
10 ns in almost half of the runs is consistent with its high ?M inhibition of human 
MacroD1 activity28.
Residues participating in hydrogen-bonding to ADP-ribose among trajectory 
frames in which the ligand remained bound were identified by using WORDOM 
with a distance cutoff of 4.0 Å between donor (D) and acceptor (A) atoms and 
a D-H··A angle larger than 130°. Predicted interactions of the distal ribose of 
ADP-ribose are predominantly with the carboxylate of Asp102 and with protein 
backbone atoms (Supplementary Fig. 4d,e).
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MacroD2 residues forming stable hydrogen bonds to structural water mole-
cules were identified by using the GROMACS g_hbond function. The most stable 
water molecules in the vicinity of the distal ribose are shown (Supplementary 
Fig. 4f) along with their interaction partners in MacroD2.
Figures were created with Pymol (http://pymol.sourceforge.net/).
41. Forst, A.H. et al. Recognition of mono-ADP-ribosylated ARTD10 substrates by ART8 
macrodomains. Structure (in the press).
42. Gülke, I. et al. Characterization of the enzymatic component of the ADP-
ribosyltransferase toxin CDTa from Clostridium difficile. Infect. Immun. 69, 
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43. Eswar, N. et al. Comparative protein structure modeling using Modeller. in  
Curr. Protoc. Bioinformatics 15, 5.6 (2006).
44. Martí-Renom, M.A. et al. Comparative protein structure modeling of genes and 
genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291–325 (2000).
45. Sali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial 
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SUMMARY
Faithful propagation of specific chromatin states
requires re-establishment of epigenetic marks after
every cell division. How the original epigenetic signa-
ture is inherited after disruption during DNA replica-
tion is still poorly understood. Here, we show that
the poly(ADP-ribose)-polymerase-1 (PARP1/ARTD1)
is implicated in the maintenance of silent rDNA chro-
matin during cell division. We demonstrate that
PARP1 associates with TIP5, a subunit of the NoRC
complex, via the noncoding pRNA and binds to silent
rRNAgenes after their replication inmid-late Sphase.
PARP1 represses rRNA transcription and is impli-
cated in the formationof silent rDNAchromatin. Silent
rDNA chromatin is a specific substrate for ADP-ribo-
sylation and the enzymatic activity of PARP1 is
necessary to establish rDNA silencing. The data
unravel a function of PARP1 and ADP-ribosylation
that serves to allow for the inheritance of silent chro-
matin structures, shedding light on how epigenetic
marks are transmitted during each cell cycle.
INTRODUCTION
Maintenance and transmission of proper chromatin organization
is fundamental for genome stability and function in eukaryotes.
During DNA replication, both heterochromatin and euchromatin
are disrupted ahead of the replication fork and are then reas-
sembled into their original epigenetic states behind the fork.
How chromatin domains are restored on new DNA and trans-
mitted through mitotic cell division remains a fundamental ques-
tion in biology, with implications for development and complex
diseases like cancer (Jasencakova and Groth, 2011). In higher
eukaryotes, the repeated ribosomal RNA (rRNA) genes represent
a striking example of how specific chromatin states are propa-
gated during the cell cycle. In each cell, a fraction of rRNA genes
is transcriptionally silent, replicates in late S phase, and is orga-
nized in heterochromatic structures by epigenetic mechanisms,
including silent histone marks and CpG methylation (Li et al.,
2005; Santoro, 2005, 2011; Santoro and Grummt, 2001; Santoro
et al., 2002). By contrast, the ‘‘active’’ euchromatic rDNA fraction
that replicates in early S phase represents rRNA genes compe-
tent for transcription whose activity is modulated according to
the requirement of cell metabolism (Moss et al., 2007). Inheri-
tance of silent rDNA chromatin is controlled by NoRC, the nucle-
olar remodeling complex comprising TIP5 and the ATPase
SNF2h (Guetg et al., 2010; Santoro and Grummt, 2005; Santoro
et al., 2002; Zhou et al., 2002). In mid-late S phase, TIP5 binds to
silent rRNA genes after the passage of the replication fork and
recruits DNA methyltransferases and histone modifier enzymes
to re-establish silent rDNA chromatin (Li et al., 2005; Santoro
et al., 2002; Zhou et al., 2002). Knockdown of TIP5 impairs
rDNA silencing and induces genome instability at the rDNA locus
and at the nearby centric and pericentric sequences (Guetg
et al., 2010; Santoro et al., 2009). NoRC function requires the
association of TIP5 with the noncoding RNA pRNA, a transcript
originating from an RNA polymerase I (Pol I) promoter located
2 kb upstream of the pre-rRNA transcription start site (Mayer
et al., 2006; Santoro et al., 2010). pRNA is synthesized by active
rRNA genes during early S phase and then processed duringmid
S phase into a 250–300 nt fragment that matches the rDNA
promoter sequences from !220 to +1 (Mayer et al., 2006;
Santoro et al., 2010). Nucleolar retention of TIP5, rDNA methyla-
tion, and silent histone modifications at rDNA depend on pRNA
(Mayer et al., 2006). Importantly, a TIP5 mutant with impaired
RNA-binding activity (W531G,Y532A; TIP5DRNA) failed to estab-
lish rDNA heterochromatin (Mayer et al., 2006). pRNA sequences
from nucleotides !127 to !49 in mouse forms a conserved
hairpin structure that is specifically recognized by the TIP5-
TAM domain. Upon pRNA binding, TIP5 undergoes a conforma-
tional change that was proposed to facilitate the interaction with
other proteins required for rDNA silencing (Mayer et al., 2008).
We have now examined the mechanism of NoRC-pRNA interac-
tion that modulates recruitment of chromatin modifier enzymes
to propagate rDNA heterochromatin during cell division.
RESULTS
PARP1 Associates with TIP5 and Binds to Silent
rRNA Genes
To dissect the mechanisms of NoRC function in rDNA hetero-
chromatin formation, we identified TIP5 interaction partners in
HEK293T cells expressing HA-FLAG-TIP5 in association with
proteomics and immunoblot analyses. As shown in Figure 1A,
we identified the poly(ADP-ribose)-polymerase-1 (PARP1, also
known as ARTD1) (Hottiger et al., 2010) as a TIP5-interacting
protein. PARP1 is an enzyme possessing NAD+-dependent
790 Molecular Cell 45, 790–800, March 30, 2012 ª2012 Elsevier Inc.
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Crosstalk between SET7/9-dependent methylation
and ARTD1-mediated ADP-ribosylation of histone
H1.4
Ingrid Kassner1,2, Marc Barandun1, Monika Fey1, Florian Rosenthal1,2 and Michael O Hottiger1*
Abstract
Background: Different histone post-translational modifications (PTMs) fine-tune and integrate different cellular
signaling pathways at the chromatin level. ADP-ribose modification of histones by cellular ADP-ribosyltransferases
such as ARTD1 (PARP1) is one of the many elements of the histone code. All 5 histone proteins were described to
be ADP-ribosylated in vitro and in vivo. However, the crosstalk between ADP-ribosylation and other modifications is
little understood.
Results: In experiments with isolated histones, it was found that ADP-ribosylation of H3 by ARTD1 prevents
H3 methylation by SET7/9. However, poly(ADP-ribosyl)ation (PARylation) of histone H3 surprisingly allowed
subsequent methylation of H1 by SET7/9. Histone H1 was thus identified as a new target for SET7/9. The SET7/9
methylation sites in H1.4 were pinpointed to the last lysine residues of the six KAK motifs in the C-terminal domain
(K121, K129, K159, K171,
K177 and K192). Interestingly, H1 and the known SET7/9 target protein H3 competed with each other for
SET7/9-dependent methylation.
Conclusions: The results presented here identify H1.4 as a novel SET7/9 target protein, and document an intricate
crosstalk between H3 and H1 methylation and PARylation, thus implying substrate competition as a regulatory
mechanism. Thereby, these results underline the role of ADP-ribosylation as an element of the histone code.
Keywords: PARP-1, SET7/9, Lysine methylation, Poly-ADP-ribosylation, Post-translational modification
Background
Histones are nuclear proteins that package and order the
DNA into nucleosomes [1]. Five major families of his-
tones exist: H1 (H5), H2A, H2B, H3, and H4. Two cop-
ies of the core histones H2A, H2B, H3 and H4 form the
octameric nucleosome core particles [2]. Unlike the
other histones, only one copy of the linker histone H1 is
present and stabilizes the DNA, which is wrapped
around the core nucleosome [3]. Linker histones bind to
both the nucleosome and the linker DNA region (ap-
proximately 20 to 80 nucleotides in length) between
nucleosomes. The interaction of H1 with the nucleo-
some and additional DNA stretches at the entry/exit of
the nucleosome forms the chromatosome and leads to
higher order chromatin structure [4]. Many experiments
addressing H1 function have been performed with puri-
fied, processed chromatin under low-salt conditions, but
the in vivo role of H1 is less clear. Cellular studies have
shown that overexpression of H1 can cause aberrant nu-
clear morphology and chromatin structure and, depend-
ing on the gene, H1 can serve as either a positive or a
negative regulator of transcription [5]. Similar to the
core histones, H1 is composed of three domains [6]. The
N-terminus is a short, flexible segment rich in basic
amino acids, the central domain exhibits a globular
structure composed of a winged helix motif [6] and
the C-terminus is predominantly composed of lysine,
alanine and proline residues and is the main determin-
ant for H1 binding to chromatin [7]. Among the five
histone families of the chromatosome, the linker his-
tone H1 is the least conserved. In the human genome,
11 genes encoding H1 variants have been identified and
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Abbreviations 
Accumulation gain control (AGC) 
Adenosine di-phosphate (ADP) 
Adenosine mono-phosphate (AMP) 
ADP-ribosyl transferase (ART) 
ART cholera toxin like (ARTC)  
ART diphtheria toxin like (ARTD) 
Bestatin (B) 
Electron capture dissociation (ECD) 
Electron transfer dissociation (ETD) 
Higher energy collisional dissociation (HCD) 
Ioadoacetamide (IAM) 
Ion trap (IT) 
Leupeptin (L) 
NCE (normalized collision energy) 
Neutral loss (NL) 
Nicotinamide adenine dinucleotide (NAD+) 
Orbitrap (FT) 
Pepstatin (P) 
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Phosphorus-32 (32P) 
Poly-ADP-ribosyl glycohydrolase PARG 
Post-translational modification (PTM) 
Product dependent (PD) 
Trichloroacetic acid (TCA) 
Wildtype (WT) 
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Summary  
ADP-ribosylation is an important post-translational modification, which is catalyzed by the 
family of ADP-ribosyl transferases (ARTs) and can occur as mono- and poly-ADP-ribosylation. 
Due to the limited availability of antibodies and mass spectrometry (MS) tools for the study of 
ADP-ribosylation, our knowledge of its acceptor amino acids and the function of ADP-
ribosylation is very limited. Here, we describe a new higher energy collisional dissociation 
(HCD)-based liquid chromatography mass spectrometry (LC-MS/MS) approach for the detection 
of ADP-ribosylated peptides and the identification of ADP-ribose acceptor sites. The presence of 
diagnostic ions of ADP-ribose in the HCD spectra allowed us to detect putative ADP-ribosylated 
peptides to target in a second LC-MS/MS analysis. The combination with electron transfer 
dissociation (ETD) fragmentation did only slightly improve the results obtained with HCD alone. 
However, a two-stage HCD-ETD approach proofed most robust for the analysis of a variety of 
samples.  
The herein described new approach led to the identification of ADP-ribosylated peptides and 
their specific modification sites in in vitro modified samples as well as in complex cell extracts. 
With these methods it was possible to identify for the first time several ADP-ribose acceptor 
sites (glutamates, lysines and arginies) on different proteins in cell extracts without prior 
enrichment of ADP-ribosylated proteins or peptides. Histones were identified as the most 
prominent ADP-ribosylated proteins in the nucleus and glutamates as well as lysines were 
discovered as the main ADP-ribose acceptor sites. Interestingly, several ADP-ribosylation sites 
correspond to residues that are also subject to acetylation or methylation and therefore suggest 
lively crosstalk between these different PTMs. This protocol can thus be applied to various 
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proteins of interest and opens the possibility to identify ADP-ribose acceptor sites in cellular 
extracts and eventually even tissue samples.   
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Introduction 
ADP-ribosylation is a post-translational protein modification (PTM) that is synthesized by ADP-
ribosyltransferases (ARTs) (1). Based on sequence similarity to bacterial diphtheria toxin or 
cholera C2 and C3 toxin, respectively, the ARTD and ARTC subfamilies are distinguished (2). 
The proteins of the ARTD subfamily comprise the main intracellular ADP-ribosyltransferases 
that are implicated in many regulatory processes and linked to various diseases and pathological 
conditions (3-5). These enzymes use nicotinamide adenine dinucleotide (NAD+) as a substrate to 
transfer the ADP-ribose moiety onto specific acceptor sites of target proteins or existing ADP-
ribose units, thereby synthesizing mono- or poly-ADP-ribosylated proteins (1). In cells, the 
ADP-ribose modification is short-lived because of the hydrolytic action of poly-ADP-ribose 
glycohydrolase (PARG) which degrades polymers of ADP-ribose as well as macrodomain 
proteins that remove mono-ADP-ribose from certain proteins (6).  
 ADP-ribosylation is an important protein modification, which is considered an element of 
the histone code and which co-regulates gene transcription, protein function, differentiation 
processes, stress responses, as well as the onset and progression of diseases (6-10). Although 
research on ADP-ribosylation has a long history, many inherent and technological difficulties are 
the reason for large gaps in the understanding of the cellular and molecular functions of this 
PTM. For example, ADP-ribose modifications can be synthesized during the sample preparation, 
because ARTD1 (PARP1) is activated by fragmented DNA. On the other hand, the modification 
is also easily lost during extraction or sample preparation. The variable length of the poly-ADP-
ribose chain is a further complication due to its high charge and the unpredictable mass shift of 
an undefined and potentially branched polymer. This problem can be addressed by enzymatically 
degrading all ADP-ribose modifications post sample preparation to the mono-ADP-ribose form 
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with PARG (6). One of the most limiting factors for the functional analysis of ADP-ribosylation 
is the lack of suitable methods to identify and quantify specific ADP-ribosylation sites and their 
modification status. Without such tools it is impossible to link physiological and cellular 
readouts to the activity of a particular ARTD or the modification status of a specific amino acid. 
Until now, only few acceptor sites for ADP-ribosyltransferases of the ARTD family have been 
identified. The acceptor sites for mono-ADP-ribose are side chains of specific amino acid 
residues and so far the following acceptor amino acids in eukaryotic cells were reported to 
covalently bind ADP-ribose: lysine, arginine, glutamate, aspartate, cysteine, diphthamide, 
phospho-serine and asparagine residues (2). Early work predicted ADP-ribosylated glutamic acid 
residues for ARTD1 (11). More recently, Tao et al. described weak mono-ADP-ribosylation 
activity of the E988Q ARTD1 mutant enzyme and identified modified aspartic and glutamic acid 
residues by liquid chromatography mass spectrometry (LC-MS) with collision induced 
dissociation (CID) fragmentation (12). This is in contrast to site directed mutagenesis studies that 
identified lysines to be modified on ARTD1 (13). A recent analysis of wildtype (WT) ARTD1 
pretreated with phosphodiesterase and subsequent CID MS/MS analysis identified glutamic acid 
and lysine residues as acceptor sites (14). Finally, LC-MS/MS with electron transfer dissociation 
(ETD) analysis of histone tails, modified by WT ARTD1 in vitro, predominantly identified 
lysines as acceptor sites (13, 15).  
LC-MS/MS strategies are frequently used to identify specific PTMs and the most commonly 
employed fragmentation method is CID. However, labile PTMs such as ADP-ribosylation are 
instable during CID fragmentation. Indeed, a typical CID MS/MS spectrum of an ADP-
ribosylated peptide is dominated by fragment ions originating from the ADP-ribose backbone, 
but lacks sufficient peptide backbone fragment ions to identify the amino acid sequence (16, 17)!"
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In particular, fragment ions corresponding to adenine, adenosine and water, adenosine mono-
phosphate (AMP), adenosine di-phosphate (ADP) and ADP-ribose are commonly observed.""
In contrast to CID, during ETD or electron capture dissociation (ECD) the ADP-ribose 
modification is maintained on the peptide, allowing the identification of the peptide sequence 
and the localization of the modification site. For this reason, these fragmentation techniques are 
so far considered the best choices for the identification of ADP-ribosylation sites (16, 18).  
Recently, a marker ion approach was proposed that circumvents the difficulties in peptide 
identification and takes advantage of the altered fragmentation pattern of ADP-ribosylated 
peptides (18). In a first LC-MS/MS run, putative ADP-ribosylated peptides are detected (based 
on the presence of marker ions in the CID spectra), which are then targeted for ETD 
fragmentation and subsequent peptide identification in a second LC-MS/MS analysis (16, 18). 
Although this strategy requires twice as much sample and instrument time and could be affected 
by the loss of low mass ions during ion trap CID fragmentation (with consequent loss of marker 
ion information), it can lead to the characterization of ADP-ribosylated peptides. 
Interestingly, the use of higher energy collision dissociation (HCD) has never been tested with 
ADP-ribosylated proteins up to now, even though the results are expected to be similar to QTOF-
like CID (with detection of low mass ions). Here, we describe for the first time the analysis of 
ADP-ribosylated peptides using HCD fragmentation, which provides a new and powerful 
method for the identification of modified peptides and their ADP-ribose modification site. The 
benefits of HCD as an alternative to or in combination with ETD fragmentation of standard 
peptides, enzymatically modified histones and nuclear extracts are discussed.  Together, HCD-
based approaches identified novel ADP-ribose acceptor sites from in vitro and in vivo ADP-
ribosylated proteins. 
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Experimental Procedures 
In vitro modification of standard peptide and histone mix 
The peptide Biotin-KAARKSAPATGGVKKPHRYR (H3) or histones were modified as 
described earlier (6). Briefly, 1 !g of peptide or 3 !g of histone mix were incubated with 
10 pmol GST-ARTD10 (818-1025) or HIS-ARTD1 for 15 min at 30°C in reaction buffer 
(50 mM Tris-HCL pH 8.0, 4 mM MgCl2, 250 µM DTT) in the presence of 160 !M NAD+. 
Reactions with HIS-ARTD1 were supplemented with 5 pmol annealed double-stranded oligomer 
(5`-GGAATTCC-3`). The reactions were stopped by the addition of PJ34 (ARTD inhibitor) and 
further processed or frozen until desalting. 
 
PARG treatment 
To shorten ADP-ribose polymers, the buffer conditions of in vitro modified HIS-ARTD1 were 
adjusted to 50 mM Tris-HCL pH 8.0, 10 mM MgCl2, 50 mM NaCl, 250 µM DTT. Subsequently, 
5 pmol HIS-PARG were added and the reactions were incubated at 30°C for 1h. The reactions 
were frozen until ZipTip C18 (Millipore, Billerica (MA), USA) desalting according to the 
suppliers guidelines. 
 
Extraction of nuclear / chromatin fraction 
To obtain ADP-ribosylated proteins, HEK293T cells were treated with 10 mM H2O2 in PBS with 
1 mM MgCl2 for 10 min at 37°C.  Nuclear and chromatin fractions were extracted as described 
earlier (19). Briefly, cells were resuspended in hypotonic lysis buffer (supplemented with Roche 
inhibitor cocktail (Roche, Mannheim, Germany), 10 !M Pj34 (Enzo, Lausen, Switzerland) and 
0.5 !M ADP-HPD (Santa Cruz, Santa Cruz (CA), USA)), incubated at 4°C for 30 min, and 
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centrifuged at 10000 g for 10 min. The pelleted nuclei were lysed in high salt buffer 
(supplemented with Roche inhibitor cocktail, 10 !M Pj34 and 0.5 !M ADP-HPD), sonicated 3 
times for 10 sec, and incubated on a roller shaker for 2 h at 4°C. Separation of the nucleoplasm 
and chromatin fraction was achieved by centrifugation at 4000 rpm for 20 min. 
 
Protein denaturation and Trypsin digestion 
Proteins were precipitated using trichloroacetic acid (TCA) and resuspended in 50 mM Tris-HCl, 
1 mM CaCl2 (pH 7.6). Nucleoplasm and chromatin fractions were pooled. Disulfide bridges were 
reduced by the addition of 10 mM DTT (in 50 mM Tris-HCl) at 50°C for 45 min. Cysteins were 
alkylated with 50 mM ioadoacetamide (IAM, in 50 mM Tris-HCl) for 1 h at RT in the dark, the 
reactions were blocked by the addition of Dithiothreitol (DTT) to a final concentration of 50 mM 
and an incubation for 10 min at RT. Sequencing grade modified trypsin (Promega, Madison 
(WI), USA) was added in a 1:100 w/w ratio and the reactions were incubated at 37°C over night. 
 
High-pH reversed-phase HPLC pre-fractionation 
Tryptic peptides were fractionated on a YMC-Triart reverse phase C18 column (150-4,8 mm i.d., 
S-5 µm, 12 nm, YMC Europe) using an Agilent 1100 series HPLC (Agilent, Waldbronn, 
Germany) at a flow rate of 850 nl/min. The buffer composition at the two channels was 5% 
acetonitrile, 25 mM K2HPO4 pH11 (buffer A) and 95% acetonitrile, 25 mM K2HPO4 pH 11 
(buffer B). Peptides were diluted with buffer A and adjusted to pH 11. Peptides were eluted with 
a linear gradient from 5 to 48% Acetonitrile over 70 min. Fractions were collected in 2 min 
intervals and dried to near completion in a SpeedVac.  
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Nano-Liquid Chromatography-Tandem Mass spectrometry 
Mass spectrometry analysis was performed on a LTQ-Orbitrap Velos ETD mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany) coupled to an Eksigent-Nano-HPLC system 
(Eksigent Technologies, Dublin (CA), USA). Solvent composition at the two channels was 0.1% 
formic acid for channel A and 0.1% formic acid, 99.9% acetonitrile for channel B. Peptides were 
loaded on a self-made tip column (75 !m " 80 mm) packed with reverse phase C18 material 
(AQ, 3 !m 200 Å, Bischoff GmbH, Leonberg, Germany) and eluted with a flow rate of 250 nl 
per min by a gradient from 2 to 35% of B in 30 minutes (for standard peptides) or 60 minutes 
(for complex histone samples).  
Full-scan MS spectra (300#1700 m/z) were acquired at a resolution of 30000 at 400 m/z, an 
accumulation gain control (AGC) of 1x106 and a maximum injection time of 250 ms. The AGC 
values for MS/MS analysis were set to 1x104 for ETD experiments with ion trap detection (IT, 
100 ms injection time) and to 1x105 for HCD and ETD experiments with detection in the 
Orbitrap (FT, 200 ms injection time) respectively. The HCD normalized collision energy was set 
to 40%, enabling the stepped collision energy (width 15%, 3 steps), and detecting the ions at a 
resolution of 7500 at 400 m/z. In all the experiments only 1 microscan was used for detection. 
The isolation width was set to 2 amu and 4 amu for HCD and ETD experiments, respectively. 
Full scans and Orbitrap MS/MS scans were acquired in profile mode, whereas ion trap mass 
spectra were acquired in centroid mode 
All the experiments were recorded in data dependent manner from signals above a threshold of 
2000.  
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Charge state screening was enabled and singly charge states were rejected. For ETD 
experiments, the ETD anion target value was set to 1e5 and the activation time to 100 ms. 
Charge-state dependent ETD reaction times were enabled, setting a reference value of 100 ms for 
doubly charged peptides. A supplemental activation with 25% normalized collision energy was 
always enabled. 
For the analysis of standard peptides, precursor masses already selected three times for MS/MS 
were excluded for further selection for 45s. For the analysis of complex histone samples, the 
dynamic exclusion was set to 1. The exclusion window was set to 10 ppm and the exclusion size 
was limited to a maximum of 500 entries. 
The following LC-MS/MS acquisition methods were performed: (a) Orbitrap full MS scan 
followed by top 10 data-dependent Orbitrap HCD MS/MS; (b) Orbitrap full MS scan followed 
by top 10 data-dependent ion trap ETD MS/MS, or (c) top 8 data-dependent Orbitrap ETD 
MS/MS; (d) Orbitrap full MS scan followed by top 10 double-play data-dependent HCD MS/MS 
and ion trap ETD MS/MS (or, (e), Orbitrap ETD MS/MS); (f) Orbitrap full MS scan followed by 
top 10 data-dependent HCD and an additional ETD ion trap event when a peak at 136.0623 
(ADP-ribose fragment ion) was observed among the top 10 most abundant peaks of the HCD 
scan (HCD-PD1-ETD); (g) Orbitrap full MS scan followed by top 10 data-dependent HCD and 
an additional ETD ion trap event when the peaks at 136.0623, 250.0940 and 348.0709 (were 
observed among the top 10 most abundant peaks of the HCD scan (HCD-PD3-ETD); (h) Two-
steps, consisting of HCD and an additional ETD ion trap MS/MS acquisition on the top 10 
precursors where the marker ions 136.0623, 250.0940 and 348.07091 were observed in a 
previous HCD run. A complete description of all tandem MS experiments employed in this study 
can be found in Table 1. 
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Database analysis and configuration of Mascot modifications 
MS and MS/MS spectra were converted into Mascot generic format (mgf) using Proteowizard 
(version 3 (20)). When both HCD and ETD scans were presents in the same raw files, separate 
mgfs for the two fragmentation techniques were created. All high-resolution HCD and ETD 
MS/MS spectra were deconvoluted using the H-score algorithm (21). The mgfs were searched 
against the UniProtKB human database (taxonomy 9606, version 20120914), including 35787 
Swiss-Prot, 37802 TrEMBL entries, 73589 decoy hits, and 260 common contaminants. In order 
to speed up the searches relative to the standard peptide, the peptide sequence 
KAARKSAPATGGVKKPHRYR was added to the database as the separate entry 
“ZZ_FGCZCont0260”. Mascot 2.4.1 (Matrix Science) was used for the identification with the 
following search settings: the combined HCD and Orbitrap ETD mgfs were searched with a 
peptide tolerance of 10 ppm and MS/MS tolerance of 0.05 Da, while the MS/MS tolerance for 
the ion trap ETD spectra was set to 0.6 Da. For the HCD runs, singly charged b and y ion series, 
immonium ions, water and ammonia loss ion series were searched. For ETD, multiply charged c, 
y, z, z+1, z+2 series were considered. In the case of histone samples, enzyme specificity was set 
to trypsin, allowing up to 3 missed cleavages. For the standard peptide, a 'non cutting' enzyme 
named NoCleave was defined and N-Term biotin was set as fixed modification. Decoy hits were 
used to control the false discovery rate on peptide and protein level. 
The ADP-ribose variable modification was set up differently for the searches of HCD or ETD 
spectra. For HCD mgfs the following modification settings were tested: (i) ADP-rib, 
corresponding to a mass shift of 541.0611; (ii) ADP-rib-HCDm, that additionally ignores for 
scoring the marker ions at m/z 428.0372, 348.0709, 250.0940, 136.0623; (iii) ADP-rib-HCDm-
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NL541/347, equal to ADP-rib-HCDm with additional scoring of the neutral losses (NL) equal to 
541.0611 and 347.0631 (coming from b and y series); (iv) ADP-rib-HCDm-NL347/249, with 
scoring of the neutral losses equal to 347.0631 and 249.0862; (v) ADP-rib-HCDm-NL347, with 
scoring of a single neutral losses equal to 347.063. Unfortunately, Mascot allowed only the 
screening for neutral losses and not for losses carrying different number of charges. 
For the identification of ADP-ribosylation from ETD spectra, only the mass shift of 541.0611 
was used (setting i, ADP-rib).  A detailed description of the Mascot modification settings can be 
found in figure 2 and in the supplementary figure S1. 
An ADP-ribosylated peptide was considered as correctly identified when a Mascot score higher 
than 20 and an expectation value lower than 0.05 was obtained. To assess the location of the 
ADP-ribosylation sites, we used the site localization analysis provided by Mascot, which is 
based on the work by Savitski et al. (22) and was developed especially for phosphorylations. 
This method is not optimized for ADP-ribosyl modification, due to the lack of standard peptides 
having known modification sites. For this reason, even if Mascot states a correctness of 95% for 
the site localization, this value is arbitrary and cannot be experimentally validated. Due to the 
lack of a better estimate, in the following we define correctness as having a confidence of at least 
95% in the Mascot site localization analysis. 
 
PTM MarkerFinder 
For LC-MS/MS experiments where HCD fragmentation has been used, the Mascot output .dat 
files have been further analyzed using PTM MarkerFinder (23). Briefly, PTM MarkerFinder 
screens the Mascot outputs for HCD spectra containing the ADP-ribose marker ions at m/z 
136.0623, 250.0940, 348.0709 and 428.0372. The spectra containing at least two marker ions 
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and where the sum of the marker ion intensities covers at least 5 % of the total ion intensities are 
considered as spectra from putative ADP-ribosylated peptides. Finally, PTM MarkerFinder 
summarizes information about the presence and the intensity of marker ions and annotates the 
spectra with the corresponding peptide sequence.  
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Results and Discussion 
Preparation of ADP-ribosylated peptides for the subsequent identification of the modification 
site(s)  
The currently available MS/MS protocols for ADP-ribosylated peptides do not allow the accurate 
and reliable detection of ADP-ribosylated peptides in a complex sample. To develop a novel 
MS-based approach, three samples with different complexities were prepared. The sample with 
the lowest complexity was a biotinylated peptide with the sequence 
KAARKSAPATGGVKKPHRYR, representing a part of the N-terminal histone H3 tail, which 
was previously described to be ADP-ribosylated by ARTD1 (15). The second sample was a 
mixture containing the ADP-ribosylated four core histones as well as the H1 linker histone as 
full-length proteins. The most complex sample was a nuclear extract of H2O2 treated HEK 293T 
cells. The H3 standard peptide and the histone mix were modified in either by recombinant 
ARTD1 stimulated with a 8mer double stranded DNA oligo or by the recombinant GST-tagged 
catalytic domain (amino acids 818-1025) of ARTD10. The modification by ARTD1 resulted in 
poly-ADP-ribosylation of the peptide or proteins, whereas ARTD10 (818-1025) catalyzed mono-
ADP-ribosylation (data now shown). Poly-ADP-ribosylated samples modified by ARTD1 were 
optionally treated with PARG to reduce the resulting ADP-ribose polymers to a single moiety 
(see below). 
 
Optimal HCD fragmentation of the ADP-ribosylated standard peptide using ramped CE 
In order to evaluate the behavior of ADP-ribosylated peptides during HCD fragmentation and to 
detect the diagnostic ions characteristic for ADP-ribose modification, the standard peptide was 
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fragmented using HCD with NCE (normalized collision energy) values ranging from 23% to 
60% (Fig. 1a,b and as described by (16)). The analysis revealed that the standard peptides either 
modified by ARTD1 or ARTD10 (poly- or mono-ADP-ribosylated), showed high intensity 
signals for the expected ADP-ribose marker ions, but low intensity signals for the peptide 
fragment at higher NCE values (Fig. S2). A good balance between the intensity of ADP-ribose 
marker ions and peptide backbone fragments was achieved by using ramped NCE (width 15%, 3 
steps centered around 40%). The HCD spectra acquired with such parameters were dominated by 
the marker ions originating from the internal fragmentation of ADP-ribose (with the ion at 136 
being the most abundant one), as well as by additional fragments corresponding to the peptide 
plus a residual mass from ADP-ribose fragmentation (Fig. 1c). These ADP-ribose fragments are 
often not caused by neutral losses and may thus exhibit charge states different from the one of 
the precursor. Based on these results, ramped NCE was defined as the optimal setting and used 
for all following analyses. 
 
Implementing ADP-ribose neutral losses improves identification of ADP-ribose acceptor sites 
by Mascot 
Considering the simple attachment of ADP-ribose as a variable modification for the Mascot 
analyses resulted in poor identification of modified peptides. In order to optimize the 
computational analysis of the generated mass spectrometry data with the modified standard 
peptide, different settings were tested. In particular, different ADP-ribose modification settings 
(described in the Experimental Procedures and as summarized in Fig. 2a) were generated to take 
advantage of the ADP-ribose marker ions and neutral losses for the Mascot searches. The criteria 
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used for the evaluation of the different settings included the overall number of identifications 
(considering a peptide identified when the Mascot score is higher than 20 and the expectation 
value lower than 0.05) and the percentage of assigned spectra for each peptide species. The 
search for ADP-ribose modifications (Fig. 2a, setting i) based on mass shift allowed the 
identification of only 20 to 40% of the spectra corresponding to the ADP-ribosylated standard 
peptide. To improve the identification, we first tested whether ignoring the ADP-ribose marker 
ions for scoring purposes increases the number of identifications or the percentage of assigned 
spectra (setting ii, ADP-rib-HCDm). As no improvement was observed (Fig. 2b), the main 
neutral losses (NL) of ADP-ribose (249, 347 and 541) were included into the search settings iii - 
v. Including the two NL 541 and 347 (setting iii) doubled the number of identified ADP-
ribosylated peptides and allowed the assignment of up to 91% of the spectra. In contrast, 
searching for the NL 347 and 249 (setting iv) or only 347 (setting v) resulted in fewer assigned 
spectra, indicating that the side NL reaction due to the loss of 249 does not provide any benefit 
for the scoring. Although the search for NL 541 and 347 lead to the reliable identification of 
modified peptides, it did not allow the exact localization of the modification (Fig. S3). We 
therefore selected the setting iv (ADP-rib-HCDm-NL347/249) as variable modification in 
Mascot for the rest of the study because it represents the best compromise between the rates of 
modified peptide identification and site-localization.  
These optimization steps led to the identification of different acceptor sites in the standard 
peptide modified by ARTD1 or ARTD10 (Fig. 2b). Predominantly arginine 20 and lysine 14 of 
the peptide were modified by both ARTDs, but arginine 20 most probably represents an in vitro 
artifact because it is the terminal amino acid (data not shown). The modification catalyzed by 
ARTD1 mainly resulted in the detection of mono-, di- and tri-ADP-ribosylations, which are 
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either derived from ADP-ribose polymers or different modified sites on the same peptide. The 
ARTD10 modified peptide on the other hand revealed mainly mono-ADP-ribose as well as a few 
di-modifications (approximately 10%). The latter can be either due to oligo-ADP-ribose 
synthesized by ARTD10 or can be caused by the modification of different sites on the same 
peptide. As the peptide contained multiple modification sites in close proximity, it was not 
possible to distinguish between these two possibilities. In general, the peptides were more 
efficiently modified by ARTD10 than by ARTD1, due to the higher efficiency and lower 
specificity of the catalytic ARTD10 domain in vitro (data not shown).  
 
The combination of HCD and ETD approaches increases the identifications of ADP-
ribosylation sites 
ETD fragmentation is considered the method of choice for ADP-ribosylated peptides and was 
therefore compared to HCD fragmentation (Table 1 / Fig. 3). In a first step, the mono- and poly-
ADP-ribosylated peptides were analyzed by HCD (as described above) or by ETD fragmentation 
acquired in the ion trap (IT) or Orbitrap (FT). Since the average charge state of the identified 
modified peptides was relatively high (more than 4, Fig. S4a), the c and z fragmentation series 
often consisted of multiple charged ions. Consequently, even if the acquisition of the spectra in 
the IT allowed a higher throughput compared to the FT detection (due to the shorter length of the 
scan cycles), the identification of the correct charge states of the fragment ions could only be 
achieved by acquiring the MS/MS spectra in the FT. More spectra were acquired via ETD (IT) 
analysis, but the number of identifications was similar for ETD (IT) and ETD (FT) (Fig. 4). 
Interestingly, these results were similar to those obtained with HCD alone, strongly suggesting 
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that the HCD fragmentation alone provides enough information for the identification of ADP-
ribosylated peptides.  
However, combination of ETD and HCD may improve the identification of ADP-ribosylated 
peptides and modification sites, as it takes advantage of the information generated by both 
approaches. Subjecting the entire sample to both, HCD-ETD (IT) and HCD-ETD (FT), resulted 
in increased cycle times, but did not significantly influence the number of identifications or 
assigned spectra (Fig. 4). This strategy is particularly inefficient for complex samples, because 
all peptides, also those that are not modified, are fragmented and analyzed twice. An alternative 
method is a previously suggested two-stage (“marker ion”) approach (16), which has not yet 
been considered and tested with HCD and ETD. To evaluate this method, samples were first 
analyzed using HCD fragmentation as described above. Subsequently, the Mascot output was 
screened for spectra containing ADP-ribose marker ions using PTM MarkerFinder (23), to obtain 
a list of precursor ions corresponding to putative ADP-ribosylated peptides. Only these precursor 
ions were targeted for HCD and ETD (IT) fragmentation in a second LC-MS/MS experiment. 
Although this method resulted in a higher number of ADP-ribosylated peptide identifications 
(Fig 4a) compared to single HCD runs, the throughput of the process was substantially reduced, 
because it required twice as much LC-MS analysis time and more computational steps.  
In order to overcome the shortcomings of these combinations, HCD was followed by ETD on the 
same precursors only when one or more marker ions were present in the HCD spectra (product 
dependent approach, HCD-PD-ETD) (16). To our knowledge, this method was never applied to 
ADP-ribosylated peptides, while it was already successfully used for glycopeptide studies (24-
26). The ETD (IT) was either triggered upon the detection of only one marker ion: 136.0623 
(HCD-PD1-ETD (IT)) or the detection of three marker ions 136.0623, 250.0940, 348.0709 
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(HCD-PD3-ETD (IT)). In general, the marker ion 136.0623 proved specific enough for the 
triggering of ETD fragmentation, while the inclusion of 3 marker ions increased the number of 
missed PD-ETD activations. Moreover, one single marker ion triggered more ETD events when 
the standard peptide was poly-ADP-ribosylated (i.e., ARTD1-modified sample, Fig 4a). For this 
ARTD1 modified peptide the HCD-PD1-ETD (IT) method proved less efficient than the two-
stage HCD-ETD (IT) combination in identifying spectra from the ADP-ribosylated peptide, but 
allowed a much higher throughput. In all samples the localization of the ADP-ribosylation site 
could be achieved only for few peptides, with the best results obtained for HCD and ETD (FT) 
spectra (supplementary Fig. S5). Due to the characteristics of the sample analyzed (one single 
highly charged peptide; Fig. S4a) and the different results from ARTD1 or ARTD10, a final 
conclusion could not be achieved after this series of analysis. HCD-PD1-ETD (IT) or two-stage 
HCD-ETD (IT) performed in general better than the other tested combination 
 
An HCD-ETD approach identifies ADP-ribosylation sites from in vitro modified full-length 
histone proteins 
Next, we applied our novel protocols to a more complex sample that reflects a typical experiment 
for the identification of in vitro modified full-length proteins (Fig. 3). A mixture of all four core 
histones and linker histone H1 was in vitro modified by ARTD10 (818-1025). ARTD10 was 
chosen, because it in vitro modified peptides more efficiently than ARTD1 (compare Fig. 4a 
upper and lower panel) and hence resulted in a larger diversity of ADP-ribose modifications. The 
performance of the different methods (HCD, ETD (IT), ETD (FT), HCD-ETD (IT), HCD-PD-
ETD (IT) or two-stage HCD-ETD (IT)) was validated by the overall number of ADP-ribosylated 
peptides and the number of differentially modified peptides. Modification sites with a Mascot 
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Site Analysis confidence of $ 95% were considered as localized, whereas all other hits were 
considered as modified peptides however, without accurately mapped modification site (Fig. 5).   
When ADP-ribosylated samples were analyzed either by HCD or ETD fragmentation alone, 
HCD resulted in nearly 3 times more identified spectra than ETD (Fig 5a). The application of 
ETD (IT) or ETD (FT) analysis led to comparable results, which was most probably due to lower 
charge states of the analyzed peptides in comparison to the highly charged peptide used in the 
first part of this study (Fig. S4b). Moreover, HCD fragmentation of the modified samples 
allowed the validation of modifications by screening for marker ions using PTM MarkerFinder. 
Screening with this software allowed the association of 1561 spectra to putative ADP-ribosylated 
peptides. A summary of the behavior of marker ions in these spectra is shown in Fig. S6. When 
marker ions were included into the LC-MS methods, the HCD-PD1-ETD (IT) approach 
identified approximately the same number of peptides as the two single HCD and ETD (IT) runs 
together, indicating that all modified peptides with a clear ion pattern were already picked and 
identified by the two single runs. In comparison, the two-stage HCD-ETD (IT) identified 
approximately 30% more modified peptides, which was most probably due to a repeated 
measurement of potentially modified precursors, increasing the chance for high-quality spectra 
and high identification scores in comparison to single HCD. The comparison of the number of 
total identified peptides to the number of different identified peptides correlated strongly 
throughout all runs (Fig. 5a,b). Interestingly, the two-stage HCD-ETD (IT) run identified fewer 
differentially modified peptides than the HCD-PD1-ETD (IT) approach, indicating that the more 
abundant modified peptides most probably suppressed the detection of less abundant ones, since 
we used different settings in dynamic exclusions between single HCD and marker ion dependent 
runs. To validate the potential benefits of the ETD fragmentation in these approaches, the 
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contributions from HCD and ETD spectra to the identified peptides from the combined HCD-
ETD (IT) runs were compared. 83 – 94% of all identified ADP-ribosylated peptides in HCD-
ETD (IT) were already present in the HCD covered fraction, suggesting that the additional ETD 
fragmentation provided only little additional information compared to HCD alone (Fig. 5c). 
Taken together, the identification and mapping of the ADP-ribosylation sites in a more complex 
sample was best achieved by the application of HCD-PD1-ETD (IT) or the two-stage HCD-ETD 
(IT) approach. Both methods identified a high number of acceptor sites and record the additional 
ETD-information. However, in most cases a single HCD run might be sufficient to capture the 
majority of ADP-ribosylated peptides and their acceptor sites.  
The different MS/MS protocols described above led to the identification of 150 ADP-ribosylated 
peptides and 41 modification sites of in vitro modified ARTD10 and histones (Table S1 and S2). 
Several sites or areas of ADP-ribosylation were covered by different overlapping peptides, 
underlining the robustness of this new approach. Interestingly, ADP-ribosylation of histones was 
not limited to a single amino acid residue, but found on glutamates as well as lysine and arginine 
residues. In contrast, for ARTD10 mainly glutamate residues were identified as auto-
modification sites. This implies that ARTD10 is able to modify more than one type of amino 
acid and/or that ARTD10 auto-modification is mainly directed towards one residue (e.g., 
glutamate), from where the modification may be transferred to other sites (e.g., lysine or 
arginine). 
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Two-stage HCD-ETD (IT) improves the identification of ADP-ribosylation acceptor sites in 
proteins from nuclear extracts  
After the identification of ADP-ribosylation sites in in vitro modified proteins, the next step is 
the analysis of ADP-ribosylated proteins in cell extracts. Therefore, nuclear lysates of H2O2 
treated HEK293T cells were digested with trypsin and analyzed (Fig. 6a). The high complexity 
of these samples as well as a high number of non-ADP-ribosylated peptides both contribute to a 
massive background and make the analysis far more challenging. To reduce this complexity, 
samples were fractioned by high-pH reversed-phase chromatography after trypsin digestion. The 
fractionated samples were subsequently analyzed with a single-HCD run to confirm the presence 
of putative ADP-ribosylated peptides. Due to the low abundance of ADP-ribosylated peptides in 
the analyzed extracts, the HCD run resulted only in a very small number of Mascot-identified 
ADP-ribosylated peptides (Fig. 6a,b). The obtained data were thus further screened with the 
PTM-MarkerFinder software, which identified 120 to 140 putative ADP-ribosylated peptides 
(Fig. S7), although some ADP-ribose maker ions had low intensities. We therefore assumed that 
in complex extracts, a single HCD run is not sufficient to properly identify ADP-ribosylated 
peptides. This observation together with the putative 120-140 modified peptides, made a two-
stage HCD-ETD (IT) run the method of choice for a further analysis. The application of the two-
stage approach allowed the identification of 10 times more ADP-ribosylated peptides (Fig 6b) as 
well as 5-7 times more different peptides (Fig. 6c, Table 2 and 3). This was true for both site 
localization confidence scores over and under 95%. As already previously observed, also in this 
case the majority (85%) of the different identified peptides were, identified by the HCD runs 
(Fig. 6d). All the spectra corresponding to correctly identified and localized ADP-ribosylated 
peptides are shown in the supplementary figure S8. Taken together, the two-stage HCD-ETD 
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(IT) approach with HPLC pre-fractionation is a powerful tool for the identification of cellular 
ADP-ribosylation sites, which can be applied to a complex cell extracts.  
 
Pre-treatment of samples with PARG provides additional information for the analysis by HCD 
The complexity of a sample is not only defined by the presence of differently modified proteins, 
but also by the complexity added by the different chain length of the ADP-ribose polymer. To 
define and address this aspect, the ARTD1-modified standard peptide, as well as the nuclear 
lysates were pre-treated with PARG to remove the ADP-ribose chain except the proximal ADP-
ribose moiety (6). As expected, only one ADP-ribose group was identified on PARG treated 
peptides modified by ARTD1 using HCD fragmentation (Fig. 2c), suggesting that only one site 
per peptide was ADP-ribosylated. The use of PARG increased the number of identified 
modification sites in all combined HCD-ETD runs (Fig. 4b). The same holds true for the nuclear 
lysates, where PARG treatment led to an increased identification (Fig. 6b,c). Here 85% of the 
HCD identifications were covered by the PARG untreated nuclear sample, which was also not 
altered using ETD fragmentation (85.7% were covered (Fig. 6d)). Therefore, PARG treatment 
(i.e., shortening of the ADP-ribose chains) resulted in a 25% benefit in terms of modification 
localization. Together, theses measurements suggest that PARG treatment is an optional step that 
increases the number of identified ADP-ribose acceptor sites by around 25%. 
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Glutamate and lysine residues are ADP-ribose acceptor sites in vivo  
Over all, the optimization of especially HCD-MS/MS and the application of two-stage HCD-
ETD (IT) allowed for the first time the identification of several ADP-ribosylation sites of 
proteins in a complex cell extract without enrichment of modified proteins (Table 2). 
Interestingly the ADP-ribosylation sites comprised both lysine and glutamate residues to the 
same extent, indicating that there is not only one general acceptor amino acid for ADP-ribose in 
cells. This could either be due to different ARTDs catalyzing the modification through different 
mechanisms or to the above mentioned possibility of a common mechanism which modifies only 
one residue (e.g., glutamate) with a very unstable linkage that allows the ADP-ribose moiety to 
be transferred on close by residues with a more stable linkage (e.g., lysines). 
Histone proteins comprised the major part of the identified ADP-ribosylated protein, which is in 
accordance to previous studies, reporting histones as the main acceptors for ADP-ribose in cells 
(9). The fact that we could not identify modification sites of ARTD1 (neither modified in vitro 
nor in vivo) could be explained by the underrepresentation of ARTD1 peptides in the analyzed 
mixture. Interestingly, we were able to identify ADP-ribose acceptor residues on histone proteins 
that are identical or in close proximity to known sites of other PTMs. We could localize ADP-
ribosylation to H2B K5, which is also acetylated (27), to H3 K14 which is acetylated (28) and to 
H1.2 at either K184 or 187 (K187 is methylated (29)). This shows that ADP-ribosylation 
acceptor sites are also targets of other PTM’s and suggest a lively crosstalk (e.g., between ADP-
ribosylation, acetylation and methylation of lysine residues). 
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Conclusions 
 
The herein described approach for the identification of ADP-ribosylated proteins and their 
specific modification sites comprises new methods for the preparation of samples of modified 
proteins, data acquisition and data analysis (Fig. 1a, 3a, 6a). The improvements and innovations 
in this HCD-based protocol, enables the identification of ADP-ribosylation sites with high 
reliability and confidence of in vitro modified proteins by preferably HCD-PD1-ETD (IT) or 
two-stage HCD-ETD (IT) and from cellular extracts. For the first time we could identify several 
ADP-ribose acceptor sites (glutamates, lysines and arginies) on different proteins. This approach 
does not require the enrichment of ADP-ribosylated proteins or peptides, although this might 
further enhance the number of identified peptides. Taken together, we present a robust method 
for the exact identification of ADP-ribosylation sites that can be applied to various proteins of 
interest and which opens the possibility to identify ADP-ribose acceptor sites in cellular extracts 
and eventually even tissue samples. 
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Figure Legends 
 
Figure 1: Optimal HCD fragmentation of the ADP-ribosylated standard peptide using 
ramped CE. A. Overview of the sample preparation, liquid chromatography mass spectrometry 
and data analysis workflow employed for the evaluation of HCD fragmentation behavior of the 
biotin-KAARKSAPATGGVKKPHRYR (H3) ADP-ribosylated peptide; B. Nomenclature of 
ADP-ribose fragments as described by Hengel et al. (16). The ADP-ribose fragment ions 
showing strong signals in the HCD MS/MS spectra are shown (m1, m3, m6, m8, m10); C. HCD 
spectrum of the biotin-KAARKSAPATGGVKKPHRYR (H3) ADP-ribosylated peptide. The 
loss of adenine, adenosine and water, adenosine mono-phosphate (AMP), adenosine di-
phosphate (ADP) and ADP-ribose can be observed in the zoomed panel. The arrows mark the 
three most abundant ADP-ribose fragment ions. 
 
Figure 2: Implementing ADP-ribose neutral losses improves identification of ADP-ribose 
acceptor sites by Mascot. A. Details of the ADP-ribose modification settings defined in the 
Mascot Server. The marker ions ignored were not considered for scoring. B. Summary of the 
results obtained by HCD analysis of the biotin-KAARKSAPATGGVKKPHRYR (H3) peptide 
treated with ARTD1 and ARTD10, using the modification settings defined in panel A. The bars 
represent the number of HCD spectra identified as peptide carrying 1 (white), 2 (grey) or 3 
(black) ADP-ribosylations. The black line shows the percentage of spectra corresponding to 
ADP-ribosylated peptides that has been correctly identified. C. Summary of the results obtained 
by HCD analysis of the biotin-KAARKSAPATGGVKKPHRYR (H3) peptide treated with 
ARTD1 and PARG. 
 
Figure 3: Analysis of ADP-ribosylated peptides using combination of HCD and ETD 
fragmentation techniques. Schematic overview of the mass spectrometry methods employed in 
the present study. Both the biotin-KAARKSAPATGGVKKPHRYR (H3) peptide and a histone 
mixture are ADP-ribosylated and analyzed using various combination of HCD and ETD 
fragmentation techniques. ETD spectra can be acquired in the ion trap (IT) or in the orbitrap 
(FT). The black circles represent ADP-ribose marker ions present in the HCD spectra, that 
trigger an ETD fragmentation event. PTM MarkerFinder is a software that screens for ADP-
ribose marker ions and creates an inclusion list containing putative ADP-ribosylated peptides to 
be targeted in a second LC-MS/MS analysis. 
 
Figure 4: Analysis of the ADP-ribosylated H3 peptide KAARKSAPATGGVKKPHRYR 
using a combination of HCD and ETD fragmentation techniques. Every pie-chart shows for 
each combination of HCD and ETD fragmentation the number of spectra unassigned (white) and 
assigned to ADP-ribosylated peptides (colored). A.: results obtained by the analysis of the 
peptide treated with ARTD1 and ARTD10. The bars report the number of spectra identified as 
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peptides carrying 1 (blue), 2 (red) or 3 (green) ADP-ribose moieties. B.: results for the peptide 
treated with ARTD1/PARG.  
 
Figure 5: Analysis of histones in vitro modified by ARTD10 using combinations of HCD 
and ETD fragmentation techniques. Histones in vitro modified by ARTD10 were analyzed by 
MS/MS usind six different combinations of HCD and/or ETD fragmentation techniques. Both 
the ADP-ribosylated peptides where the site localization confidence score is higher than 95% 
(black bars) and lower than 95% (grey bar) are plotted. A.: number of spectra assigned to ADP-
ribosylated peptides. B.: number of different ADP-ribosylated peptides identifications (different 
modification sites on the same peptide are considered as different peptides).  C.: Venn diagrams 
showing the differences and overlaps between HCD and ETD identifications. The diagrams refer 
only to the peptides having a site localization score higher than 95%. 
 
Figure 6: Results of the analysis of HEK 293T nuclear lysates using combinations of HCD 
and ETD fragmentation techniques. A.: identification of ADP-ribosylated peptides in nuclear 
lysate of HEK 293T cells by LC-MS/MS analysis using a two-stage HCD-ETD (IT) approach. 
Panel B. and C. show the identified ADP-ribosylated peptides having a site localization 
confidence score both higher (black bars) and lower (grey bar) than 95%. B.: number of spectra 
assigned to ADP-ribosylated peptides. C.: number of different ADP-ribosylated peptides 
identifications (different modification sites on the same peptide are considered as different 
peptides). D.: Venn diagrams showing the differences and overlaps between HCD and ETD 
identifications as well as untreated and PARG treated samples. The diagrams refer only to the 
peptides having a site localization score higher than 95%. 
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Table Legends 
 
Table 1: Overview of evaluated tandem mass spectrometry methods  
 
Table 2: Identification of ADP-ribosylated peptides from nuclear lysates having 
unambiguous site localization. Newly identified ADP-ribosylation sites are highlighted in bold 
red. All ADP-ribosylated peptides with a Mascot localization score over 95% are listed. The 
number of identifications represents, how often the peptide was independently identified. 
 
Table 3: Identification of ADP-ribosylated peptides from nuclear lysates having ambiguous 
site localization. Newly identified ADP-ribosylation sites are highlighted in bold red. All ADP-
ribosylated peptides with a Mascot localization score under 95% are listed. The number of 
identifications represents, how often the peptide was independently identified. 
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Legend supplementary figures / tables 
Fig. S1: Mascot modification settings used for the configuration of ADP-ribose 
modification. Page 1: ADP-rib, corresponding to a mass shift of 541.0611; Page 2: ADP-rib-
HCDm, that additionally ignores for scoring the marker ions at m/z 428.0372, 348.0709, 
250.0940, 136.0623; Page 3: ADP-rib-HCDm-NL541/347, equal to ADP-rib-HCDm with 
additional scoring of the neutral losses (NL) equal to 541.0611 and 347.0631 (coming from b and 
y series); Page 4: ADP-rib-HCDm-NL347/249, with scoring of the neutral losses equal to 
347.0631 and 249.0862; Page 5: ADP-rib-HCDm-NL347, with scoring of a single neutral losses 
equal to 347.063. 
 
Fig. S2: HCD spectra of peptide Biotin-KAARKSAPATGGVKKPHRYR + 1 ADP-ribose. 
HCD spectra of the ADP-ribosylated Biotin-KAARKSAPATGGVKKPHRYR peptide using 
different normalized collision energies (NCE). A.:  NCE 23%; B.:  NCE 30%; C.:  NCE 38%; D.:  
NCE 45%; E.:  NCE 52%; F.:  NCE 60%; G.:  NCE 40% using stepped NCE (3 steps, step width 
15%) 
 
Fig. S3: Results of the Mascot Site Localization Analysis of HCD spectra of peptide Biotin-
KAARKSAPATGGVKKPHRYR + 1 ADP-ribose. Results of the Mascot Site Localization 
Analysis using different configuration of ADP-ribose modifications for the analysis of HCD 
spectra.  
 
Fig. S4: Average charge state of the identified ADP-ribosylated peptides. A.: Biotin- 
KAARKSAPATGGVKKPHRYR peptide carrying 1 ADP-ribose modification; B.: histone 
mixture, digested with trypsin at 30ºC, overnight; C.: HEK 293T nuclear lysate 
 
Fig. S5: Localization of ADP-ribosylation sites in standard peptide sample using multiple 
fragmentation techniques. Results of the Mascot Site Localization analysis for the peptide 
Biotin- KAARKSAPATGGVKKPHRYR + 1 ADP-ribose  using different combinations of HCD 
and ETD fragmentation. The figure shows both the sites localized with a score higher (black) and 
lower (grey) than 95%. 
 
Fig. S6: Behaviour of ADP-ribose marker ions during HCD fragmentation. The PTM 
MarkerFinder analysis of all the LC-MS/MS analysis of histone mixtures detected  1561 HCD 
spectra containing ADP-ribose marker ions. The box plot shows the log[10] intensities of the 
ADP-ribose marker ions at m/z 136.0623, 250.0940, 348.0709 and 428.0372. 
90
 Fig. S7: PTM MarkerFinder analysis of HEK 293T nuclear lysate. Number of putative ADP-
ribosylated peptides detected by PTM MarkerFinder analysis of HCD spectra from HEK 293T 
nuclear lysate.  
 
Fig. S8: Spectra of ADP-ribosylated peptides identified in HEK 293T nuclear lysates, 
having modification site correctly localized. The panels show the spectrum, Mascot results, 
fragment ion annotation and marker ion information for all the ADP-ribosylated peptides 
identified in HEK 293T nuclear lysates with a Mascot score higher than 20, Expect value lower 
than 0.05 and Mascot Site Localization analysis higher than 95%. 
 
Table S1: Identification of ADP-ribosylated histone peptides having unambiguous site 
localization. Newly identified ADP-ribosylation sites from histones in vitro modified by 
ARTD10. The modification sites are presented in brackets. All ADP-ribosylated peptides with a 
Mascot localization score over 95% are listed. The number of identifications represents, how 
often the peptide was independently identified. 
 
Table S2: Identification of ADP-ribosylated histone peptides having ambiguous site 
localization. Newly identified ADP-ribosylation sites from histones in vitro modified by 
ARTD10. The modification sites are presented in brackets. All ADP-ribosylated peptides with a 
Mascot localization score under 95% are listed. The number of identifications represents, how 
often the peptide was independently identified. 
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Summary 
Poly(ADP-ribos)ylation (PARylation) is a reversible post-translational modification 
found in higher eukaryotes, but little is known about the acceptor proteins of 
PARylation. Here we describe a sensitive proteomics approach based upon 
quantitative mass spectrometry for identification of PARylated proteins induced 
under different conditions of cellular stress. Our screen identifies novel candidates 
not previously reported to be targets of PARylation, while confirming the majority of 
known PARylated proteins. In vivo and in vitro validation of novel acceptor proteins 
confirms that our methodology targets direct covalent PARylation. Nuclear proteins 
encompassing nucleic binding properties are most prominently found to be 
PARylated upon genotoxic stress, in agreement with the nuclear functions ascribed 
to ARTD1/PARP1 and ARTD2/PARP2. Distinct differences in proteins becoming 
PARylated upon various genotoxic insults are observed. Most significantly, proteins 
involved in RNA metabolism are PARylated upon oxidative and alkylation damage, 
demonstrating that post-transcriptional processes are controlled through specific 
genotoxic stress-induced PARylation. 
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Introduction 
 
Mammalian cells are constantly exposed to genotoxic stress and have therefore 
developed sophisticated mechanisms to detect and signal the presence of damaged DNA 
in order to accomplish efficient DNA repair processes. Post-translational modifications 
(PTMs) of proteins significantly contribute to the regulation of these processes, of which 
phosphorylation and ubiquitylation recently have been studied extensively on a proteome-
wide scale(Bennetzen et al., 2010; Bensimon et al., 2010; Matsuoka et al., 2007; Povlsen 
et al., 2012). Although the importance of phosphorylation and ubiquitylation in maintaining 
genomic integrity in the DNA damage response are indisputable, one of the earliest 
cellular response following exposure to genotoxic stress happens through the reversible 
PTM poly(ADP-ribosyl)ation (PARylation) (Altmeyer and Lukas, 2013; Lukas et al., 2011; 
Polo and Jackson, 2011). Activation of poly(ADP-ribose) polymerases (ARTDs, formerly 
PARPs) entails the rapid synthesis of long, branched poly(ADP-ribose) (PAR) chains from 
nicotinamide adenine dinucleotide (NAD+)  that can lead to a transient 10 to 500-fold 
increase of cellular PAR levels  (Hassa and Hottiger, 2008). PAR polymers have been 
suggested to play a key role in the regulation of chromatin structure modulation, DNA 
repair, transcription and cell death related processes (Kraus and Hottiger, 2013; Luo and 
Kraus, 2012). The importance of this modification is emphasized by the fact that knockout 
mice for ARTD1/PARP1 or ARTD2/PARP2 are hypersensitive to DNA damaging agents 
and show increased genomic instability following genotoxic stress (de Murcia et al., 1997; 
Menissier de Murcia et al., 2003; Trucco et al., 1998). Intriguingly, double knockouts for 
ARTD1 and ARTD2 result in early embryonic lethality indicating that these two enzymes 
might functionally compensate for each other (Menissier de Murcia et al., 2003). PAR 
turnover is tightly controlled by the activity of PAR degrading enzymes, of which poly(ADP-
ribose) glycohydrolase (PARG) accounts for the major activity in mammalian cells 
(Bonicalzi et al., 2005). Despite PARylation has been known for 50 years, surprisingly little 
is known about the molecular targets of the modification, and which processes these 
specifically regulate. At present, only a limited number of in vivo PARylated proteins 
(PARP substrates) is reported in the literature and public databases, primarily due to the 
absence ??? ??????????? ????????????? ???? ??????????PARylated proteins on a global scale. 
Thus, proteome-wide identification of PARylated proteins would greatly expand the 
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number of currently known PARylated proteins. In particular, a systems-wide elucidation of 
PARylated proteins under various stress responses would lead to a deeper understanding 
of the biological mechanisms related to PARylation, especially in light of the fact that 
PARP inhibitors are currently tested in clinical trials to treat cancer patients (Javle and 
Curtin, 2011). 
Mass spectrometry (MS)-based proteomics has emerged as a key technology for 
comprehensive identification of PTM substrates and site-specific mapping of various types 
of PTMs (Choudhary et al., 2009). In addition, MS is often employed in interaction studies 
???? ??????????????? ??? ????????? ???????????? ????? ?? ??????. In such interaction experiments a 
central challenge is to distinguish unspecifically binding proteins (background binders) 
from genuine interactors (specific binders) of the bait of interest. To alleviate this problem 
interaction screens can be performed in a quantitative manner, most accurately by using 
isotope labeling approaches such as Stable Isotope Labeling with Amino Acids in Cell 
culture (SILAC) (de Godoy et al., 2008; Ong et al., 2002). The use of quantitative 
approaches was recently described for the study of PAR-binding proteins (Gagne et al., 
2012), but has until now not been employed for a systems-wide identification of PARylated 
proteins under genotoxic stress. Previous attempts to identify in vivo PARylated proteins 
did not utilize quantitative information, and only focused on proteins modified under basal 
(unstressed) cellular conditions (Dani et al., 2009). PAR formation, however, dramatically 
increases in response to certain genotoxic stress (Malanga and Althaus, 1994). As a 
consequence, only a subset of PARylated proteins was identified in previous studies, and 
the functional relevance of the identified PARylated proteins was not investigated.  
Here, we describe a MS-based SILAC approach for assessing the extent of PARylated 
proteins under various types of genotoxic stress. The presented approach entails growing 
mammalian cells in three SILAC conditions by incorporating respectively ????????? ? ???????
???????????amino acids (13C and 15N isotope-labeled lysines and arginines) into all cellular 
proteins (Ong et al., 2002). From these SILAC encoded lysates pull-down experiments are 
performed under stringent conditions using a PAR-binding module known to recognize 
covalently PARylated proteins (Karras et al., 2005) in combination with a binding-defective 
mutant allowing for quantitative distinction between PARylated proteins and background 
binders. Briefly, the binding-defective mutant is used for pull-???????????????????????????????
while the wild-type PAR binding module is used for pull-down experiments in both 
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? ???????????????????????????????????igure 1A). Protein eluates from all three pull-down 
conditions are combined, digested to peptides and PARylated proteins are identified by 
liquid chromatography tandem mass spectrometry (LC MS/MS). Collectively, this allows 
for identification of covalently ?????????? ????????? ??? ?? ????????????? ??????????? ??? ????????
???? ? ??????? ?????? ???????? ?????? ????????????? ????????? ???? ?????????????? ??? stress-
dependent modulations of protein PARylation ???????????????????????????????????????????? 
Using the established approach we identify a large number of PARylated proteins induced 
under various types of genotoxic stress, and confirm several novel PARylated protein 
targets through biochemical in vitro and in vivo assays. Moreover, the presented method 
identifies for all four tested stresses the majority of already known modified proteins, 
involved in DNA metabolism, collectively demonstrating the ability of the methodology to 
recognize PARylated proteins and in agreement with the nuclear functions ascribed to the 
major PAR-inducing enzymes, ARTD1 and ARTD2. A comparison of the different types of 
genotoxic stress revealed that oxidative and alkylation stress induces PARylation of a 
large number of proteins involved in RNA metabolism. This positions PARylation as an 
important functional link between the DNA and RNA metabolic processes. To emphasize 
this connection our data reveals that pre-mRNA splicing protein THRAP3 is PARylated 
under oxidative damage. THRAP3 has previously been demonstrated to play a role in the 
DDR in a manner that parallels transcription inhibition (Beli et al., 2012). Moreover, we 
demonstrate that under transcriptional inhibition PARylation of THRAP3 affects its cellular 
localization and prevents the protein from co-localizing with splicing factors in nuclear 
speckles. Collectively, the presented dataset provides a clearer definition of PARylated 
proteins in human cells, and describes how they vary under different genotoxic stress 
conditions. 
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Results 
Establishing a proteomic approach for identification of genotoxic stress-dependent protein 
PARylation 
As an initial step we decided to evaluate the binding properties of Af1521_wt in a SILAC 
setup as compared to its binding-deficient counterpart Af1521 G42E. To this end, we 
performed a specific triple-encoded SILAC pull-down experiment, where we incubated 
untreated light-labeled U2OS cell lysate with unbound glutathione-sepharose beads 
containing no Af1521 domain. In contrast to this, a medium-labeled U2OS lysate was 
incubated with crosslinked GST-Af1521_mut beads while a heavy-labeled lysate was 
incubated with GST-Af1521_wt beads (Figure S1A). Eluates from all three SILAC states 
were mixed 1:1:1 and subsequently analyzed by LC-M/MS. To assess the technical 
reproducibility of the experimental setup a replicate ???????????????? ??? was performed, 
where medium and heavy SILAC labels were swapped (Figure S1B). Statistical analysis 
revealed that results derived from the pull-down experiments were highly consistent 
yielding a Pearson correlation of >0.83 when plotting corresponding SILAC ratios from the 
replicate experiments (Figure S1C). It should be noted that the actual ratios in SILAC-
based interaction studies do not have to be identical between experiments, as they 
primarily serve to segregate background binders from specific interactors. However, strong 
correlation coefficients indicate high quantitative reproducibility between replicate 
experiments. 
We next investigated which proteins were differentially bound between Af1521_wt and 
Af1521_mut pull-downs. This was achieved through a direct comparison of their SILAC 
ratios, which revealed a large fraction of proteins with increased abundance (stronger 
affinity) for Af1521_wt compared to Af1521_mut (Figure 2A). A functional Gene Ontology 
(GO) enrichment analysis of the regulated proteins identified these as factors primarily 
involved in DNA repair processes. Analyzing the same experiment by immunoblot using a 
PAR-antibody demonstrated a strong increase in protein PARylation for pull-down with 
Af1521_wt, including the known major target ARTD1 (Figure 2B). In contrast, no 
PARylation signal was observed for Af1521_mut. 
Although our results confirm that Af1521_wt can be employed as a PAR-binding module in 
a SILAC-based manner, we were intrigued by the observed enrichment of PARylated 
proteins in the absence of genotoxic stress (Figure 2A). The basal in vivo activity of 
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ARTD1 has previously been described as low, considerably stimulated only through 
genotoxic stress and regulated by the opposing actions of PARG (Bonicalzi et al., 2005). 
However, cell lines growing in culture are usually characterized by a high proliferation 
status and consequently enhanced levels of genomic instability (Bartkova et al., 2005; 
Gorgoulis et al., 2005). This increases the risk of accumulating genotoxic byproducts from 
metabolic processes, which might contribute to elevated genotoxic stress response in 
otherwise untreated cells. Alternatively, it is well established that in vitro PAR formation by 
ARTD1 solely requires the presence of NAD+ and DNA fragments (Altmeyer et al., 2009; 
Langelier et al., 2012). Thus shearing of DNA during cell lysis could also be the cause of 
unphysiological activation of PAR formation despite fast and gentle sample handling being 
employed (see methods section). 
To investigate whether sample handling or endogenous cellular processes account for the 
activation of ARTD1 and the observed protein PARylation, we performed another SILAC 
screen employing PARP inhibitors during sample preparation. To this end, we set up a 
triple-encoded SILAC experiment using only the Af1521_wt domain as pull-??????????? for 
all three SILAC states (Figure S2A). For light and medium SILAC cells PARP inhibitor (PJ-
34 or 3-aminobenzamide) was added to the lysis buffer, while heavy SILAC cells were left 
untreated during the entire sample handling. Additionally, light SILAC cells were pretreated 
with the same PARP inhibitor for 2 hours prior to cell lysis, essentially exposing them to 
PARP inhibitor throughout the entire experimental sample procedure (Figure S2A). 
Following MS analysis of the pull-downs a substantial fraction of proteins was found 
regulated more than 4-fold in the heavy SILAC sample (complete absence of PARP 
inhibitor; Figure S2B; H/L ratios). Contrary to this, very little ADP-ribosylation was detected 
in cells only exposed to PARP inhibitors in the lysis buffer, strongly supporting the notion 
that post-lysis mechanical shearing stress triggers ARTD enzymatic activity (Figure S2B) 
(Beneke et al., 2012). Western blot analysis of the same pull-down samples using PAR 
and ARTD1 antibodies further corroborated these results, with enrichment of PARylated 
proteins only being observed in the absence of PARP inhibitor 3-AB or PJ-34 (Figure 2C 
and S2C). Moreover, hierarchical clustering of the PARylated proteins affected by the 
sample preparation procedure (+/- PARP inhibitors) revealed, as expected, that mainly 
DNA repair pathways are affected by these processes (Figure 2D). On the basis of these 
findings we included PARP inhibitors in all sample preparations and set out to investigate 
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the extent of PARylation upon induction of various types of genotoxic stress. Immunoblot 
analysis of cells exposed to oxidative stress by hydrogen peroxide (H2O2) treatment 
showed only a relatively mild increase in PAR levels (Figure 2E), which could be related to 
the short half-life of PAR polymers. The steady-state levels of PAR are tightly controlled by 
the opposing action of PAR-degrading enzymes, of which PARG exhibits the greatest 
enzymatic activity (Cortes et al., 2004). As a result, the half-life of cellular PARylation has 
been estimated to less than a few minutes (Alvarez-Gonzalez and Althaus, 1989). Thus, in 
order to sustain PAR levels throughout the pull-down procedure and hereby increase the 
sensitivity of our system, we decided to reduce PARG activity by protein depletion via an 
RNAi-based approach. Figure 2E confirms that knockdown of PARG resulted in increased 
PAR levels in response to H2O2 treatment. Based on these observations, we decided to 
alleviate the opposing PARG activity by siRNA-dependent depletion, and include PARP 
and PARG inhibitors in the lysis buffer for all following experiments.  
 
Proteomic investigation of the differential impact of various types of genotoxic stress on 
protein PARylation  
Having established a robust SILAC-based workflow for enrichment of PARylated proteins, 
we next investigated the effects of genotoxic agents described to inflict various types of 
genotoxic stress to elicit different repair responses to these lesions. To this end, we 
performed four SILAC experiments respectively investigating PARylated proteins upon 
treatment with H2O2 to induce oxidative stress, methyl methane sulfonate (MMS) to induce 
alkylating damage, ultraviolet radiation (UV) for the formation of CPDs and 6-4 PPs, and 
ionizing radiation (IR) primarily for induction of double strand breaks (DSBs) (Figure 3A).  
Only cells grown in heavy SILAC media were exposed to genotoxic agents, hence 
PARylated substrates should exhibit an increase in Heavy/Light (H/L) SILAC ratio as 
compared to the M/L ratios (cells not exposed to genotoxic stress). To validate this, we 
plotted the logarithmized M/L and H/L SILAC ratios of the quantified proteins derived from 
the SILAC experiment exposed to H2O2 insult (Figure 3B). These data showed that the 
distribution of SILAC ratios of quantified proteins indeed is shifted towards higher H/L 
SILAC ratios as compared to the M/L counterparts, demonstrating significantly increased 
(p = 9.69e-35) protein PARylation upon genotoxic stress (Figure 3B). Moreover, since light 
and medium SILAC conditions essentially are the same for all four SILAC experiments, 
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they constitute an internal control condition between pull-downs. Hence, to ensure proper 
comparability between the acquired SILAC experiments we compared the M/L ratios of all 
four datasets by Q-Q probability plots (Wilk and Gnanadesikan, 1968). All Q-Q plots 
followed a straight 45 degree line (y = x) for the investigated sample pairs with strong 
correlation coefficients (R2>0.98), hence, the SILAC experiments can be regarded 
comparable (Figure S3A). As further validation of the data, box plot analysis for all M/L 
ratios demonstrated identical distributions across all investigated samples (Figure 3C). In 
contrast, box plot analysis of genotoxic stress-induced samples (H/L ratios) revealed much 
broader distributions confirming that PARylated proteins are induced in all applied 
treatments (Figure 3D). Strikingly, the degree of regulation was dependent upon the 
source of exogenous damage, which in the instance of H2O2 revealed the strongest 
response followed by MMS, UV and IR in a steadily decreasing manner (Figure 3D). 
Western blot analysis of cellular PARylation generated by the different genotoxic stress 
treatments revealed an identical pattern (Figure 3E), confirming the direct association 
between PARylated proteins and measured SILAC ratios. In support of the varying degree 
of PARylation caused by the different genotoxic stress treatments, a heat map clustered 
H2O2 and MMS samples together demonstrating that these chemical agents cause the 
greatest degree of PARylation (Figure 3F).  In order to determine which proteins are 
significantly enriched in each pull-down experiment, we used ??????????????-???????? strategy 
based upon the student t-test to establish statistical significance (p < 0.01) (Cox and 
Mann, 2008). In doing so, a total of 165 proteins could be determined as significantly 
upregulated in the four experiments. However, these measurements take only a normal 
distribution of the dataset into account, while PARylation during the H2O2 and MMS 
treatments affect a much larger proportion of proteins compared to UV or IR damage 
(Figure 3D and 3E). This causes an overall augmentation of the H/L ratios disproportioned 
to the background binders, which can lead to an underestimation of significance 
measurements that are based on normal distributions. As a consequence, we included 
PARylated substrates from the H2O2 and MMS experiments if they exhibited at least 2.5-
fold upregulation in their H/L ratios, concomitantly assuring stringency for determining true 
interaction partners. Taken together, we identified 235 proteins from the four pull-down 
experiments as being significantly enriched under the investigated genotoxic stress 
conditions (Table S2).  
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To assess the sensitivity of our SILAC screen we compared our identified PARylome to a 
comprehensive proteomic study that analyzed the expression levels of >11,500 proteins 
from 11 different cell lines including U2OS cells, which we also used for our PARylation 
study  (Geiger et al., 2012),. Interestingly, within this large protein expression repository 
five PARylated proteins identified in our screen were not found in any of the investigated 
cell lines. These PARylated proteins could in principle entail false-positive identifications 
from our screen, but considering each protein was identified with sub ppm accuracy, 
between 2-12 unique peptides and significant SILAC ratios renders this unlikely to be the 
case (Figure S3B). Instead, the detection and quantification of low abundant proteins in 
our pull-down experiment highlights the sensitivity of our approach, and validates that the 
established approach is not biased towards abundant proteins. 
Investigation of the cellular distribution of the identified substrates by GO enrichment 
analysis revealed that 76% of the PARylated proteins belong to the nucleus (Figure 3G), 
signifying a strong enrichment of nuclear PARylation targets considering pull-down 
experiments were performed on whole cell lysates. This is in full agreement with the 
known nuclear localization of ARTD1 and ARTD2, which together account for the majority 
of genotoxic stress-induced PAR formation in cells.  
 
Proving direct ADP-ribosylation of novel target proteins 
In order to select novel candidates for further investigation of PARylation-dependent 
processes, we first compared our dataset to previously published PARylation targets 
involved in DNA repair as defined by GO annotation. We identified several of the proteins 
proposed to be PARylated, including ARTD1, FACT140 (SUPT16H), XRCC5, XRCC6, 
PCNA, RPA1, RPA2, XRCC1, TOP2 and HMGB1, further strengthening the reliability of 
our SILAC approach (Figure 4A). Cell-type specific protein expression or the requirement 
for specific genotoxic conditions could account for not identifying six previously suggested 
PARylated proteins. However, besides confirming the majority of known PARylated 
proteins involved in DNA metabolism, we additionally found 18 new PARylation targets 
specifically described to play a role in DNA-repair related processes (Figure 4A). 
Moreover, we identified several histones previously proven by mass spectrometry-based 
approaches to be direct targets of PARylation in vitro (Messner et al., 2010).  
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As a further demonstration that our established method targets PARylated proteins, we 
biochemically verified covalent PAR modification of purified proteins by in vitro PARylation 
assays. Recombinant protein substrates were incubated with purified ARTD1 or ARTD2 
enzymes in the presence of [32P]-NAD+ and a DNA fragment in order to measure 
incorporation of NAD+ radioactivity by autoradiography. Activation of ARTD1 and ARTD2 
was confirmed by detection of strongly auto-modified ARTD1 or ARTD2 in the upper part 
of the gel lanes (Figure 4B and 4C respectively). Using ARTD1 in the assay a strong 
PARylation of PNKP, MPG, MECP2, NUSAP1 and POLR2E, and to a lesser degree of 
CETN and CDK2 could be detected. For XPC it was difficult to confirm in vitro PARylation 
as the protein runs with an almost similar size as ARTD1 (103 kDa versus 111 kDa). 
Consequently, PARylation signal from XPC is completely overlaid by the signal arising 
from auto-modified ARTD1. A similar problem arises for ARTD2, which at a mass of 64 
kDa further limits the detection range. Still, MPG is validated as PARylated by ARTD2 in 
vitro (Figure 4C). Collectively, we conclude that our methodology targets covalently 
PARylated proteins and not proteins that non-covalently bind PAR. Several of the newly 
identified PARylated proteins including PNKP, MPG, NUSAP1, CETN2 and CDK2, have 
also previously been assigned with a functional role in DNA repair processes, indicative of 
PARylation influencing their mode of operation in DNA metabolism.  
Notably, the derived in vitro results are in agreement with the fact that ARTD1 is 
responsible for the largest part of cellular PAR, whereas ARTD2 accounts only for up to 
15% of PAR formation (Ame et al., 1999). This characteristic seems to be reflected not 
only in the amount of poly(ADP-ribose) formed but also the number of actual targets. In 
support of ARTD1 being the primary enzyme responsible for the identified PARylated 
substrates, siRNA-mediated knockdown of ARTD1 resulted in a strong decline of the PAR 
signal. In contrast, siARTD2-treated cells hardly showed any difference compared to cells 
treated with control siRNA (Figure 4D). Although residual PAR-signal in siARTD1-treated 
cells could arise from the activity of ARTD2, the incomplete knockdown of the abundantly 
expressed ARTD1 could equally account for low-level PAR formation (Figure 4D). Notably, 
we detected a reduced signal for phospho-p53 (Ser15) for all investigated genotoxic stress 
treatments following ARTD1 down-regulation. This in agreement with previous reports 
showing comprised DDR signaling for PAR-inhibited cells (Haince et al., 2007), 
highlighting the role of PAR as an early genotoxic stress sensory molecule.   
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With ARTD1 being the most active ARTD enzyme in our experiments it is not surprising 
that ARTD1 itself was found to be PARylated under all four genotoxic stress conditions 
(Figure 4E). In contrast, ARTD2 was significantly determined as being PARylated merely 
under H2O2 treatment, highlighting the stringent criteria set to ensure strong confidence in 
identification of PARylated substrates. Among the entire ARTD family we additionally 
found ARTD16/PARP8 and ARTD12/PARP12 to be PARylated under specific types of 
genotoxic stress (Fig. 4E). Although the functional role of these two enzymes is still largely 
unknown, their postulated nuclear localization could make them likely targets for ARTD1 
activity, which in conjunction with the identification of genotoxic stress regulated 
phosphorylation sites in ARTD16 (Matsuoka et al., 2007) opens up the possibility that their 
functional regulation could be associated with genotoxic stress responses.    
 
Novel targets for poly(ADP-ribosyl)ation in vivo are involved in different cellular processes  
To corroborate the in vitro validation of PARylated substrates with in vivo data, we verified 
a number of newly in vitro identified PARylation targets by immunoblot analysis using 
specific antibodies following Af1521_wt pull-down. In response to H2O2-induced stress we 
found enrichment of MPG (MID1), PNKP, MECP2, XPC and NUSAP1, while NF-?B p65 
served as a negative control (Figure 5A). Pre-treatment of the cells with PARP inhibitor PJ-
34 completely abolished the signal confirming that enrichment occurs in a PARP-
dependent manner.  
To further demonstrate PARylation of novel targets under physiological in vivo conditions, 
we performed immunoprecipitation of stably expressed GFP-tagged proteins under the 
control of their endogeneous promoters (Poser et al., 2008), and blotted them with PAR-
antibody. In order to cover the functional diversity of targets in our dataset best way 
possible, we selected proteins regulating different nuclear processes. We verified our 
findings for TAF15, which belongs to the TET (TLS/FUS, EWS, TAF15) protein family of 
RNA and DNA-binding proteins. Members of this family have been reported to modulate 
gene expression by controlling transcription, splicing, RNA transport and DNA repair 
processes (Ballarino et al., 2012; Law et al., 2006; Tan and Manley, 2009). Using GFP-
TAF15 expressing HeLa cells we could confirm the results of the Af1521 pull-down by 
Western Blot; and similarly, GFP-TAF15 was validated to be PARylated by GFP-
immunoprecipitation in a genotoxic stress- and PARP inhibitor-repressed manner (Figure 
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5B). Strikingly, we found all three members of the TET protein family to be PARylated 
proteins under genotoxic stress conditions (Table S2), suggesting a common role for 
PARylation in regulating the function of these proteins in response to genotoxic stress.  
Another RNA-associated factor that we discovered to be PARylated in a genotoxic stress-
dependent manner was THRAP3 (TRAP150), which has been shown to control mRNA-
splicing and nuclear mRNA degradation and was recently assigned a role in the DDR (Beli 
et al., 2012; Lee et al., 2010). In support of our SILAC data, we found GFP-THRAP3 to be 
enriched in the Af1521 pull-down in a PARP-dependent manner by immunoblotting, and 
conversely, validated it to be strongly PARylated upon GFP-immunoprecipitation (Figure 
5B).  
The ATPase SMARCA5 (SNF2h) is a chromatin remodeler belonging to the SWI/SNF 
family of proteins, and has recently been linked to genotoxic stress signaling in a manner 
dependent on PAR formation (Smeenk et al., 2012). Despite harboring a putative PAR-
binding motif, the sequence was shown to be dispensable for PAR binding in vitro (Gagne 
et al., 2008) as well as for PARP-dependent accumulation of SMARCA5 at DSBs (Smeenk 
et al., 2012). On the other hand, no direct in vivo PARylation of SMARCA5 was detected 
following DNA damage (Smeenk et al., 2012), which could be the consequence of the 
transient nature or low degree of PARylation of SMARCA5. In the background of reduced 
PARG activity we could effectively confirm direct in vivo PARylation of SMARCA5 by GFP- 
immunoprecipitation and Af1521 pull-down (Figure 5B). In a recent study ARTD1 was 
demonstrated to PARylate several components of a tandem affinity purified TIP5 complex, 
hereby contributing to the repression of rRNA transcription and the establishment of silent 
rDNA chromatin during cell division (Guetg et al., 2012). SMARCA5 was found to be part 
of this complex, which is also referred to as nucleolar remodeling complex NoRC, 
indicating that PARylation of SMARCA5 could regulate additional processes than the 
DDR. Interestingly, in our genotoxic stress screen we also identify H2O2 and MMS-
dependent PARylation of UBTF/UBF1, another factor involved in regulation of nucleolar 
chromatin, supporting the idea of PARylation as a mean to coordinate nucleolar function in 
response to genotoxic stress.  
Chromatin remodelers have recently been recognized as important signaling coordinators 
in genome stability pathways (Papamichos-Chronakis and Peterson, 2013). Compelling 
evidence shows that PARylation governs access and activities of some of these factors at 
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sites of DNA damage, as recently demonstrated for CHD1L (ALC1) and CHD4 (Ahel et al., 
2009; Chou et al., 2010; Pines et al., 2012). Intriguingly, we observed a strong PARylation 
of CHD1L in all four genotoxic stress treatments, while CHD2 was only modified in 
response to H2O2 and MMS and CHD4 only after MMS treatment, indicating that direct 
PARylation of these proteins may regulate their functions (Table S2). In support of this 
notion, loss of CHD2 has recently been reported to result in defective genotoxic stress 
signaling and genomic instability (Nagarajan et al., 2009). It would therefore be of interest 
to study how PARylation regulates the function of CHD2 and other chromatin remodeling 
factors function at the chromatin level, but such investigations were out of the scope of this 
study. 
 
Comparative analysis of the genotoxic stress-induced PARylome reveals distinct 
regulation of RNA metabolism in response to oxidative and alkylating damage   
A functional GO analysis of regulated proteins from all SILAC experiments revealed, as 
expected, that DNA metabolic processes are significantly enriched (Figure 6A). A 
considerable portion of these factors are involved in DNA repair (p-value < 9e-5) including 
many of the previously published candidates (Figure S4A). Strikingly, more than 60% of all 
significantly regulated proteins also comprise nucleic acid binding activity (Figure 6B). 
Although the proportion of RNA binding proteins in the complete dataset was less 
compared to DNA binding proteins, their enrichment in relation to the total number of RNA-
binding proteins in the genome was more than 2-fold higher with a concomitantly 
enhanced p-value. This strongly suggests that post-transcriptional processes such as 
splicing, polyadenylation, mRNA stability and transport, and translation are readily 
controlled by PARylation-induced genotoxic stress. This finding is supported by recent 
genome-wide siRNA screens establishing a functional intersection of RNA processing with 
DNA repair (Adamson et al., 2012; Paulsen et al., 2009), although very few RNA 
processing factors hitherto have been examined in detail for their link to the DDR (Li and 
Manley, 2005; Moumen et al., 2005; Ramachandran et al., 2011). Our data therefore infers 
that PARylation of RNA-processing factors upon genotoxic insult may provide an 
additional layer for the participation of RNA-binding proteins in the DDR.  
In order to assess the specific functional consequences of PARylation under different 
types of genotoxic stress we compared the significantly regulated protein population of 
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each single genotoxic stress experiment to all others (Figure 6A and Suppl. Table S2). In 
doing so, we identified ten proteins to be PARylated in all four genotoxic stress conditions 
(ARTD1, RPA1, MPG, TAF15, FUS, RBMX, ALC1, DTX2, RUNX1 and ZNF384). 
Interestingly, dissection of the single genotoxic stress-specific datasets revealed that 
particularly H2O2 and MMS treatment affect proteins involved in RNA metabolic processes 
including transcription, RNA processing and RNA splicing (Figure 6C and Figure S4A). 
This observation is also reflected by the overrepresentation of RNA-binding proteins in 
H2O2 and MMS samples, whereas the enrichment of regulated DNA-binding proteins is 
equal for all genotoxic stress conditions (Figure S4B). A functional network analysis 
showed that a large number of PARylated substrates involved in RNA metabolic 
processes are interconnected (Figure 6D). The majority of proteins involved in RNA 
metabolic processes is hitherto unknown to be targeted for PARylation with only few 
proteins previously published to be modified including members of the HNRNP family and 
SUPT16H (FACT140) (Huang et al., 2006; Ji and Tulin, 2009). However, emerging 
evidence indicates that PARylation plays an important role in RNA processes during 
genotoxic stress. In fact, in a recent siRNA screen the RNA-binding protein RBMX was 
identified as positive regulator of homologues recombination and found to localize to sites 
of DNA damage in PARylation-dependent manner (Adamson et al., 2012). Notably, we 
identify RBMX as a PARylation target upon all applied genotoxic stress treatments in our 
SILAC screen supporting the concept of ARTD1-dependent regulation of RBMX (Table 
S1). To further investigate the role of PARylation in RNA metabolic processes during 
genotoxic stress, we decided to conduct more detailed analysis of the two proteins TAF15 
and THRAP3, for which we confirmed genotoxic stress-dependent PARylation using in 
vivo assays (Figure 5B).  
The biological role of THRAP3 has previously been reported to be functionally linked to its 
localization in nuclear speckles (Lee et al., 2010). Dynamic spatio-temporal reorganization 
of subnuclear structures and their constituents are important to efficiently coordinate 
nuclear processes and cellular stress responses. Nuclear speckles have been shown to 
function in storage, assembly and modification of splicing factors. Hereby, a cell-type 
specific basal exchange level of splicing factors occurs between speckles and 
nucleoplasm, which is modulated upon stress conditions such as transcriptional inhibition.  
In contrast to the cytoplasm, compartmentalization within the nucleus is not dependent on 
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diffusion barriers, such as membranes. Thus, reorganization of subnuclear structures are 
often regulated by protein modifications such as phosphorylation/dephosphorylation 
events (Lamond and Spector, 2003). As a result, we surmised that PARylation of THRAP3 
could constitute another mechanism to regulate stress-dependent assembly of factors in 
nuclear speckles.  
To investigate this in more detail, we analyzed the cellular localization of GFP-tagged 
THRAP3 under transcriptional inhibition of RNAP I and II using the known inhibitor 
Actinomycin D (ActD) (Shav-Tal et al., 2005). Incubation of THRAP3-GFP expressing cells 
with ActD for 3 hours hardly changed the size of THRAP3 containing speckles albeit 
speckles appeared to round up (Figure 7A). Additional exposure of ActD-treated cells to 
oxidative stress led to the formation of enlarged, rounded speckles within 2 hours of H2O2 
treatment, possibly reflecting a more substantiated inhibition of transcription. Intriguingly, 
pre-incubation with PARP inhibitor PJ-34 largely prevented accumulation of THRAP3 in 
enlarged nuclear speckles (Figure 7A) upon oxidative stress, supporting a concept, in 
which the stress-related function of THRAP3 is regulated in a PARylation-dependent 
manner.  
Another phenomenon of nuclear restructuring involves the accumulation of a specific set of 
proteins in perinuleolar caps (Shav-Tal 2005). Transcriptional inhibition using ActD has 
been shown to induce nucleolar segregation of nucleolar components resulting in the 
formation of nucleolar cap structures typically surrounded by a dense chromatin ring. All 
members of the TET family of proteins (TAF15, FUS and EWS) are known to accumulate 
in these caps (Joberts, EMBO Rep. 2009, Shav-Tal 2005), and we find all of them to be 
highly regulated in our screen for PARylated targets in response to H2O2, MMS and UV 
radiation. This led us to further investigate whether PARylation would also contribute to the 
regulation of nucleolar cap formation upon genotoxic stress. In agreement with previous 
observations we found TAF15-GFP to be enriched in cap-like structures upon 
transcriptional inhibition with ActD (Figure 7B) (Joberts, EMBO Rep. 2009) but not upon 
exposure to oxidative stress alone (Figure S5A). Interestingly, nucleolar cap formation was 
abrogated when ActD-treated cells were exposed for 1h to H2O2, indicating that oxidative 
stress regulates reorganization of nucleolar structures. Even more strikingly, the presence 
of PARP inhibitor PJ34 rescued the formation of TAF15 containing cap-like structures after 
H2O2 but also after exposure to alkylating stress using MMS (Figure 7B). Collectively, we 
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reason that PARylation regulates the spatio-temporal dynamics of nuclear factors THRAP3 
and TAF15 thereby coordinating RNA metabolic processes in response to genotoxic 
stress. 
 
Discussion 
Here, we describe a SILAC-based enrichment strategy for high confidence in vivo 
detection of PARylated proteins under various types of genotoxic stress, providing the 
largest dataset for covalently modified ARTD substrates to date. Substantial efforts were 
made on establishing an optimized technical protocol including the important use of PARP 
inhibitors during sample preparation to circumvent artificial PARylation of proteins, which 
otherwise could lead to overestimation or misinterpretation of the quantitative data. In 
strong support of the acquired data we prove covalent PARylation of several new targets 
by in vitro and in vivo approaches. Intriguingly, functional analysis of the dataset 
establishes extensive regulation of processes related to DNA metabolism but significantly 
also RNA metabolism including transcription, RNA splicing and transport. We specifically 
uncover a novel role of PARylation for THRAP3 and TAF15 in the coordination and 
assembly of subnuclear structures thereby facilitating the efficient regulation of cellular 
responses to genotoxic stress.      
The activity of ARTD1 has long been known to have an impact on base excision repair 
(BER) and single strand break repair (SSBR) (Dantzer et al., 2000; Fisher et al., 2007), 
although its specific role in these processes has remained under debate. Recent reports 
proposed a model in which ARTD1 activity increases the repair capacity by recurring 
binding to SSBs for their protection if excessive amount of DNA damage limits the 
immediate availability of actual repair proteins (Dianov and Hubscher, 2013; Helleday, 
2011). In our screen we identified several proteins of the BER and SSBR machinery to be 
PARylated (ARTD1, XRCC1, MPG, LIG3, PCNA) extending the list of previously known 
targets by the DNA glycosylase MPG and DNA ligase LIG3 (Rouleau et al., 2007; 
Sedgwick et al., 2007; Simbulan-Rosenthal et al., 1996), indicating that direct PARylation 
of repair factors could constitute an additional level of regulating repair efficiency. Another 
newly identified and in vitro validated PARylation target, PNKP, has also been described to 
serve a critical role in processing broken DNA strands to allow an efficient repair process 
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(Weinfeld et al., 2011) indicating that PARylation might affect the enzymatic activity of its 
substrate proteins. Additionally, ARTD enzymes have been demonstrated to play 
important roles in other DNA repair pathways such as nucleotide excision repair, mismatch 
repair and non-homologues end joining, which is supported by our findings of regulated 
pathway-specific proteins such as XPC and CETN2, MSH2 and MSH6, XRCC5 and 
XRCC6, respectively. Whether PARylation of pathway-specific proteins either positively or 
negatively regulates their function, and how specific types of DNA lesions are involved in 
these processes, remains to be elucidated.  
Besides direct PARylation of target proteins cellular responses to genotoxic stress are 
regulated by the recruitment of PAR-binding proteins through one of the four described 
PAR-binding modules (Kalisch et al., 2012). Recent proteomic studies focused on the 
identification and regulation of non-covalently PAR-binding proteins by employing non-
denaturing affinity purification methods, which however cannot avoid co-enrichment of 
PARylated proteins (Gagne et al., 2012).  We specifically determined the extent of 
covalently PARylated proteins under various types of genotoxic stress using denaturing 
enrichment methods. In support of our method targeting specifically PARylated substrates 
we did not identify PAR-binding factors such as macro H2A.1, APLF, CHFR and RNF146 
which have been reported to rapidly accumulate at sites of DNA damage through their 
PAR-binding motifs (Grundy et al., 2013; Kang et al., 2011; Li et al., 2010; Liu et al., 2013; 
Timinszky et al., 2009). Nevertheless, it cannot be excluded that PAR-binding proteins 
also become subject to direct PARylation, which according to our dataset appears to be 
the case for ALC1, C6orf130 and Trip12, suggesting a complex interplay between PAR-
binding activities and PARylation of substrate proteins. Macrodomain-containing protein 
Af1521 was recently also identified to be a mono-ADP-ribosyl hydrolase (Jankevicius et 
al., 2013; Rosenthal et al., 2013a). However, this activity did not interfere with our 
experimental setup, since all reactions were performed at 4?C and the proteins we 
primarily monitored were poly(ADP-ribos)ylated.  
We found that PARylation affects a large number of proteins involved in RNA metabolic 
processes, with a significant enhancement in response to oxidative and alkylation stress 
as compared to UV or IR. It has only started to become apparent in recent years that 
PARylation seems to provide an important link between the DNA damage response (DDR) 
and RNA metabolism (Adamson et al., 2012; Kruhlak et al., 2007; Paulsen et al., 2009; 
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Shanbhag et al., 2010). Moreover, mutations in the spliceosome machinery are frequent in 
malignancies (Papaemmanuil et al., 2011; Yoshida et al., 2011), implying a potential role 
for RNA splicing factors in maintaining genome stability and protection against cancer. 
This connection is supported by detailed analysis of pre-mRNA splicing factor THRAP3 
that we show to be PARylated in vivo under oxidative damage. THRAP3 has previously 
been demonstrated to play a role in the DDR in a manner that parallels transcription 
inhibition (Beli et al., 2012) and we find that under transcriptional inhibition PARylation of 
THRAP3 affects its cellular localization and prevents the protein from co-localizing with 
splicing factors in nuclear speckles. Further emphasizing the considerable enrichment of 
RNA-binding proteins in our dataset, we selected TAF15 for further follow-up studies 
thereby proving in vivo PARylation of TAF15 and establishing a role for PARylation in 
coordinating its subnuclear distribution and function. TAF15 is a member of the TET 
protein family, that has been described to contribute to the control of transcription, splicing, 
RNA transport and DNA repair processes (Ballarino et al., 2012; Law et al., 2006; Tan and 
Manley, 2009). The TET proteins are frequently discovered to be involved in genetic-
translocations in sarcomas, where their aminoterminal transactivation domain is fused to 
DNA binding domains of transcription factors, hereby causing inappropriate transcriptional 
activation of target genes (Law et al., 2006). Furthermore, depletion of FUS or EWS leads 
to increased genomic instability and sensitivity to UV and ionizing radiation (Hicks et al., 
2000; Kuroda et al., 2000; Li et al., 2007; Paronetto et al., 2011). In fact, recent studies 
????? ????? ????????????? ???????? ???coma cells and xenografts, harbouring genomic 
fusions of EWS with specific transcription factors, to be highly sensitive towards ARTD1 
inhibition (Brenner et al., 2012; Garnett et al., 2012). Suggested mechanisms for the 
increased sensitivity included both enforced accumulation of DNA damage and ARTD1-
dependent positive feedback loops specifically of EWS-FLI1 fusion proteins for 
transcriptional activation (Brenner et al., 2012). Direct PARylation of EWS as well as of 
other TET family members, as we identify in our SILAC screen, could provide another 
means to regulate the function and activity of these proteins and its translocation-based 
fusion products.  
Previously, PARylation has received much attention as a potential target in cancer 
therapy. PARP inhibitors showed promising results in early clinical trials with a particular 
focus on treatment of tumors from HR-defective BRCA-mutation carriers, for which PARP 
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inhibition is speculated to interfere with efficient SSB-repair resulting in synthetic lethality 
of tumor cells (Fong et al., 2009). Since our results confirm PARylation of proteins involved 
in RNA metabolic processes, further elucidation of the regulatory role of PARylation in 
these processes upon genotoxic stress might provide valuable information for future 
strategies to effectively treat specific cancer subtypes with PARP inhibitors.  
Only recently, the phenomenon of PAR-dependent ubiquitylation has emerged highlighting 
an important regulatory crosstalk between PARylation and ubiquitylation. The E3 ligase 
RNF146 was recently reported to become recruited to PARylated ARTD1 through its PAR-
binding WWE domain, which activates its ligase activity in order to poly-ubiquitinate 
specifically auto-modified ARTD1, thereby targeting ARTD1 for proteasomal degradation 
(Kang et al., 2011). Similarly, the E3 ligase CHFR/RNF196, comprising a PAR-binding zinc 
finger, has been reported to contribute to PAR-dependent ubiquitylation of PARylated 
ARTD1 at DSBs but also upon mitotic stress (Kashima et al., 2012; Liu et al., 2013). It is 
therefore likely that other PARylated proteins are substrates for PAR-dependent 
ubiquitylation upon induction of genotoxic stress-induced PAR formation in order to assure 
target-specific degradation. Additional studies using our quantitative pull-down strategy 
could specifically identify such targets in cells exposed to genotoxic stress or microtubule 
inhibitors to investigate novel regulatory PAR-dependent functions controlling the DNA 
damage response or the mitotic checkpoint. 
In summary, our SILAC-based enrichment approach largely extends the current 
knowledge on PARylation substrates that become targeted under various types of 
genotoxic stress. The next step will be to determine specific amino acids that act as 
acceptor sites for PAR chains in vivo, preferentially using mass-spectrometry-based 
techniques. Advances have recently been made in identifying lysine residues as novel 
acceptor sites for PAR (Altmeyer et al., 2009; Chapman et al., 2013; Messner et al., 2010). 
However, the complexity of the PAR polymer chain raises technical challenges, and highly 
advanced protocols will be required for the specific enrichment of PARylated peptides and 
their subsequent mass spectrometric analysis. Still, future investigations most likely will 
center on pinpointing specific amino acids as acceptors for PARylation of proteins, as well 
as the detailed circumstances and effects of the occurrence of this modification.    
 
  
138
#!"
"
Experimental Procedures 
Cell Culture and Transfection 
U2OS and HeLa cells were grown in D-MEM (Invitrogen) supplemented with 10% FCS 
and penicillin/ streptomycin (100U/ml) (Gibco). Stable HeLa-Kyoto cells expressing 
SMARCA5, TAF15 or THRAP3 tagged with C-terminal GFP under an endogenous 
promoter were generated by transfecting BAC transgenes and were kindly provided by 
Anthony Hyman (Max Planck Institute, Dresden, Germany). Selection was maintained by 
adding 400 ?????????????????????????????????? 
For SILAC labeling U2OS cells were grown in SILAC-DMEM (Invitrogen) supplemented 
with 10% dialyzed FBS (Invitrogen), sodium-pyruvate, L-glutamine, penicillin/ streptomycin 
and either L-lysine (Lys0) and L-arginine (Arg0), L-lysine 4,4,5,5-D4 (Lys4) and L-
arginine?U-13C6 (Arg6) or L-lysine?U-13C6-15N2 (Lys8) and L-arginine?U-13C6-15N4 
(Arg10) (Cambridge Isotope Laboratory) as described previously (Ong et al., 2002). The 
siRNA oligonucleotides against endogenous proteins were purchased from Ambion for 
human PARG (ID: s16158 and s16159), PARP1 (ID: s1098), PARP2 (ID: s19504) and 
Negative Control siRNA#1. SiRNA transfections were performed using Lipofectamine 
RNAiMAX (Invitrogen) according to the manufacturer's protocol. 
Enrichment of PARylated Proteins 
Cells were exposed to the following genotoxic agents and harvested at the indicated time 
points unless otherwise stated: IR (10 Gy, 1h), UV (40 J/m2, 1h), MMS (10 mM, 0.5-1h) 
and H2O2 (10 mM in PBS, 10 min). Cells were washed with PBS and lysed in 50 mM Tris 
pH 7.5, 400 mM NaCl, 1mM EDTA, 1% NP-40, 0.1% Na-deoxycholate, protease inhibitor 
cocktail (Roche) supplemented with 2 mM Na-orthovanadate, 5 mM NaF, 5 mM Glycero-2-
phosphate, 1 µM ADP-HPD (Millipore) and 40 µM PJ-34 (Enzo Life Sciences) or 5 mM 3-
aminobenzamide (Sigma) as appropriate. Lysates were cleared by high speed 
centrifugation, diluted in modified lysis buffer to final concentrations of 150 mM NaCl, 0.5% 
NP-40 and 0.05 % Na-dexycholate. Protein concentrations were determined using 
Bradford assay.  Equal protein amounts were incubated with GST-Af1521 for 2h at 4?C 
and bound complexes were eluted in Laemmli sample buffer. Eluates were combined and 
resolved on 4-20% SDS-PAGE. The Coomassie-stained gel was cut into slices, reduced 
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with 1 mM DTT, alkylated with 5 mM chloroacetamide (Nielsen et al., 2008), digested 
using modified sequencing grade trypsin (Sigma) and loaded on to C18 stage tips prior to 
mass spectrometric analysis. 
Mass spectrometric analysis 
All MS experiments were performed on a nanoscale HPLC system (EASY-nLC from 
Proxeon Biosystems) connected to an Orbitrap Q-Exactive equipped with a 
nanoelectrospray source (Thermo Fisher Scientific). Each peptide fraction was auto-
sampled and separated on a 15 cm analytical column (75 um inner diameter) in-house 
packed with 3-um C18 beads (Reprosil Pur-AQ, Dr. Maisch) with a 2 h gradient ranging 
from 5% to 40% acetonitrile in 0.5% acetic acid at a flow rate of 250 nl/min. The effluent 
from the HPLC was directly electrosprayed into the mass spectrometer. The Q Exactive 
mass spectrometer was operated in data-dependent acquisition mode and all samples 
??????????????????????????????? ?????????? ???????????? ??????????????????? (Kelstrup et al., 
2012). 
Identification of peptides and proteins 
All raw data analysis was performed with MaxQuant software suite (Cox and Mann, 2008) 
version 1.3.0.5 supported by the Andromeda search engine (Cox et al., 2011). Data was 
searched against a concatenated target/decoy (Elias and Gygi, 2007) (forward and 
reversed) version of UniProtKB database encompassing 71,434 protein entries. We 
followed the step-by-step protocol of the MaxQuant software suite to generate MS/MS 
peak lists that were filtered to contain at most six peaks per 100 Da interval prior to the 
Andromeda database search. Mass tolerance for searches was set to maximum 7 ppm for 
peptide masses and 20 ppm for HCD fragment ion masses. Data was searched with 
carbamidomethylation as a fixed modification and protein N-terminal acetylation, 
methionine oxidation as variable modifications. A maximum of two mis-cleavages was 
allowed while requiring strict trypsin specificity. Peptide assignments were statistically 
evaluated in a Bayesian model on the basis of sequence length and Andromeda score. 
Only peptides and proteins with a false discovery rate (FDR) of less than 1% were 
accepted, estimated on the basis of the number of accepted reverse hits. Protein 
sequences of common contaminants such as human keratins and proteases used were 
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added to the database. Statistical analysis and hierarchical clustering was performed using 
Perseus (Max-Planck Institute of Biochemistry, Department of Proteomics and Signal 
Transduction, Munich). Significantly enriched Gene Ontology terms were determined using 
the Functional Annotation Tool of the DAVID Bioinformatics database (Huang da et al., 
2009). Protein interaction networks were analyzed using the interaction data from the 
STRING database (v. 9.05) (Szklarczyk et al., 2011)and visualized using Cytoscape (v. 
2.8.3) (Smoot et al., 2011) 
Cloning, Expression and Purification of Proteins 
Recombinant proteins were generated using the Bacterial or Baculovirus Expression 
System with Gateway® Technology (Invitrogen). Expression clones were created by 
recombining entry clones from the Ultimate ORF clone library (human cDNA for PNKP, 
CETN2, MID1/MPG, MECP2, ANKT, POLR2E and CDK2) with destination vector 
????????? ????????? ???? ??????? ??? ????????? ?or bacterial expression using LR 
?????????????????????? and transforming NEB5-? E. coli. Sequence-verified expression 
clones were transformed into ???? ???????????? ????????? ?????????? E. coli. 
Recombinant bacmid DNA was isolated from cultures of restreaked white colonies, verified 
by PCR and sequencing reactions, and then used to transfect Sf21 insect cells using 
Cellfectin® II Reagent to generate baculovirus. Concentrated viral stocks were further 
used to infect fresh insect cells for protein expression. Recombinant proteins were purified 
?????????????????????-Chelating Resin. 
Expression plasmids (pGEX) for GST-tagged Af1521 wildtype and its mutant G42E were 
kindly provided by Maria di Girolamo (Consorzio Mario Negri Sud, Santa Maria Imbaro, 
Italy). Bacterial recombinant proteins were purified using Glutathione Sepharose 4B (GE 
Healthcare) and covalently crosslinked to the resin using dimethylpimelimidate as 
described in Bar-Peled M, Raikhel NV (1996). Crosslinking was stopped using 
ethanolamine and non-coupled proteins were washed off with glycine?HCl at pH 2.5. 
Resin was stored in 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT at 4?C prior to use. 
 
In vitro modification of candidate proteins 
The candidate proteins were modified as described earlier (Rosenthal et al., 2013b). 
Briefly, 20 pmol of target protein were incubated with 10 pmol HIS-ARTD1 or HIS-ARTD2 
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for 15 min at 30°C in reaction buffer (50 mM Tris-HCL pH 8.0, 4 mM MgCl2, 250 ?M DTT) 
in the presence of 100 nM 32P-NAD+. Reactions with HIS-ARTD1 were supplemented with 
5 pmol annealed double-stranded oligomer (5`-GGAATTCC-3`). The reactions were 
stopped by addition of SDS-loading buffer and boiling. Proteins were separated on an 
SDS-gel and visualized by autoradiography. 
Immunochemical methods  
The following antibodies were used in this study: mouse monoclonal GFP (B-2) (Santa 
Cruz, sc-9996), rabbit polyclonal PARP-1/2 (H-250) (Santa Cruz), rabbit polyclonal PARP2 
(Active Motif), rabbit polyclonal Poly(ADP-ribose) (Enzo Life Sciences), rabbit polyclonal 
Phospho-p53 (Ser15) (Cell Signaling), mouse monoclonal XPC (Abcam, ab6264), rabbit 
??????????????????????-20) (Santa Cruz), mouse monoclonal GAPDH (6C5) (Calbiochem) 
and mouse ??????????? ?-Actin Clone AC-74 (Sigma). Rabbit polyclonal Prestige 
Antibodies for MPG (HPA006531), PNKP (HPA006782), NUSAP1 (HPA042904) and 
MECP2 (HPA000593) were kindly provided by Jan Mulder (SciLifeLab, Karolinska 
Institute, Stockholm). GFP-immunoprecipitaion was performed with GFP-Trap®_A 
agarose beads (Chromotek) and Western blot analysis was done using standard 
protocols. For immunofluorescence analysis cells were grown on coverslips, fixed in 
icecold methanol, additionally permeabilized in 0.25% Triton X-100/PBS, blocked in 10% 
FBS/PBS and incubated with primary antibody (GFP) in 5% FBS/PBS overnight at 4?C. 
After staining with secondary antibody Alexa Fluor 488 (Invitrogen) for 30 min at room 
temperature coverslips were mounted in Vectashield (Vector Laboratories) containing 
nuclear DAPI stain. Images were acquired on an LSM-780 confocal microscope (Carl 
Zeiss Microimaging) mounted on a Zeiss-Axioimager with an oil immersion objective (Plan-
Apochromat 40!/1.3). Image acquisition and analysis was carried out with ZEN2012 
software.  
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Figure legends. 
Figure 1 ? Proteome-wide identification of PARylated proteins in response to 
genotoxic stress using a SILAC-based quantification. 
(A)  Schematic representation of the SILAC-based enrichment strategy. U2OS cells were 
?????????????????????? ? ?????????????????????????????????????????????-labeled cells were 
treated with genotoxic stress. Separate pull-downs were performed from equimolar 
amounts of SILAC-encoded lysates using a PAR-binding defective mutant (G42E) for light 
SILAC state and a PAR-binding GST-Af1521 wildtype (wt) macrodomain for medium and 
heavy SILAC states. Eluates were combined equally, resolved by SDS-PAGE, cut into 
slices and subjected to tryptic in-gel digestion. Peptide fractions were analyzed by high 
resolution LC-MS/MS on an Orbitrap Q-Exactive instrument and the data was further 
processed by bioinformatic tools. 
(B)  Quantitative comparison of tryptic peptide abundances. Each peptide occurs as a 
SILAC triplet. SILAC peptide intensity ratios of 1:1:1 between all 3 SILAC states indicate 
unspecific background binders, whereas proteins most abundant in heavy SILAC state 
correspond to PARylated proteins in response to genotoxic stress. Proteins with increased 
abundance in medium-isoptope encoded samples only are considered PARylated under 
basal conditions.  
 
Figure 2 ? Technical optimization of SILAC-strategy for specific enrichment of 
PARylated proteins 
(A) SILAC-based enrichment of PARylated proteins in the absence of exogenous 
genotoxic stress (see experimental setup in Figure S1A and 1B). Logarithmized H/M 
?????? ??????? ????? ???? ?????????? ?????? ???? ???? ???? ?????? ??????? ????? ???? ??????????
experiment were plotted against each other. GO functional annotation of significantly 
regulated proteins in the combined dataset reveal strong enrichment of proteins involved in 
DNA repair processes compared to annotated GO genes across the entire human genome 
(indicated p-values < 0.005). 
(B) Pull-downs performed on untreated U2OS cells using GST-Af1521 wt and mutant 
G42E were analyzed by immunoblotting using antibodies to PAR and PARP1. 
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(C) U2OS cell lysate preparation in the absence or presence of 5 mM PARP-inhibitor 3-AB 
in the lysis buffer to prevent unphysiological activation of protein PARylation (compare 
lane 6 and 5), and separate cells treated with 3-AB (5 mM, 1h) prior to cell lysis (lane 4). 
Pull-downs were performed using GST-Af1521 wt and analyzed by immunoblotting with 
the indicated antibodies.  
(D) Hierarchical clustering of proteins derived from SILAC-based U2OS lysate pull-down 
(see experimental setup in Figure S2A) in the absence (-) or presence (+) of 3-AB (5 mM) 
or PJ-34 (40 µM) in the lysis buffer. Functional GO analysis of regulated proteins in the 
absence of PARP inhibitors reveals strong enrichment of PARylated proteins involved in 
DNA repair. 
(D) U2OS cells were transfected with PARG siRNA for 72h and treated with H2O2 (1 mM, 
10 min) as indicated and analyzed by immunoblotting with PAR antibody.  
 
Figure 3 ? Quantitative analysis of DNA damage-induced protein PARylation. 
(A) Four biological SILAC experiments were performed to investigate the impact of 
different DNA damaging agents on protein PARylation (see also Figure 1A). In the single 
experiments cells were treated in heavy SILAC state with H2O2 (1 mM, 10 min), MMS (10 
mM, 1h), UV (40 J/m2, 1h) or IR (10 Gy, 1h) respectively. All pull-downs were performed 
with siPARG-treated U2OS cells and the use of 1 µM PARG inhibitor ADP-HPD and 40 
µM PARP inhibitor PJ-34 in the lysis buffer.    
(B) Significantly upregulated PARylated proteins in response to oxidative stress. 
Logarithmized M/L and H/L SILAC ratios from the H2O2 experiment were plotted, 
representing untreated and treated cells. M/L SILAC ratios cumulate around 1 and follow a 
normal distribution while H/L ratios are shifted upwardly corresponding to induced protein 
PARylation. Statistical significance was calculated using Wilcoxon rank sum test. 
(C) Boxplot analysis of logarithmized M/L SILAC ratios from all four SILAC experiments 
(see Figure 3A). No regulation of PARylated proteins is observed in the absence of 
genotoxic stress. 
(D) Boxplot analysis of logarithmized H/L SILAC ratios for each SILAC experiments (see 
Figure 3A). Significant regulation reveals strong induction of protein PARylation upon 
genotoxic stress. 
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(E) siPARG-transfected cells were treated with DNA damaging agents and analyzed by 
immunoblotting with the indicated antibodies. Notably, the extent of protein PARylation 
follows the distribution of SILAC ratios in Figure 3D.  
(F) Heat map of quantified proteins from the combined pull-down experiments in the 
absence (-) or presence (+) of DNA damage. PARylated proteins induced by genotoxic 
stress are clustered together. 
(G) GO term annotation enrichment for cellular distribution of significantly upregulated 
proteins in all four SILAC experiments. 
 
Figure 4 ? Identification and in vitro validation of novel protein PARylation targets. 
(A) Overlap of total number of PARylated proteins identified in this study with proteins that 
were previously published to be PARylated and assigned with a role in DNA repair based 
on GO term annotation.  
(B) In vitro PARylation of newly identified protein targets in the SILAC screen. Purified full-
length human ARTD1 (left panels) and ARTD2 (right panels) were incubated with 
recombinantly expressed proteins in the presence of 32P-NAD and double-stranded DNA 
oligomer. Samples were resolved by SDS-PAGE, stained with Coomassie (lower panels) 
and 32P-incorporation was detected by autoradiography (AR) (upper panels). (*ARTD1, 
**ARTD2, Ctrl: Histone H1 and zinc finger 1+2 from ARTD1). 
(C) ARTD1 accounts for the majority of protein PARylation in response to genotoxic stress. 
U2OS cells were co-transfected with PARG siRNA and either control, ARTD1 or ARTD2 
siRNA. Cells were treated with DNA damaging agents as described in Figure 3A and 
analyzed by immunoblotting with the indicated antibodies.  
(D) Logarithmized SILAC ratios of all identified PARP/ARTD family members from the 
individual SILAC experiments. 
 
Figure 5 ? In vivo PARylation of novel protein targets. 
(A) SiPARG-transfected U2OS cells were incubated with PJ-34 (40 µM, 1.5h) or left 
untreated prior to treatment with H2O2 (1 mM, 10 min) as indicated. Cell lysates were 
pulled down with GST-Af1521 WT and analyzed by immunoblotting with the indicated 
antibodies to detect enriched PARylated ?????????????????????????????????????????????
control. 
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(B) HeLa cells stably expressing TAF15, THRAP3 or SMARCA5 as GFP-fusion proteins 
were transfected with PARG siRNA and treated with PJ-34 and H2O2 as in (A). Lysates 
were subjected to Af1521 WT pull-down or GFP-immunoprecipitation and subsequently 
analyzed by immunoblotting with PAR and GFP antibodies (*PARylated GFP-target 
protein).   
 
Figure 6 ? Functional consequences of distinct types of DNA damage treatment on 
protein PARylation. 
(A) Protein interaction networks of significantly PARylated proteins from all SILAC 
experiments grouped into DNA metabolism by GO term annotation for biological process 
(p-value < 8e-14). Network interaction data was extracted from STRING database and 
visualized using Cytoscape. 
(B) InterPro domain annotation associated with the molecular function of significantly 
regulated proteins from all SILAC experiments as compared to annotated GO genes in the 
entire genome (indicated p-values < 1.5e-17 ). Strong enrichment for RNA- and DNA-
binding proteins is observed. 
(C) Venn diagram demonstrating the overlap of PARylated proteins from the individual 
DNA damage experiments (as described in Figure 3A). 
(D) GO enrichment analysis reveals specific enrichment of RNA metabolic processes in 
H2O2 and MMS experiment, while proteins involved in DNA metabolic processes are 
equally identified across all DNA damage experiments. Analysis was performed using GO 
term annotations for biological processes of significantly regulated protein sets in each 
DNA damage SILAC experiment (specific p-values are listed in Figure S4C). 
(E) Protein interaction networks of significantly PARylated proteins from the H2O2 (upper 
panel) and MMS (lower panel) experiments grouped into RNA metabolism by GO term 
annotation for biological process (p-value < 2e-16).  
 
Figure 7 ? PARylation-dependent redistribution of TAF15 and THRAP3 in subnuclear 
structures in response to genotoxic stress. 
(A) Stable THRAP3-GFP expressing HeLa cells were left untreated or pre-treated with 40 
µM PJ-34 for 15 min, followed by an incubation with 5 µg/ml ActinomycinD (ActD) up to 3 
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h. Prior to fixation cells were exposed to 2 mM H2O2 for the indicated time points and 
immunostained with GFP antibody. 
(B) Stable TAF15-GFP expressing HeLa cells were similarly left untreated or pre-treated 
with 40 µM PJ-34 for 15 min, followed by an incubation of 5 µg/ml ActinomycinD (ActD) up 
to 3 h. Prior to fixation cells were exposed to 2 mM H2O2 for 1h or 1 mM MMS for 2 h and 
immunostained with GFP antibody.  
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Figure S1 ? SILAC experiments for comparison of binding properties for GST-
Af1521 wt and the mutant G42E in the absence of exogenous genotoxic stress. 
(A) In a forward experiment U2OS cell lysates grown in light SILAC condition were 
subjected to pull-down with Glutathione sepharose beads, while pull-down of cell lysates in 
medium SILAC condition was performed with mutant GST-Af1521 G42E and in heavy 
SILAC state with GST-Af1521 wt. Eluates were combined equally, resolved by SDS-
PAGE, cut into slices and subjected to tryptic in-gel digestion. Peptide fractions were 
analyzed by high resolution LC-MS/MS.  
(B) A reverse SILAC experiment was carried out in exactly the same manner as in (A) 
except for a SILAC label swap between the medium and heavy SILAC condition for pull-
down with GST-Af1521 wt and G42E. 
(C) High reproducibility between forward and reverse SILAC experiments for GST-AF1521 
pull-downs. For analysis of GST-Af1521 G42E pull-down efficiency logarithmized M/L 
SILAC ratios of the forward experiment and H/L ratios of the reverse experiment were 
plotted against each other. Similarly, logarithmized H/L SILAC ratios of the forward 
experiment and M/L ratios of the reverse experiment were plotted against each other for 
analysis of GST-Af1521 wt pull-down efficiency. Pearson correlation coefficient was 
calculated for each plotted dataset. 
 
Figure S2 ? SILAC experiments showing the indispensability of PARP inhibitors 
during sample preparation. 
(A) U2OS cells grown in light SILAC condition were pre-treated with PARP inhibitors in two 
different SILAC experiments (experiment A: 5 mM 3-AB, 2 h; experiment B: 40 µM PJ-34, 
2 h). Cell lysates for light and medium SILAC condition additionally contained 40 µM PJ-34 
or 5 mM 3-AB, respectively, in the lysis buffer. Equal protein amounts from cell lysates of 
all 3 SILAC conditions were subjected to pull-down with GST-Af1521 wt. Eluates were 
combined, resolved by SDS-PAGE, cut into slices and subjected to tryptic in-gel digestion. 
Peptide fractions were analyzed by high resolution LC-MS/MS.   
(B) Summed peptide intensities were plotted against logarithmized SILAC ratios in the 
presence or absence of PJ-34 or 3-AB as indicated. Upregulation of SILAC ratios for 
PARylated proteins occured only in the absence of PARP inhibitors in the lysis buffer 
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(H/L), while inclusion of PARP inhibitors in the lysis buffer did not result in enrichment of 
PARylated proteins with increased M/L SILAC ratios.   
(C) U2OS cell lysate preparation excluded or involved 40 µM PARP-inhibitor PJ-34 in the 
lysis buffer (LB) to prevent unphysiological activation of protein PARylation (compare lane 
6 and 5), or cells were additionally treated with PJ-34 (40 µM, 1h) prior to lysis (lane 4). 
Pull-downs were performed using GST-Af1521 wt and analyzed by immunoblotting with 
the indicated antibodies.  
 
Figure S3 ? Reproducibility and sensitivity of different DNA damage SILAC 
experiments. 
(A) Q-Q probability plots show correlation of logarithmized M/L ratios from the single DNA 
damage SILAC experiments as indicated.  
(B) Overlap of previously published dataset for in-depth proteome analysis of the U2OS 
cell line (Geiger et al., 2012) with significantly regulated proteins identified with at least 2 
peptides and indicated sequence coverage in the DNA damage SILAC experiments. 
 
Figure S4 ? Functional consequences of distinct types of DNA damage treatment on 
protein PARylation. 
(A) Protein interaction networks of significantly PARylated proteins from each SILAC 
experiment grouped into DNA repair by GO term annotation for biological process (p-value 
< 8e-5). Network interaction data was extracted from the STRING database and visualized 
using Cytoscape. 
(B) Fold enrichment of GO term annotations of significantly upregulated proteins with RNA 
binding and DNA binding activities in each DNA damage SILAC experiment.   
(C) P-values for the specific enrichment of the listed GO term annotated biological 
processes for significantly upregulated proteins in each DNA damage SILAC experiment 
(graphical representation of GO term enrichment in Figure 6C). 
Figure S5 ? Control samples for analysis of PARylation-dependent redistribution of 
TAF15 and THRAP3 in subnuclear structures in response to genotoxic stress. 
(A) Stable THRAP3-GFP expressing HeLa cells were left untreated or pre-treated with 40 
µM PJ-34 for up to 3 h. Prior to fixation cells were exposed to 2 mM H2O2 for the indicated 
time points, fixed and immunostained with GFP antibody. 
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(B) Stable TAF15-GFP expressing HeLa cells were pre-treated with 40 µM PJ-34 for 15 
min, followed by an incubation of 5 µg/ml ActinomycinD (ActD) up to 3 h where indicated, 
fixed and immunostained with GFP antibody. 
 
Table S1 ? List of identified proteins in total for the SILAC experiment comparing 
the binding properties for GST-Af1521 wt and the mutant G42E in the absence of 
exogenous genotoxic stress (related to Figure 2 and S1). 
 
Table S2 ? List of identified proteins for the SILAC experiments comparing different 
types of genotoxic stress (related to Figure 1, 3, 4A, 6, S3 and S4). 
 
(A) Proteins that were found to be significantly regulated in response to a specific type of 
genotoxic stress as indicated.  
(B) Total list of proteins identified in the SILAC experiments comparing different genotoxic 
stress conditions.    
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3.3 Unpublished results !
3.3.1.1 ADPRibase-Mn hydrolyzes the pyrophosphate of mono/poly-ADP-ribose 
bound to proteins 
ADP-ribose and especially branched PAR chains represent a challenge for mass 
spectrometric analysis because they are unstable and complex structures without 
defined mass. Previously, PARG was shown to enzymatically degrade PAR to the last 
protein-bound moiety (47). This step obviously reduces the complexity of the samples 
and simplifies the MS/MS analysis, resulting in increased ADP-ribose identifications 
(139). To further simplify and standardize sample preparation, phosphodiesterase 1 
PDE1 was used to cleave the pyrophosphate bond within ADP-ribose units (148). 
Unfortunately, PDE1 purified from snake venom was very unstable, difficult to store 
and thus very costly (data not shown). As an alternative method, the application of +,-.%)#/#,)#,'! 012%3*45&#6712%8$95:5$! /;35/:5&/:8'8&# (ADPRibase-Mn) 
from rat liver was investigated. ADPRibase-Mn belongs to a <#'8$$5/:5&/:5%#&'#38&#! &(/#3=8<*$;, which efficiently hydrolyzes free ADP-ribose and PAR 
comparable to nudix hydrolases (149). Incubation of in vitro poly-ADP-ribosylated 
ARTD1 with recombinant ADPRibase-Mn massively decreased the signal of 
radioactive labeled auto-modified ARTD1 (Figure 7A). The loss of radioactive ADP-
ribose was even stronger when compared to treatment of ARTD1 by PARG, indicating 
that less than one ADP-ribose moiety (possibly a phospho-ribose) remained attached 
on ARTD1 after ADPRibase-Mn treatment. Further MS-analysis of the ADPRibase-
Mn treated samples indeed confirmed the cleavage of the pyrophosphate bond, which 
results in a defined phospho-ribose moiety that is easily detectable by mass 
spectrometry (Figure 7B). Taken together, recombinant ADPRibase-Mn could be 
confirmed as a pyrophosphate hydrolase that is able to cleave human ARTD1 bound 
ADP-ribose, resulting in a phospho-ribose moiety, which is readily detectable by mass 
spectrometry. 
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3.3.2 Phospho-ribose can be used in Mascot to identify a modified standard 
peptide 
To further investigate the eligibility of the ADPRibase-Mn treatment for sample 
preparations and the subsequent identification of ADP-ribosylated peptides, the 
phospho-ribose modification was included as a variable modification to the Mascot 
software. First, we tested the procedure with a biotinylated standard peptide with the 
sequence >00?>@020ABBC>>2D?E?F! 3#/3#&#,'*,G a part of the histone H3 
unstructured N-terminal tail (139). The peptide was either in vitro modified with 
ARTD1 or with the catalytic domain of ARTD10 (ARTD10 (818-1025)), resulting in a 
poly- or mono-ADP-ribosylated peptide, respectively. The modified peptide was 
subsequently treated with ADPRibase-Mn or PARG (for ARTD1) or only with 
ADPRibase-Mn (for ARTD10 modified peptide) and subsequently analyzed with the 
different fragmentation techniques or combinations thereof, as described (139) (Figure 
8). The HCD fragmentation of the phospho-ribose modification attached to the 
standard peptide generated no indicative ions, thus not allowing a product dependent 
Figure 7:  ADPRibase-Mn cleaves protein-bound PAR. A. ARTD1 was poly-ADP-
ribosylated in the presence of radioactively labeled 32P-NAD+ and subsequently treated with 
PARG or ADPRibase-Mn. The reactions were separated on a SDS-PAGE and visualized by 
autoradiography. B. HCD spectrum of the ADP-ribosylated biotin-
KAARKSAPATGGVKKPHRYR H3-peptide after ADPRibase-Mn treatment. The different 
charge states of the unmodified and the phospho-ribose modified peptide can be observed. 
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or two-stage HCD-ETD analysis (data not shown). Therefore, samples treated with 
ADPRibase-Mn were only analyzed by one-stage analysis with HCD, ETD or a 
combination of both fragmentation techniques without analyzing the indicative ions of 
the ADP-ribose (139). 
 
 
Surprisingly, these MS measurements revealed that ADPRibase-Mn treatment did in 
general not improve the identification of the modification acceptor site, when 
compared to untreated (for ARTD10 modified peptide) or PARG treated samples (for 
ARTD1 modified peptide) (compare Figure 8A and B). The only benefit of the 
ADPRibase-Mn treatment was observed when modified samples were analyzed by 
high accuracy ETD (FT) data analysis. Although, the phospho-ribose was expected to 
provide a more stable and defined moiety for the MS analysis, this seemed, for 
unknown reasons, not to be the case for the tested standard peptide.  
 
!" #"
!$%&'"(")!$*" !$%&'"("!&)$+,-./012"
!$%&'3"("0" !$%&'3"("!&)$+,-./012"
Figure 8: Analysis of the ADPRibase-Mn treated H3 peptide by HCD and ETD 
fragmentation. Every pie-chart shows for each combination of HCD and ETD fragmentation 
the number of unassigned spectra (white) and those assigned to ADP-ribosylated or phospho-
ribose modified peptides (colored). A. Results obtained by the analysis of the peptide treated 
with ARTD1/PARG and ARTD10. The bars report the number of spectra identified as peptides 
carrying 1 (blue) or 2 (red) modifications. B. Results for the peptide treated with 
ARTD1/ADPRibase-Mn and ART10/ADPRibase-Mn!
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3.3.3  Phospho-ribose can be used to identify a modified peptides in complex 
mixtures 
To investigate whether the enzymatically-generated phospho-ribose would provide 
advantages in more complex samples, a heterogeneous mixture of all four core 
histones and the linker histone H1 was modified by ARTD10 (818-1025) in vitro. 
After trypsin digestion and subsequent ADPRibase-Mn treatment, samples were 
analyzed by HCD, ETD(IT), ETD(FT) or a HCD-ETD(IT) combination. As observed 
with the standard peptide, the overall number of ADP-ribosylated peptides as well as 
the number of differentially modified peptides were comparable between ADPRibase-
Mn treated and untreated samples. Modification sites with a probability of # 95% were 
considered as accurately identified, whereas all other hits were defined as modified 
peptides without accurately defined modification site. In general, no benefit for the 
ADPRibase-Mn treatment was observed when samples were analyzed by HCD. The 
number of modified peptides with an accuracy of <95% even decreased after 
ADPRibase-Mn treatment. Only for the analysis of samples with ETD(IT) and (FT), 
the ADPRibase-Mn treated samples allowed the identification of a higher number of 
modified peptides (Fig. 9 A-C). Therefore, ADPRibase-Mn treatment might be 
advantageous in samples containing mainly long and highly charged peptides, which 
fragment better in ETD. In addition, the ADPRibase-Mn treatment could potentially be 
used as an elution step in enrichment protocols for ADP-ribosylated peptides with 
binding modules (macro domains) or resins (boronic acid). Moreover, it could be used 
as a pre-treatment for phospho-enrichment protocols as recently introduced for PDE1 
(136). 
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3.3.4 Methods to unpublished results 
 
ADPRibase-Mn purification 
The bacterial GST-expression vector for rADPRibase-Mn was kindly provided by José 
Carlos Cameselle (149). GST-tagged proteins were expressed in BL21 bacteria and 
purified with Glutathione Sepharose 4 Fast Flow (GE Healthcare, Uppsala, Sweden) as 
described (41). 
 
ADPRibase-Mn treatment 
To hydrolyze ADP-ribose polymers, in vitro modified GST-ARTD10 (818-1025) or 
HIS-ARTD1 with histones or peptides were used in a buffer consisting of 50 mM Tris-
HCL pH 8.0, 10 mM MgCl2, 50 mM NaCl, 250 µM and 100 nM MnCl2, 5 pmol GST-
ADPRibase-Mn were added, and the reaction was incubated for 1h at 30°C.  ! !
Figure 9: Analysis of histones modified in vitro by ARTD10 and treated with ADPRibase-
Mn. Histones modified in vitro by ARTD10 and treated with ADPRibase-Mn were analyzed by 
MS/MS using four different combinations of HCD and/or ETD fragmentation techniques. Both, 
ADP-ribosylated peptides where the site localization confidence score was higher than 95% 
(black bars) and lower than 95% (grey bar) are plotted. A. Number of spectra assigned to ADP- 
ribosylated peptides. B. Number of different ADP-ribosylated peptides identifications (different 
modification sites on the same peptide are considered as different peptides). C. Venn diagrams 
showing the differences and overlaps between HCD and ETD identifications. The diagrams refer 
only to the peptides having a site localization score higher than 95%. !
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4 DISCUSSION AND PERSPECTIVES    !
4.1 Summary of the results 
One aim of this thesis was to identify ADP-ribosylated peptides from cells and to 
localize the modification site(s) by mass spectrometry. To gain more insight into the 
ADP-ribosylome and ADP-ribose acceptor sites, we first established an optimized 
mass spectrometry based protocol allowing the specific enrichment of ADP-
ribosylated proteins and peptides with phenylboronic acid resins to subsequently map 
their ADP-ribosylation sites by ETD mass spectrometry (150). Although we could 
provide evidence that the ETD fragmentation results in the stabilization of ADP-
ribosylation (compared to HCD), the method nevertheless revealed other weaknesses. 
First, long and highly charged peptides are required for the efficient analysis by ETD. 
Second, even in cases when the peptides are sufficiently long, the number of gained 
ions is often very low and a mapping of the ADP-ribosylation site with a good 
confidence (>95%) is difficult to reach. The MS-based data analysis methods had thus 
to be further improved (139). Along this line, HCD was identified as the method of 
choice for the analysis of ADP-ribosylated peptides, since it generates indicative ions 
of ADP-ribose, which allows the detection of modified peptides and their modification 
site(s) with high accuracy. When combining with ETD in a product dependent or two-
stage approach, the advantages of both methods could be combined and the quality of 
data further improved (139). Applying this improved protocol to a not-enriched lysate 
of H2O2 treated cells, we could, for the first time, identify several ADP-ribosylation 
sites of proteins, opening new possibilities for the further characterization of the ADP-
ribosylome (see below).  
We furthermore identified human macrodomain MacroD1, MacroD2 and 
C6orf130, as well as Af1521 from archaebacteria, as a novel class of enzymes able to 
hydrolyze mono-ADP-ribosylated glutamic-acid residues (151). Structural modeling 
and mutagenesis of the macrodomains suggested a common enzymatic mechanism 
requiring Asp102 and His106 for the catalytic reaction. Macrodomain containing 
proteins were able to fully de-ADP-ribosylate in vitro modified ARTD10. Furthermore, 
mono-ADP-ribosylation of glycogen synthase 3! (GSK3!) by ARTD10 inhibited its 
kinase activity, which could be reversed by MacroD2 in vivo. Together, we established 
mono-ADP-ribosylation of acidic residues by ARTD10 as a dynamic modification that 
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can be reversed by macrodomain containing proteins and thus identified a missing link 
in the ADP-ribosylation cycle (151). 
 
4.2 Towards identifying ADP-ribose acceptor sites  
The identification of the ADP-ribosylation sites on different ARTDs as well as on their 
target proteins is, due to the complexity and heterogeneous nature of PAR, which has 
been an obstacle for more than 30 years. The first insights were obtained by studying 
the stability of protein-attached ADP-ribose to treatment with different chemical 
compounds (114,152). Based on the chemical sensitivity of the modification (1.4 and 
Table 1), glutamic acid residues on ARTD1, histone H2B and H1 were suggested to be 
ADP-ribosylated. As these studies were never confirmed by site directed mutagenesis 
analyses and performed with chemically and not enzymatically ADP-ribosylated 
peptides and proteins, the identified sites remained under dispute (35). More recent 
work, utilizing site directed mutagenesis, provided evidence for a strong reduction of 
ARTD1 auto-ADP-ribosylation in vitro when specific lysine residues in the ARTD1 
auto-modification domain were mutated to arginines (119). These studies indicated 
that lysine residues might serve as ADP-ribose acceptor sites. But since the 
mutagenesis of amino acids could also disrupt the protein structure, the identification 
of the ADP-ribose acceptor site(s) was still not resolved and, because of the strong 
recent medical interest, urgently sought.  
 Only the recent advances in mass spectrometry with more advanced 
instrumentation and new possibilities to map labile PTMs such as ADP-ribose, opened 
novel perspectives for the ADP-ribosylation research. The newly invented 
fragmentation technique ETD stabilizes labile post-translational modifications on 
peptides and was recently successfully used to analyze ADP-ribosylated peptides 
(153). When ETD was applied to histone peptides modified in vitro by ARTD1, lysine 
residues could be identified as acceptor amino acids (41). Beside our own published 
ETD study, two studies aimed to identify the automodification sites of ARTD1 by 
conventional CID fragmentation (135,136). The first group analyzed the auto-
modification sites of the E988Q ARTD1 mutant, which hampers PAR formation and 
also strongly reduces the ability to catalyze mono-ADP-ribosylation, and identified the 
acidic amino acids D387, E488 and E491 as ADP-ribose acceptor sites (135). Since 
mutating the catalytically important glutamic acid residue E988 of ARTD1 might 
change the chemical reaction as well as the modification specificity, and also because 
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of the very high NAD+ concentrations (500µM) that were used for the 
automodification, these data do not necessarily reflect the physiological situation. A 
second group used PDE1 to reduce PAR of in vitro auto-modified ARTD1 to generate 
a single phospho-ribose moiety (136). The terminal phosphate of the remaining protein 
bound phospho-ribose was subsequently used to enrich the modified peptides with a 
phospho-enrichment resin. Subsequent CID-based MS/MS analysis revealed that both, 
glutamic acid and lysine residues are serving as acceptor sites. The CID approach was, 
however, not able to accurately assign the acceptor sites when glutamic acid and lysine 
residues were found in close proximity, underlining the problems to precisely pinpoint 
ADP-ribosylation to a certain amino acid and leaving the question open, which amino 
acids serve as acceptor site. These initial studies clearly reveal that further 
experimental efforts are required to clarify and confirm these findings and that ADP-
ribosylation sites should be preferentially identified with proteins extracted from cells 
in order to determine whether the above described in vitro findings indeed represent 
the in vivo situation.  
 
4.3 Combining different MS technologies for the accurate identification of 
ADP-ribosylation acceptor sites  
The optimization of HCD fragmentation with stepped collision energies allowed the 
reliable detection of ADP-ribose specific ions, providing an additional indication for 
the existence of ADP-ribosylation on fragmented peptides (139,153). When these ions 
were implemented in the Mascot search engine as neutral losses, ADP-ribosylation 
sites could be reproducibly identified. This result was surprising since HCD was 
expected to completely remove the ADP-ribose from its acceptor amino acid. As this 
was not the case, HCD became a promising tool for the identification of ADP-ribose 
acceptor sites and was further combined with the previously applied ETD technique to 
combine the advantages of both fragmentation techniques in one MS/MS analysis. As 
a result, different proteins and their ADP-ribosylation sites could be identified for the 
first time with high confidence and reliability, demonstrating the advantages of the 
newly established protocol. Interestingly, glutamic acid, lysine and arginine residues 
on histone proteins were detected as ADP-ribose acceptor sites under the tested 
conditions. This finally confirms that more than one type of amino acid can indeed 
serve as in vivo ADP-ribose acceptor sites in cells. Several of the identified sites are 
located within histone proteins, which were reported to be targets of other PTMs. This 
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provides evidence that the mapped sites are accessible in vivo and in generally 
regulated by PTMs. Moreover, a functional crosstalk of ADP-ribosylation with other 
PTMs can be foreseen. 
Applying the HCD-ETD mass spectrometry approach to other treated lysates 
will help to shed more light on this topic and will help us to understand, which amino 
acids are ADP-ribosylated under which conditions and which ARTD is responsible for 
the modification of specific acceptor sites. Additional experiments should help to 
answer which ADP-ribosylation patterns are induced under basal or cellular stress 
conditions, such as oxidative stress, DNA-damage or inflammation. The cellular ADP-
ribosylation reactions might thus be divided into a basal “maintenance” ADP-
ribosylation and a “stress induced” ADP-ribose modification.  
 
4.4 Modification of different amino acids by the same ARTD 
The identification of different modified ADP-ribosylated amino acids in vivo 
challenges the existing views and invites the research community to review the dogma 
that all ARTDs in the mammalian cell catalyze the same biochemical raction and thus 
modify the same amino acid residue (15). Different ARTD family members might thus 
modify different amino acids or one ARTD might alternatively be able to modify 
several different types of amino acids, depending on whether the modification is 
catalyzed in cis or in trans. In this scenario, even the auto-modification of an ARTD 
might lead to targeting of different acceptor sites, depending on the molecular 
concentration and the experimental conditions (favoring the formation of monomers 
and modification in cis or formation of dimers and the modification in trans). 
Consequently, modification of a target protein would always be catalyzed in trans and 
should thus reveal the same acceptor site. Moreover, it needs to be further investigated 
whether ADP-ribosylation is only regulated by a directed enzymatic reaction or if non-
enzymatic chemical reactions are involved in the transfer of the modification to 
adjacent amino acids. Knocking down defined ARTDs or using ARTD knockout cells, 
combined with the new MS/MS workflow, will now make it possible to address 
several of these points and will provide valuable insight into the cellular ADP-
ribosylation reactions. Such information will also help to further characterize the 
family of ARTDs and open the possibility to raise antibodies against specific ADP-
ribosylated proteins. Obtaining antibodies would allow applying many standard and 
state of the art techniques, such as western blot, immunofluorescence, chromatin 
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immunoprecipitation (ChIP) and ChIP-sequencing, that cold so far not be applied in 
the ADP-ribosylation research.  
Finally, as the new MS approach is potentially applicable to other PTMs, which 
produce indicative ions upon HCD fragmentation, it could help to characterize other 
labile PTMs such as phosphorylated or glycosylated serine and threonine and 
nitrosylated cysteine (154,155). 
 
4.5 Cell lysis-dependent induction of ADP-ribosylation 
Some ARTDs (e.g., ARTD1/2) can be activated by DNA in vitro (119) and might thus 
also be activated by DNA fragments generated during protein extraction or fixation of 
cells (156), leading to ADP-ribosylation that does not reflect the physiological 
situation in the cell (157). To prevent false positive identifications, lysis-induced ADP-
ribosylation has to be inhibited by including PARP inhibitors in all buffers during 
extraction. This prevents overestimation and misinterpretation of mass spectrometric 
results and helps to identify the physiologically relevant ADP-ribosylome (157).  
As ADP-ribosylation is a transient PTM and quickly degraded by the cellular 
PARG enzymes, experiments are also performed under conditions of PARG inhibition 
or depletion (158). This generally facilitates the analysis of modified proteins, as 
PARylation is enhanced, and increases the number of modified proteins. Whether 
proteins identified under such conditions are indeed modified in vivo under untreated 
conditions needs to be further addressed. !
4.6 Functional aspects of ADP-ribosylated lysine acceptor sites. 
Modification of proteins by ADP-ribosylation often alters their structure or binding 
properties of other proteins or DNA (38,39). As indicated, enzymes with de-ADP-
ribosylating activities towards modified arginines and glutamates could be identified, 
proving that mono-ADP-ribosylation of these residues is revertible ((57), and this 
thesis). The fact that PARG and MacroD2 can only reverse some ARTD1 auto-
modifications further strengthens the point that additional amino acids of ARTD1 are 
modified (e.g., lysine residues) and points at the need for additional hydrolase(s) with 
activity towards other amino acids (e.g., lysine residues). Identifying a lysine-specific 
hydrolase would be of great interest, especially because lysine histone modifications 
could be identified and their ADP-ribosylation cycle might be of great importance for 
the histone code (41,139,159). A potential hydrolase that was reported to remove 
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mono-ADP-ribose from glutamic acid or lysine residues was purified over 30 years 
ago (62,63). This enzyme was already postulated to be the lysine specific ADP-ribose 
hydrolase (121) but was unfortunately never fully characterized and is unknown until 
today. An alternative scenario foresees that lysine mono-ADP-ribosylation is a 
permanent (non-hydrolysable) modification, which cannot be reversed by any enzyme 
and therefore marks proteins for a final destiny. This would imply that in order to 
remove the accompanied signal, the lysine-ADP-ribosylated protein would need to be 
degraded, otherwise removed or shielded.  !
4.7 Macrodomains are glutamic acid specific mono-ADP-ribosylhydrolases 
Poly- and mono-ADP-ribosylation are dynamic modifications and defects in their 
synthesis and turnover are implicated in various diseases (13,34,69). Therefore, both 
mechanisms have to be tightly regulated by enzymes catalyzing specific enzymatic 
reactions in the ADP-ribose metabolism. Up to now, two enzymes (PARG and ARH3) 
where identified that hydrolyze PAR, but both are unable to remove the protein-
proximal ADP-ribose moiety (47,55). This might be due to different types of linkages 
within PAR on the one side and the protein proximal ADP-ribose linkage to the amino 
acid on the other side. Alternatively, steric hindrance could interfere with the removal 
of the last ADP-ribose (160). As a result of these PAR-hydrolyzing activities and the 
activity of mono-ADP-ribosyltransferases such as ARTD10 a massive pool of mono-
ADP-ribosylated proteins in the cell could potentially be generated. In order to reverse 
mono-ADP-ribosylated proteins into their unmodified state, enzymes with activities 
towards mono-ADP-ribose are expected to exist. This is especially valid for ADP-
ribosylation on lysines, arginines and glutamic acid residues, which were detected in 
human cells (139). So far, ARH1 is the only in vitro characterized enzyme with 
activity against mono-ADP-ribosylated arginine (55,57). This enzyme stands in 
contrast to the huge family of ARTDs and ARTCs, which also underlines the 
substantial lack of knowledge in the field of mono-ADP-ribosylhydrolases. 
 Up to now, over 300 proteins, including 14 human proteins, with 
macrodomains were identified (87). Macrodomains are found in histone proteins, 
ARTDs and other proteins involved in chromatin metabolism (88,90) and bind mono- 
and/or poly-ADP-ribose and OAADPr (96,100). In addition, human MacroD1, 
MacroD2 and C6orf130 contain C2- or C3-specific OAADPr deacetylase activity as 
well as weak C1-specific phosphatase activity towards ADP-ribose-1$$-phosphate 
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(103,104). A subgroup of macrodomain containing proteins was identified in this 
thesis work to be able to reverse mono-ADP-ribosylation catalyzed by ARTD10 in 
vitro (151). This new class of enzymes could be furthermore shown to de-ADP-
ribosylate glutamic acid residues and to release intact ADP-ribose and thus completely 
reverses ADP-ribosylation. Hence, macrodomain-containing proteins represent a 
missing link in the mono-ADP-ribosylation cycle and the first characterized family of 
enzymes able to revert glutamic acid mono-ADP-ribosylation. In parallel to our study, 
others have also identified MacroD1, MacroD2 and Af1521 as mono-ADP-
ribosylhydrolases towards ARTD10 catalyzed modifications (161). In addition, Poa1p 
from yeast could be identified as member of the mono-ADP-ribosylhydrolase family, 
underlining that this new mechanism is conserved throughout many kingdoms of life. 
Interestingly, MacroD2 was also able to remove a sub-fraction of ADP-ribose 
modifications of ARTD1, which was mono-ADP-ribosylated under low NAD+ 
conditions (161).  
In a third publication, C6orf130 was not only observed to hydrolyze mono-ADP-
ribose, but in addition also released whole polymers from automodified ARTD1 (162). 
In contrast to PARG, which hydrolyzes the glycosidic linkages within PAR and thus 
generates free mono-ADP-ribose, C6orf130 was described to release the intact 
polymer, which can potentially act as a signaling molecule for mitochondria to trigger 
apoptosis (163). As the release of a complete PAR chain could not be observed for 
MacroD1 or MacroD2 by us and others (151,161), C6orf130 might catalyze a different 
enzymatic reaction or structural differences might enable C6orf130 to access the 
protein-attachment site of PAR in a different manner. The other macrodomain-
containing proteins, in contrast, might thus not be able to reach this bond due to steric 
hindrance or other structural interferences. Clearly, further studies will have to address 
this question in order to characterize and sort the different macrodomain containing 
proteins and to identify additional members of the relevant protein families. This 
knowledge will help to understand the ADP-ribose metabolism, the involved players 
and its regulation. 
 
4.8 Functionality of the ribose C-atom bound to glutamic acids in ADP-
ribosylation 
An additional important aspect to be considered for protein ADP-ribosylation is, 
which C-atom of the ribose moiety is linked to the modified acceptor residue. The 
181
!
exact type of linkage affects the position of the ribose, but also influences the stability 
of the modification. Theoretically, the ribose could be linked through the C1, C2 or C3 
atom to glutamic acidic residues, while only a C1 linkage has been proposed for basic 
amino acids such as lysines (124). Consecutively, this linkages might furthermore be 
converted into a ketoamine bond (124). The ability of macrodomain containing 
proteins to hydrolyze OAADPr and molecular modeling suggest that they are able to 
hydrolyze a C2 or C3 linkage and experimental evidence from others also suggests 
that C1 linkages can be hydrolyzed by MacroD2 (161). Whether only one type or 
different kinds of linkages are synthesized and the potential specificity of hydrolases 
for a particular type of linkage has yet to be defined. To provide further evidence, the 
activity of the so far identified hydrolases towards synthesized standard peptides that 
are ADP-ribosylated via a C1, C2 or C3 linkages and NMR studies would be of great 
value. Very recently, progress in this direction was made and could in the near future 
provide tools to address this issue (164). 
 
4.9 Reversal of mono-ADP-ribosylation is important for cellular functions 
The kinase GSK3! is involved in various signaling pathways and defects are linked to 
diseases like cancer, Alzheimer and type II diabetes (165). It was previously shown 
that the mono-ADP-ribosylation of GSK3! leads to the inhibition of its kinase activity 
(126) and excitingly, we could show in this work that the inhibitory effect of GSK3! 
ADP-ribosylation can be reversed by MacroD2, thus making mono-ADP-ribosylation 
of GSK3! a reversible PTM that regulates GSK3! enzymatic activity (151). This 
important finding opens a variety of research possibilities and raises interesting 
questions, especially about the specificity of macrodomain containing proteins and the 
regulation of the hydrolysis reaction, for example by other PTMs or the recruitment 
through other factors. In addition, it is important to investigate whether certain ADP-
ribosylhydrolases can be linked to specific mechanisms in the cell, such as signal 
transduction, inflammation or transcriptional regulation, which are all influenced by 
ADP-ribosylation (10,22). 
 
4.10 Medical relevance of macrodomains and ADP-ribosylation 
A very recent study identified a homozygous mutation in C6orf130 to be the cause of a 
neurodegenerative disorder in an extended consanguineous family over two 
generations (162). This mutation leads to a dramatic loss in hydrolysis activity, 
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confirming that a defect in the de-ADP-ribosylation activity of the mutant C6orf130 
was indeed the cause for the observed disease phenotype. Unfortunately, no substrates 
for C6orf130 in cells have been identified so far. Therefore, the authors speculate that 
the defect in hydrolysis leads to perturbations in the DNA damage response, 
proliferation and senescence, which subsequently lead to cell death and 
neurodegeneration, but additional efforts are required in order to understand the 
molecular background of this observations. 
 Taken together, the above mentioned results clearly emphasize the importance 
of mono-ADP-ribose hydrolysis by macrodomain-containing proteins and the need to 
further characterize and identify how the mono-ADP-ribosylation cycle influences 
cellular functions. In addition, the disease-relevance of macrodomain-containing 
proteins sets the stage for the evaluation of macrodomains as potential therapeutic 
targets. Especially the availability of structural information about the three identified 
human macrodomains will help to accelerate this process. Recent findings, defining 
roles for macrodomain containing proteins in diseases such as breast cancer, Kabuki 
syndrome and neuroblastoma, could lead to interesting new results and applications 
for ADP-ribosylhydrolase inhibitors (95,96). !!
 !  
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5 ABBREVIATIONS 
 
3-AB 3-aminobenzamide        
32P phosphorus-32        
ADP Adenosine diphosphate       
ADPr ADP-ribose        
ADPRibase-Mn Mn2+-dependent ADP-ribose/CDP-alcohol pyrophosphatase 
ALC1 Amplified in liver cancer protein 1   
AMP Adenosine monophosphate 
APLF Aprataxin and PNK-like factor     
ARH ADP-ribosylhydrolase        
ART ADP-ribosyltransferase        
ARTC ART cholera toxin like     
ARTD ART diphteria toxin like     
Asp Aspartic acid 
ATM Ataxia telangiectasia mutated      
ATP Adenosine triphosphate 
BAL B-aggressive lymphoma       
BRCA Breast cancer type susceptibility protein homolog 
C cysteine        
C6orf130 O-acetyl-ADP-ribose deacetylase 1 
CHFR Checkpoint with forkhead and RING finger domains protein 
ChIP Chromatin immunoprecipitation  
CID Collision induced dissociation      
D Aspartate        
DDH2 DDHD domain-containing protein 2     
DNA  Desoxyribonucleic acid        
DNA-PK DNA-dependent protein kinase      
Dph Diphtamide        
E Glutamate / glutamic acid     
ECD Electron capture dissociation      
ETD Electron transfer dissociation      
FT Fourier transform       
GDAP2 Ganglioside-induced differentiation-associated protein 2 
GDH1 Glutamate dehydrogenase 1      
GHD1 Glucose 1-dehydrogenase 1 
GSK3! Glycogen synthase kinase 3 beta 
GST  Glutathione S-transferase        
H Histidine 
HCD Higher energy collisional dissociation     
HEV Hepatitis E virus      
His  Histidine        
HPLC High performance liquid chromatography     
HR Homologous recombination       
IT Ion trap       
K Lysine        
kDa Kilodalton        
Ku70/86 Lupus Ku autoantigen protein p70/p86    
LC Liquid chromatography       
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MacroD1 MACRO domain-containing protein 1 
MacroD2 MACRO domain-containing protein 2 
MgCl2 Magnesium chloride 
Mn Manganese        
MnCl2 Manganese(II) chloride       
MNNG N-methyl-N’ -nitro-N’-nitro- soguanidine 
MRE11 Meiotic recombination 11 homolog 1    
MS Mass spectrometry       
N Asparagine        
NaCl  Sodium chloride        
NAD+ Nicotinamide adenine dinucleotide      
NH2OH Hydroxylamine        
NMR Nuclear magnetic resonance      
Nudix Nucleoside diphosphate linked to X    
NUDT Nucleoside diphosphate-linked moiety X motif  
OAADPr O-acetyl-ADP-ribose        
p53 Cellular tumor antigen p53 
PAR Poly-ADP-ribose        
PARG Poly-ADP-ribose glycohydrolase       
PARP Poly-ADP-ribose polymerase       
PBM PAR-binding motif       
PBZ PAR-binding zinc-finger       
PDE1 Phosphodiesterase 1       
PNK Polynucleotide kinase       
pS Phospho-serine        
PTEN Phosphatase and tensin homolog 
PTM Post-translational modification       
Q Glutamine 
R Arginine        
rDNA Ribosomal DNA       
RhoA Transforming protein RhoA 
RING Really interesting new gene     
RNA Ribonucleic acid       
RNF146 RING finger protein 146     
S Serine 
SARS-CoV Severe acute respiratory syndrome coronavirus    
SDS Sodium dodecyl sulfate      
SET7/9 SET domain-containing protein 7     
SFV Simian foamy virus      
SILAC Stable isotope labeling by amino acids in cell 
Snf2 Transcription regulatory protein      
SUMO Small ubiquitin-like modifier      
Trip12 Thyroid receptor-interacting protein 12     
UV Ultraviolet        
W Tryptophane        
XRCC1 X-ray repair cross-complementing protein 1    
Y Tyrosine 
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